Henry Seth Friedman
James B. Powell, Jr. Distinguished Professor of Pediatric Oncology, in the School of Medicine
Overview:
Our laboratory is pursuing a comprehensive analysis of the biology and therapy of adult and childhood central nervous system malignancies, particularly high-grade medulloblastoma, glioma, and ependymoma.
Laboratory Studies: Active programs, using human adult and pediatric CNS tumor continuous cell lines, transplantable xenografts growing subcutaneously and intracranially in athymic nude mice and rats, and as well as in the subarachnoid space of the athymic nude rats, and patients tumor specimens, are defining:
1) the chemotherapeutic profile of medulloblastoma, adult and childhood glioma and ependymoma
2) mechanisms of resistance to classical bifunctional alkylators, nitrosoureas and methylators operational in malignant glioma and medulloblastoma, particularly DNA adduct and crosslink repair, O6-alkylguanine-DNA alkyltransferase elevation and DNA mismatch repair deficiency.
3) modulations designed to over come or circumvent specific mechanisms of resistance
4) the activity of signal pathway inhibitors of EGFR, m-tor and other targets
5) the therapeutic advantages of intrathecal and intratumoral drug delivery in the treatment of neoplastic meningitis and intracranial malignancies, respectively.
The results of the therapeutic studies to date have demonstrated the marked activity of alkylating agents, particularly melphalan and cyclophosphamide and the role of glutathione, AGT glutathione-S-transferase, abnormal drug transport and alterations in formation and repair of DNA-DNA crosslinks in modulating cytotoxicity of these agents. Modulations shown to be effective in enhancing alkylator activity/reversing alkylator resistance include BSO-mediated glutathione depletion, inhibition of DNA-DNA crosslink repair and inhibition of 06-alkylguanine-DNA alkyltransferase by 06-benzylguanine. Recent studies have demonstrated profound activity of temozolomide, CPT-11 topotecan, irofulven, and karenitecin as well as the combination of CPT-11 or topotecan plus BCNU or temozolomide. Successful treatment of neoplastic meningitis in nude rats with intrathecal 4-hydroperoxycyclophosphamide, melphalan, temozolomide and busulfan, and intracranial glioma in nude rats with intratumoral temozolomide has also been demonstrated. More recent studies have revealed cyclophosphamide resistance secondary to DNA interstrand crosslink repair. Additional studies have shown that cyclophosphamide crosslinks are formed at the 1,3 N7 position, serving as the basis for construction of a defined crosslink in a plasmid vector to assay for crosslink repair and allowing demonstration of the lack of a role of nucleotide excision repair. Mismatch repair deficiency has been shown as a mechanism mediating acquired methylator (procarbazine and temozolomide) resistance in an adult glioblastoma xenograft.
Clinical Studies: Clinical investigations are designed to translate laboratory programs into successful treatment for adults and children with malignant brain tumors, particularly medulloblastoma. Clinical trials for adults include phase II trials of temozolomide, ZD1839 (Iressa), karenitecin, and temozolomide plus O6-BG as well as phase I trials of topotecan plus BCNU, CPT-11 plus temozolomide, and PTK787 ± temozolomide or CCNU. Studies are in progress in children evaluating the activity CPT-11 plus temozolomide, intrathecal busulfan and cyclophosphamide/melphalan or cyclophosphamide/busulfan plus autologous bone marrow support . Extension of these studies to a larger cohort of patients is being performed nationally under the auspices of the Pediatric Brain Tumor Consortium (Henry S. Friedman -- Head of New Agents Committee).
Future studies will address the role of agents designed to decrease repair of interstrand crosslinks when given in combination with alkylating agents, as well as newer signal pathway inhibitors such as RAD001, PKI166, and DB-67.
Laboratory Studies: Active programs, using human adult and pediatric CNS tumor continuous cell lines, transplantable xenografts growing subcutaneously and intracranially in athymic nude mice and rats, and as well as in the subarachnoid space of the athymic nude rats, and patients tumor specimens, are defining:
1) the chemotherapeutic profile of medulloblastoma, adult and childhood glioma and ependymoma
2) mechanisms of resistance to classical bifunctional alkylators, nitrosoureas and methylators operational in malignant glioma and medulloblastoma, particularly DNA adduct and crosslink repair, O6-alkylguanine-DNA alkyltransferase elevation and DNA mismatch repair deficiency.
3) modulations designed to over come or circumvent specific mechanisms of resistance
4) the activity of signal pathway inhibitors of EGFR, m-tor and other targets
5) the therapeutic advantages of intrathecal and intratumoral drug delivery in the treatment of neoplastic meningitis and intracranial malignancies, respectively.
The results of the therapeutic studies to date have demonstrated the marked activity of alkylating agents, particularly melphalan and cyclophosphamide and the role of glutathione, AGT glutathione-S-transferase, abnormal drug transport and alterations in formation and repair of DNA-DNA crosslinks in modulating cytotoxicity of these agents. Modulations shown to be effective in enhancing alkylator activity/reversing alkylator resistance include BSO-mediated glutathione depletion, inhibition of DNA-DNA crosslink repair and inhibition of 06-alkylguanine-DNA alkyltransferase by 06-benzylguanine. Recent studies have demonstrated profound activity of temozolomide, CPT-11 topotecan, irofulven, and karenitecin as well as the combination of CPT-11 or topotecan plus BCNU or temozolomide. Successful treatment of neoplastic meningitis in nude rats with intrathecal 4-hydroperoxycyclophosphamide, melphalan, temozolomide and busulfan, and intracranial glioma in nude rats with intratumoral temozolomide has also been demonstrated. More recent studies have revealed cyclophosphamide resistance secondary to DNA interstrand crosslink repair. Additional studies have shown that cyclophosphamide crosslinks are formed at the 1,3 N7 position, serving as the basis for construction of a defined crosslink in a plasmid vector to assay for crosslink repair and allowing demonstration of the lack of a role of nucleotide excision repair. Mismatch repair deficiency has been shown as a mechanism mediating acquired methylator (procarbazine and temozolomide) resistance in an adult glioblastoma xenograft.
Clinical Studies: Clinical investigations are designed to translate laboratory programs into successful treatment for adults and children with malignant brain tumors, particularly medulloblastoma. Clinical trials for adults include phase II trials of temozolomide, ZD1839 (Iressa), karenitecin, and temozolomide plus O6-BG as well as phase I trials of topotecan plus BCNU, CPT-11 plus temozolomide, and PTK787 ± temozolomide or CCNU. Studies are in progress in children evaluating the activity CPT-11 plus temozolomide, intrathecal busulfan and cyclophosphamide/melphalan or cyclophosphamide/busulfan plus autologous bone marrow support . Extension of these studies to a larger cohort of patients is being performed nationally under the auspices of the Pediatric Brain Tumor Consortium (Henry S. Friedman -- Head of New Agents Committee).
Future studies will address the role of agents designed to decrease repair of interstrand crosslinks when given in combination with alkylating agents, as well as newer signal pathway inhibitors such as RAD001, PKI166, and DB-67.
Current Appointments & Affiliations
- James B. Powell, Jr. Distinguished Professor of Pediatric Oncology, in the School of Medicine, Neurosurgery, Neuro-Oncology, Neurosurgery 2003
- Professor of Neurosurgery, Neurosurgery, Neuro-Oncology, Neurosurgery 2003
- Professor of Pediatrics, Pediatrics, Clinical Science Departments 2010
- Professor of Medicine, Medicine, Medical Oncology, Medicine 2018
- Professor of Pathology, Pathology, Clinical Science Departments 2019
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 1981
Contact Information
- 047 Baker House, Durham, NC 27710
- Box 3624 Med Ctr, Durham, NC 27710
-
henry.friedman@duke.edu
(919) 684-5301
- Background
-
Education, Training, & Certifications
-
Previous Appointments & Affiliations
- Assistant Professor of Pathology, Pathology, Clinical Science Departments 2009 - 2019
- Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2010 - 2018
- Professor of Pediatrics, Pediatrics, Clinical Science Departments 2006 - 2010
- Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2005 - 2009
- Assistant Professor of Pathology, Pathology, Clinical Science Departments 2002 - 2006
- Professor of Pediatrics, Pediatrics, Clinical Science Departments 2003 - 2005
- Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2003 - 2004
- Professor of Pediatrics with Tenure, Pediatrics, Clinical Science Departments 1990 - 2003
- Chief, Division of Neuro-Oncology in the Department of Pediatrics, Pediatrics, Clinical Science Departments 1995 - 2003
- James B. Powell, Jr. Distinguished Professor of Pediatric Oncology, in the School of Medicine, Pediatrics, Clinical Science Departments 1999 - 2003
- Associate Professor of Surgery, Surgery, Clinical Science Departments 2001 - 2003
- Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 1999 - 2002
- Assistant Professor of Pathology, Pathology, Clinical Science Departments 2000 - 2001
- Associate Professor of Surgery, Surgery, Clinical Science Departments 1997 - 2000
- Assistant Professor of Pathology, Pathology, Clinical Science Departments 1998 - 1999
- Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 1996 - 1998
- Assistant Professor of Pathology, Pathology, Clinical Science Departments 1984 - 1997
- Assistant Professor of Pediatrics, Pediatrics, Clinical Science Departments 1983 - 1990
- Recognition
-
In the News
-
MAY 16, 2016 -
MAY 16, 2016 Duke Today -
MAR 31, 2015 Forbes -
MAR 31, 2015 Forbes -
MAR 31, 2015 Fox Business -
MAR 31, 2015 Fox Business -
MAR 30, 2015 CBS “60 Minutes” -
MAR 30, 2015 CBS “60 Minutes -
NOV 5, 2014 NBC News
-
- Research
-
Selected Grants
- PVSRIPO in melanoma awarded by National Institutes of Health 2020 - 2025
- Therapies for Glioblastoma Multiforme 2022 - 2023
- Oncolytic Polovirus, Immunotoxin, and Checkpoint Inhibitor Therapy of Gliomas awarded by National Institutes of Health 2015 - 2022
- Therapies for Glioblastoma Multiforme 2007 - 2022
- Research Training In Neuro-Oncology awarded by National Institutes of Health 1998 - 2016
- Adoptive Immunotherapy for GBM During Hematopoietic Recovery from Temozolomide awarded by National Institutes of Health 2009 - 2014
- Gene Targeted Therapy of Brain Tumors awarded by National Institutes of Health 2009 - 2012
- Targeting Brain Tumor Stem Cells awarded by National Institutes of Health 2009 - 2011
- Research Training In Neuro-Oncology awarded by National Institutes of Health 2005 - 2010
- Temodar Resistance in CNS Tumors awarded by National Institutes of Health 1992 - 2010
- Changes in Functional Status Across Therapy for Primary Gilioma awarded by National Cancer Institute 2006 - 2009
- TGFbeta-PTEN Interactions in Glioma Biology & Therapy awarded by National Institutes of Health 2006 - 2008
- Molecular Mechanisms of SPARC Mediated Glioma Invasion awarded by National Institutes of Health 2006 - 2008
- DNA Methylation and GSTP1 Gene Regulation in Gliomas awarded by National Institutes of Health 2002 - 2008
- Biomarker Studies for Novel Anti-Cancer Agents awarded by National Institutes of Health 2003 - 2008
- Imaging of O6-Alkylguianine-DNA Alkyltransferase awarded by National Institutes of Health 2002 - 2007
- Phase II Study of 44Gy from 131I-81C6 for CNS Tumors awarded by National Institutes of Health 2003 - 2006
- Astatine-211 & Radioiodine Labeled Octreotide Conjugates awarded by National Institutes of Health 2001 - 2006
- Regional AGT Depletion of CNS and Leptomeningeal Tumors awarded by National Institutes of Health 2002 - 2006
- AGT Depletion for therapy of CNS tumors awarded by National Institutes of Health 2000 - 2005
- GCRC CAP awarded by National Institutes of Health 2000 - 2005
- Therapy of Temodar plus O6-Benzulguanine in Malignant Glioma awarded by National Institutes of Health 2003 - 2005
- A Molecular Classification of Brain Tumors awarded by National Institutes of Health 2000 - 2003
- ZD1839 Therapy of Glioblastoma Multiforme awarded by National Institutes of Health 2001 - 2003
- Intrathecal Busulfan Therapy of Neoplastic Meningitis awarded by Food and Drug Administration 1998 - 2002
- GRT-Photo-Documentary/Patients/Brain Tumors 1999 - 2002
- Same awarded by National Institutes of Health 1999 - 2001
- Src On Primary And Matastatic Tumors Of The Cns awarded by National Institutes of Health 1994 - 1999
- Src On Primary And Metastatic Tumors Of The Cns awarded by National Institutes of Health 1997 - 1999
- Cyclophosphamide Resistance In Medulloblastoma awarded by National Institutes of Health 1996 - 1998
- Phase I Trial Of 06-Benzylguanine Plus Bcnu In Glioma awarded by National Institutes of Health 1996 - 1998
- Cyclophosphamide Resistance In Medulloblastoma awarded by National Institutes of Health 1995 - 1998
- Cyclophoshamide Resistance In Medulloblastoma awarded by National Institutes of Health 1992 - 1998
- Phase I Trial Of 06-Benzylguanine Plus Bcnu In Glioma awarded by National Institutes of Health 1995 - 1997
- Pediatric Oncology Group Studies awarded by National Institutes of Health 1995
- Gluathione Modulation Of Alkylators In Medulloblastoma awarded by National Institutes of Health 1992 - 1995
- Glutathione Modulation Of Alkylators In Medulloblastoma awarded by National Institutes of Health 1993 - 1995
- Pediatric Oncology Group Studies awarded by National Institutes of Health 1991 - 1994
- Src On Malignant Human Gliomas And Medulloblastomas awarded by National Institutes of Health 1993 - 1994
- Melphalan Cytotoxicity And Resistance In Medulloblastoma awarded by National Institutes of Health 1990 - 1991
- Neurobiology And Rational Therapy Of Human Medulloblastoma awarded by National Institutes of Health 1987 - 1990
- Neurobiology And Rational Therapy Of Human Medulloblasto awarded by National Institutes of Health 1986 - 1990
-
External Relationships
- Istari Oncology
- Leaf Vertical
- Publications & Artistic Works
-
Selected Publications
-
Books
-
Sampson, J. H., D. D. Bigner, A. H. Friedman, H. S. Friedman, and R. McLendon. The Duke glioma handbook: Pathology, diagnosis, and management, 2016. https://doi.org/10.1017/CBO9781107588721.Full Text
-
-
Academic Articles
-
Peters, Katherine B., Mary L. Affronti, Sarah Woodring, Eric Lipp, Patrick Healy, James E. Herndon, Elizabeth S. Miller, et al. “Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial.” Support Care Cancer 30, no. 4 (April 2022): 3463–71. https://doi.org/10.1007/s00520-021-06738-0.Full Text Link to Item
-
Kent, Collin L., Yvonne M. Mowery, Olayode Babatunde, Ato O. Wright, Ian Barak, Frances McSherry, James E. Herndon, et al. “Long-Term Outcomes for Patients With Atypical or Malignant Meningiomas Treated With or Without Radiation Therapy: A 25-Year Retrospective Analysis of a Single-Institution Experience.” Adv Radiat Oncol 7, no. 3 (2022): 100878. https://doi.org/10.1016/j.adro.2021.100878.Full Text Link to Item
-
Kang, Jennifer H., Christa B. Swisher, Evan D. Buckley, James E. Herndon, Eric S. Lipp, John P. Kirkpatrick, Annick Desjardins, et al. “Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis.” Cns Oncol 10, no. 3 (September 1, 2021): CNS77. https://doi.org/10.2217/cns-2021-0009.Full Text Open Access Copy Link to Item
-
Randazzo, Dina M., Frances McSherry, James E. Herndon, Mary L. Affronti, Eric S. Lipp, Elizabeth S. Miller, Sarah Woodring, et al. “Spiritual well-being and its association with health-related quality of life in primary brain tumor patients.” Neurooncol Pract 8, no. 3 (June 2021): 299–309. https://doi.org/10.1093/nop/npaa084.Full Text Link to Item
-
Gromeier, Matthias, Michael C. Brown, Gao Zhang, Xiang Lin, Yeqing Chen, Zhi Wei, Nike Beaubier, et al. “Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.” Nat Commun 12, no. 1 (January 13, 2021): 352. https://doi.org/10.1038/s41467-020-20469-6.Full Text Open Access Copy Link to Item
-
Lee, Jessica W., John P. Kirkpatrick, Frances McSherry, James E. Herndon, Eric S. Lipp, Annick Desjardins, Dina M. Randazzo, et al. “Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis.” Front Oncol 11 (2021): 631618. https://doi.org/10.3389/fonc.2021.631618.Full Text Open Access Copy Link to Item
-
Tan, Aaron C., David M. Ashley, Giselle Y. López, Michael Malinzak, Henry S. Friedman, and Mustafa Khasraw. “Management of glioblastoma: State of the art and future directions.” Ca Cancer J Clin 70, no. 4 (July 2020): 299–312. https://doi.org/10.3322/caac.21613.Full Text Link to Item
-
Patel, Mallika P., Sarah Woodring, Dina M. Randazzo, Henry S. Friedman, Annick Desjardins, Patrick Healy, James E. Herndon, et al. “Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.” Support Care Cancer 28, no. 5 (May 2020): 2229–38. https://doi.org/10.1007/s00520-019-05039-x.Full Text Link to Item
-
Patel, Mallika P., John P. Kirkpatrick, Margaret O. Johnson, Patrick Healy, James E. Herndon, Eric S. Lipp, Elizabeth S. Miller, et al. “Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.” J Neurooncol 147, no. 2 (April 2020): 477–83. https://doi.org/10.1007/s11060-020-03446-3.Full Text Link to Item
-
Johnson, Margaret O., John P. Kirkpatrick, Mallika P. Patel, Annick Desjardins, Dina M. Randazzo, Henry S. Friedman, David M. Ashley, and Katherine B. Peters. “The role of chemotherapy in the treatment of central neurocytoma.” Cns Oncol 8, no. 3 (November 1, 2019): CNS41. https://doi.org/10.2217/cns-2019-0012.Full Text Open Access Copy Link to Item
-
Kim, Jung-Young, Jennifer G. Jackman, Sarah Woodring, Frances McSherry, James E. Herndon, Annick Desjardins, Henry S. Friedman, and Katherine B. Peters. “Second primary cancers in long-term survivors of glioblastoma.” Neurooncol Pract 6, no. 5 (September 2019): 386–91. https://doi.org/10.1093/nop/npz001.Full Text Link to Item
-
Randazzo, Dina M., Frances McSherry, James E. Herndon, Mary L. Affronti, Eric S. Lipp, Charlene Flahiff, Elizabeth Miller, et al. “Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population.” Complement Ther Clin Pract 36 (August 2019): 43–48. https://doi.org/10.1016/j.ctcp.2019.05.002.Full Text Link to Item
-
Hansen, Landon J., Ran Sun, Rui Yang, Simranjit X. Singh, Lee H. Chen, Christopher J. Pirozzi, Casey J. Moure, et al. “MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation.” Cancer Res 79, no. 13 (July 1, 2019): 3383–94. https://doi.org/10.1158/0008-5472.CAN-18-1010.Full Text Link to Item
-
Desjardins, Annick, James E. Herndon, Frances McSherry, Arliene Ravelo, Eric S. Lipp, Patrick Healy, Katherine B. Peters, et al. “Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice.” Health Sci Rep 2, no. 4 (April 2019): e114. https://doi.org/10.1002/hsr2.114.Full Text Link to Item
-
Lipp, Eric S., Patrick Healy, Alan Austin, Alysha Clark, Tara Dalton, Kathryn Perkinson, James E. Herndon, et al. “MGMT: Immunohistochemical Detection in High-Grade Astrocytomas.” J Neuropathol Exp Neurol 78, no. 1 (January 1, 2019): 57–64. https://doi.org/10.1093/jnen/nly110.Full Text Link to Item
-
Shen, Erica, Margaret O. Johnson, Jessica W. Lee, Eric S. Lipp, Dina M. Randazzo, Annick Desjardins, Roger E. McLendon, et al. “Performance of a nomogram for IDH-wild-type glioblastoma patient survival in an elderly cohort.” Neurooncol Adv 1, no. 1 (2019): vdz036. https://doi.org/10.1093/noajnl/vdz036.Full Text Link to Item
-
Affronti, Mary Lou, Dina Randazzo, Eric S. Lipp, Katherine B. Peters, Susan C. Herndon, Sarah Woodring, Patrick Healy, Christina K. Cone, James E. Herndon, and Susan M. Schneider. “Pilot Study to Describe the Trajectory of Symptoms and Adaptive Strategies of Adults Living with Low-grade Glioma.” Semin Oncol Nurs 34, no. 5 (December 2018): 472–85. https://doi.org/10.1016/j.soncn.2018.10.006.Full Text Link to Item
-
Affronti, Mary Lou, Jennifer Gamboa Jackman, Frances McSherry, James E. Herndon, Elwood C. Massey, Eric Lipp, Annick Desjardins, et al. “Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.” Oncologist 23, no. 8 (August 2018): 889-e98. https://doi.org/10.1634/theoncologist.2018-0149.Full Text Link to Item
-
Desjardins, Annick, Matthias Gromeier, James E. Herndon, Nike Beaubier, Dani P. Bolognesi, Allan H. Friedman, Henry S. Friedman, et al. “Recurrent Glioblastoma Treated with Recombinant Poliovirus.” N Engl J Med 379, no. 2 (July 12, 2018): 150–61. https://doi.org/10.1056/NEJMoa1716435.Full Text Link to Item
-
Keir, Stephen T., Vidyalakshmi Chandramohan, Carlee D. Hemphill, Michael M. Grandal, Maria Carlsen Melander, Mikkel W. Pedersen, Ivan D. Horak, et al. “Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.” J Neurooncol 138, no. 3 (July 2018): 489–98. https://doi.org/10.1007/s11060-018-2832-6.Full Text Open Access Copy Link to Item
-
Diplas, Bill H., Xujun He, Jacqueline A. Brosnan-Cashman, Heng Liu, Lee H. Chen, Zhaohui Wang, Casey J. Moure, et al. “The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.” Nat Commun 9, no. 1 (May 25, 2018): 2087. https://doi.org/10.1038/s41467-018-04448-6.Full Text Link to Item
-
Vaslow, Zachary, Katherine Peters, John Kirkpatrick, Frances McSherry, James Herndon, Eric Lipp, Margaret O. Johnson, et al. “Long-term outcomes of adult patients with ependymoma.” Neurology 90, no. 15 (April 10, 2018): P6.150-P6.150.Link to Item
-
Peters, Katherine B., Eric S. Lipp, Elizabeth Miller, James E. Herndon, Frances McSherry, Annick Desjardins, David A. Reardon, and Henry S. Friedman. “Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.” J Neurooncol 137, no. 2 (April 2018): 349–56. https://doi.org/10.1007/s11060-017-2724-1.Full Text Link to Item
-
Wang, K. H., T. A. Thompson, D. Galusha, H. Friedman, C. M. Nazario, M. Nunez, R. G. Maharaj, O. P. Adams, M. Nunez-Smith, and M. ECHORN Writing Group. “Non-communicable chronic diseases and timely breast cancer screening among women of the Eastern Caribbean Health Outcomes Research Network (ECHORN) Cohort Study.” Cancer Causes Control 29, no. 3 (March 2018): 315–24. https://doi.org/10.1007/s10552-018-1005-4.Full Text Link to Item
-
Dunn-Pirio, Anastasie M., Sarah Woodring, Eric Lipp, James E. Herndon, Patrick Healy, Mallika Weant, Dina Randazzo, Annick Desjardins, Henry S. Friedman, and Katherine B. Peters. “Adjunctive perampanel for glioma-associated epilepsy.” Epilepsy Behav Case Rep 10 (2018): 114–17. https://doi.org/10.1016/j.ebcr.2018.09.003.Full Text Link to Item
-
Reap, Elizabeth A., Carter M. Suryadevara, Kristen A. Batich, Luis Sanchez-Perez, Gary E. Archer, Robert J. Schmittling, Pamela K. Norberg, et al. “Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.” Cancer Res 78, no. 1 (January 1, 2018): 256–64. https://doi.org/10.1158/0008-5472.CAN-17-0469.Full Text Link to Item
-
Waitkus, Matthew S., Christopher J. Pirozzi, Casey J. Moure, Bill H. Diplas, Landon J. Hansen, Austin B. Carpenter, Rui Yang, et al. “Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities.” Cancer Res 78, no. 1 (January 1, 2018): 36–50. https://doi.org/10.1158/0008-5472.CAN-17-1352.Full Text Link to Item
-
Randazzo, Dina M., Frances McSherry, James E. Herndon, Mary Lou Affronti, Eric S. Lipp, Charlene Flahiff, Elizabeth Miller, et al. “A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population.” J Neurooncol 134, no. 2 (September 2017): 363–69. https://doi.org/10.1007/s11060-017-2535-4.Full Text Link to Item
-
Esbenshade, Adam J., Mehmet Kocak, Linda Hershon, Pierre Rousseau, Jean-Claude Decarie, Susan Shaw, Peter Burger, Henry S. Friedman, Amar Gajjar, and Albert Moghrabi. “A Phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma (protocol POG 9631): A report from the Children's Oncology Group.” Pediatr Blood Cancer 64, no. 6 (June 2017). https://doi.org/10.1002/pbc.26373.Full Text Link to Item
-
Batich, Kristen A., Elizabeth A. Reap, Gary E. Archer, Luis Sanchez-Perez, Smita K. Nair, Robert J. Schmittling, Pam Norberg, et al. “Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.” Clin Cancer Res 23, no. 8 (April 15, 2017): 1898–1909. https://doi.org/10.1158/1078-0432.CCR-16-2057.Full Text Link to Item
-
Affronti, Mary Lou, Sarah Woodring, Katherine B. Peters, James E. Herndon, Frances McSherry, Patrick N. Healy, Annick Desjardins, James J. Vredenburgh, and Henry S. Friedman. “A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab.” Ther Clin Risk Manag 13 (2017): 33–40. https://doi.org/10.2147/TCRM.S122480.Full Text Link to Item
-
Friedman, H., N. Ator, N. Haigwood, W. Newsome, J. S. Allan, T. G. Golos, J. H. Kordower, et al. “The critical role of nonhuman primates in medical research.” Pathogens and Immunity 2, no. 3 (January 1, 2017): 352–65. https://doi.org/10.20411/pai.v2i3.186.Full Text
-
Randazzo, Dina, and Katherine B. Peters. “Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients.” Cns Oncol 5, no. 4 (October 2016): 241–49. https://doi.org/10.2217/cns-2016-0010.Full Text Link to Item
-
Kent, C. L., Y. M. Mowery, A. O. Wright, G. J. Kim, A. Desjardins, K. B. Peters, G. Vlahovic, et al. “Long-Term Outcomes for Patients With Atypical or Malignant Meningiomas Treated With Radiation Therapy: A Single-Institution Retrospective Analysis.” Int J Radiat Oncol Biol Phys 96, no. 2S (October 1, 2016): E83–84. https://doi.org/10.1016/j.ijrobp.2016.06.802.Full Text Link to Item
-
Desjardins, Annick, Gordana Vlahovic, and Henry S. Friedman. “Vaccine Therapy, Oncolytic Viruses, and Gliomas.” Oncology (Williston Park) 30, no. 3 (March 2016): 211–18.Link to Item
-
Okamura, Tatsunori, Gamil Antoun, Stephen T. Keir, Henry Friedman, Darell D. Bigner, and Francis Ali-Osman. “Phosphorylation of Glutathione S-Transferase P1 (GSTP1) by Epidermal Growth Factor Receptor (EGFR) Promotes Formation of the GSTP1-c-Jun N-terminal kinase (JNK) Complex and Suppresses JNK Downstream Signaling and Apoptosis in Brain Tumor Cells.” J Biol Chem 290, no. 52 (December 25, 2015): 30866–78. https://doi.org/10.1074/jbc.M115.656140.Full Text Link to Item
-
Peters, Katherine B., Emil Lou, Annick Desjardins, David A. Reardon, Eric S. Lipp, Elizabeth Miller, James E. Herndon, Frances McSherry, Henry S. Friedman, and James J. Vredenburgh. “Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.” Oncologist 20, no. 7 (July 2015): 727–28. https://doi.org/10.1634/theoncologist.2015-0135.Full Text Link to Item
-
McLendon, Roger E., Eric Lipp, Diane Satterfield, Melissa Ehinger, Alan Austin, Debra Fleming, Kathryn Perkinson, et al. “Prognostic marker analysis in pediatric intracranial ependymomas.” J Neurooncol 122, no. 2 (April 2015): 255–61. https://doi.org/10.1007/s11060-014-1711-z.Full Text Link to Item
-
Mitchell, Duane A., Elias J. Sayour, Elizabeth Reap, Robert Schmittling, Gabriel DeLeon, Pamela Norberg, Annick Desjardins, et al. “Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.” Cancer Immunol Res 3, no. 4 (April 2015): 320–25. https://doi.org/10.1158/2326-6066.CIR-14-0100.Full Text Link to Item
-
Mitchell, Duane A., Kristen A. Batich, Michael D. Gunn, Min-Nung Huang, Luis Sanchez-Perez, Smita K. Nair, Kendra L. Congdon, et al. “Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.” Nature 519, no. 7543 (March 19, 2015): 366–69. https://doi.org/10.1038/nature14320.Full Text Open Access Copy Link to Item
-
Flores, Catherine, Christina Pham, David Snyder, Shicheng Yang, Luis Sanchez-Perez, Elias Sayour, Xiuyu Cui, et al. “Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas.” Oncoimmunology 4, no. 3 (March 2015): e994374. https://doi.org/10.4161/2162402X.2014.994374.Full Text Link to Item
-
Di, Kaijun, Stephen T. Keir, Daniela Alexandru-Abrams, Xing Gong, Howard Nguyen, Henry S. Friedman, and Daniela A. Bota. “Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models.” J Neurooncol 120, no. 3 (December 2014): 473–81. https://doi.org/10.1007/s11060-014-1579-y.Full Text Link to Item
-
Peters, Katherine B., Miranda J. West, Whitney E. Hornsby, Emily Waner, April D. Coan, Frances McSherry, James E. Herndon, Henry S. Friedman, Annick Desjardins, and Lee W. Jones. “Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients.” J Neurooncol 120, no. 3 (December 2014): 499–506. https://doi.org/10.1007/s11060-014-1574-3.Full Text Link to Item
-
Brown, Michael C., Elena Y. Dobrikova, Mikhail I. Dobrikov, Ross W. Walton, Sarah L. Gemberling, Smita K. Nair, Annick Desjardins, et al. “Oncolytic polio virotherapy of cancer.” Cancer 120, no. 21 (November 1, 2014): 3277–86. https://doi.org/10.1002/cncr.28862.Full Text Link to Item
-
Keir, S. T., M. A. Roskoski, D. Gasinski, M. K. Kwatra, H. S. Friedman, and D. D. Bigner. “Identification and preliminary treatment data of xenografts representing tcga-defined subtypes.” Neuro Oncol 16 Suppl 3 (July 2014): iii35. https://doi.org/10.1093/neuonc/nou208.45.Full Text Link to Item
-
Zhang, Liwei, Lee H. Chen, Hong Wan, Rui Yang, Zhaohui Wang, Jie Feng, Shaohua Yang, et al. “Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.” Nat Genet 46, no. 7 (July 2014): 726–30. https://doi.org/10.1038/ng.2995.Full Text Link to Item
-
Affronti, Mary Lou, Susan M. Schneider, James E. Herndon, Susan Schlundt, and Henry S. Friedman. “Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice.” Support Care Cancer 22, no. 7 (July 2014): 1897–1905. https://doi.org/10.1007/s00520-014-2136-0.Full Text Link to Item
-
Desjardins, A., J. H. Sampson, K. B. Peters, T. Ranjan, G. Vlahovic, S. Threatt, J. E. Herndon, et al. “Oncolytic polio/rhinovirus recombinant (pvsripo) in recurrent glioblastoma (gbm): first phase I clinical trial evaluating the intratumoral administration.” Neuro Oncol 16 Suppl 3 (July 2014): iii43. https://doi.org/10.1093/neuonc/nou209.5.Full Text Link to Item
-
Killela, Patrick J., Christopher J. Pirozzi, Zachary J. Reitman, Sian Jones, B Ahmed Rasheed, Eric Lipp, Henry Friedman, et al. “The genetic landscape of anaplastic astrocytoma.” Oncotarget 5, no. 6 (March 30, 2014): 1452–57. https://doi.org/10.18632/oncotarget.1505.Full Text Link to Item
-
Killela, Patrick J., Christopher J. Pirozzi, Patrick Healy, Zachary J. Reitman, Eric Lipp, B Ahmed Rasheed, Rui Yang, et al. “Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.” Oncotarget 5, no. 6 (March 30, 2014): 1515–25. https://doi.org/10.18632/oncotarget.1765.Full Text Open Access Copy Link to Item
-
Zhang, L., L. H. Chen, H. Wan, R. Yang, Z. Wang, J. Feng, S. Yang, et al. “Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.” Nature Genetics 46, no. 7 (January 1, 2014): 726–30. https://doi.org/10.1038/ng.2995.Full Text
-
Desjardins, Annick, and Henry S. Friedman. “Bevacizumab therapy for glioblastoma: a passionate discussion.” Cns Oncol 3, no. 1 (January 2014): 1–3. https://doi.org/10.2217/cns.13.53.Full Text Link to Item
-
Gururangan, Sridharan, Jason Fangusaro, Tina Young Poussaint, Roger E. McLendon, Arzu Onar-Thomas, Shengjie Wu, Roger J. Packer, et al. “Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.” Neuro Oncol 16, no. 2 (January 2014): 310–17. https://doi.org/10.1093/neuonc/not154.Full Text Link to Item
-
Bota, Daniela A., Daniela Alexandru, Stephen T. Keir, Darell Bigner, James Vredenburgh, and Henry S. Friedman. “Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.” J Neurosurg 119, no. 6 (December 2013): 1415–23. https://doi.org/10.3171/2013.7.JNS1323.Full Text Link to Item
-
Gururangan, S., G. A. Grant, T. Driscoll, G. Archer, E. J. Sayour, J. E. Herndon, H. S. Friedman, et al. “ADOPTIVE LYMPHOCYTE THERAPY (ALT) PLUS DENDRITIC CELL VACCINATION (DCV) AFTER MYELOABLATIVE (MA) OR NON-MYELOABLATIVE (NMA) CONDITIONING IN PATIENTS WITH RECURRENT CENTRAL PNET (C-PNET).” Pediatric Blood & Cancer 60 (September 1, 2013): 13–13.Link to Item
-
Tarbell, Nancy J., Henry Friedman, William R. Polkinghorn, Torunn Yock, Tianni Zhou, Zhengjia Chen, Peter Burger, Patrick Barnes, and Larry Kun. “High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031).” J Clin Oncol 31, no. 23 (August 10, 2013): 2936–41. https://doi.org/10.1200/JCO.2012.43.9984.Full Text Link to Item
-
Cabrera, Alvin R., Kyle C. Cuneo, Annick Desjardins, John H. Sampson, Frances McSherry, James E. Herndon, Katherine B. Peters, et al. “Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial.” Int J Radiat Oncol Biol Phys 86, no. 5 (August 1, 2013): 873–79. https://doi.org/10.1016/j.ijrobp.2013.04.029.Full Text Link to Item
-
Jiang, Xiaoyin, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Jennifer A. Quinn, Alan D. Austin, James E. Herndon, Roger E. McLendon, and Henry S. Friedman. “O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma.” J Neurooncol 114, no. 1 (August 2013): 135–40. https://doi.org/10.1007/s11060-013-1162-y.Full Text Link to Item
-
Killela, Patrick J., Zachary J. Reitman, Yuchen Jiao, Chetan Bettegowda, Nishant Agrawal, Luis A. Diaz, Allan H. Friedman, et al. “TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.” Proc Natl Acad Sci U S A 110, no. 15 (April 9, 2013): 6021–26. https://doi.org/10.1073/pnas.1303607110.Full Text Link to Item
-
Lou, Emil, Katherine B. Peters, Ashley L. Sumrall, Annick Desjardins, David A. Reardon, Eric S. Lipp, James E. Herndon, et al. “Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.” Cancer Med 2, no. 2 (April 2013): 185–95. https://doi.org/10.1002/cam4.58.Full Text Open Access Copy Link to Item
-
Keir, Stephen T., Henry S. Friedman, David A. Reardon, Darell D. Bigner, and Lloyd A. Gray. “Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model.” J Neurooncol 111, no. 2 (January 2013): 97–102. https://doi.org/10.1007/s11060-012-0995-0.Full Text Link to Item
-
Bueren, Andre O. von, Manny D. Bacolod, Christian Hagel, Karl Heinimann, Andre Fedier, Uwe Kordes, Torsten Pietsch, et al. “MISMATCH REPAIR DEFICIENCY: A TEMOZOLOMIDE RESISTANCE FACTOR IN MEDULLOBLASTOMA CELL LINES WHICH IS UNCOMMON IN PRIMARY MEDULLOBLASTOMA TUMORS.” Pediatric Blood & Cancer 59, no. 6 (December 1, 2012): 1083–1083.Link to Item
-
Gururangan, Sridharan, Jason Fangusaro, Tina Young Poussaint, Arzu Onar-Thomas, Richard J. Gilbertson, Sridhar Vajapeyam, Amar Gajjar, et al. “Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.” Neuro Oncol 14, no. 11 (November 2012): 1404–12. https://doi.org/10.1093/neuonc/nos213.Full Text Link to Item
-
Reardon, D. A., J. E. Herndon, K. B. Peters, A. Desjardins, A. Coan, E. Lou, A. L. Sumrall, et al. “Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.” Br J Cancer 107, no. 9 (October 23, 2012): 1481–87. https://doi.org/10.1038/bjc.2012.415.Full Text Open Access Copy Link to Item
-
Bueren, A. O. von, M. D. Bacolod, C. Hagel, K. Heinimann, A. Fedier, U. Kordes, T. Pietsch, et al. “Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.” Br J Cancer 107, no. 8 (October 9, 2012): 1399–1408. https://doi.org/10.1038/bjc.2012.403.Full Text Link to Item
-
Reardon, David A., Annick Desjardins, James J. Vredenburgh, James E. Herndon, April Coan, Sridharan Gururangan, Katherine B. Peters, et al. “Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.” Cancer 118, no. 19 (October 1, 2012): 4759–67. https://doi.org/10.1002/cncr.26541.Full Text Link to Item
-
Lou, Emil, Ashley L. Sumrall, Scott Turner, Katherine B. Peters, Annick Desjardins, James J. Vredenburgh, Roger E. McLendon, et al. “Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.” J Neurooncol 109, no. 1 (August 2012): 63–70. https://doi.org/10.1007/s11060-012-0861-0.Full Text Link to Item
-
Friedman, H. S., and A. Desjardins. “Adjuvant PCV chemo hikes oligodendroglioma survival: Commentary.” Oncology Report, no. JULY (July 1, 2012): 6.
-
Jiao, Yuchen, Patrick J. Killela, Zachary J. Reitman, Ahmed B. Rasheed, Christopher M. Heaphy, Roeland F. de Wilde, Fausto J. Rodriguez, et al. “Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.” Oncotarget 3, no. 7 (July 2012): 709–22. https://doi.org/10.18632/oncotarget.588.Full Text Open Access Copy Link to Item
-
Reardon, David A., James J. Vredenburgh, Annick Desjardins, Katherine B. Peters, Sith Sathornsumetee, Stevie Threatt, John H. Sampson, et al. “Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.” J Neurooncol 108, no. 3 (July 2012): 499–506. https://doi.org/10.1007/s11060-012-0848-x.Full Text Link to Item
-
Reardon, David A., Charles A. Conrad, Timothy Cloughesy, Michael D. Prados, Henry S. Friedman, Kenneth D. Aldape, Paul Mischel, et al. “Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients.” Cancer Chemother Pharmacol 69, no. 6 (June 2012): 1507–18. https://doi.org/10.1007/s00280-012-1854-6.Full Text Link to Item
-
Keir, Stephen T., Lloyd Gray, and Henry S. Friedman. “Abstract LB-76: Mibefradil, a novel therapy for glioblastoma: An interlaced therapy approach.” Cancer Research 72, no. 8_Supplement (April 15, 2012). https://doi.org/10.1158/1538-7445.am2012-lb-76.Full Text
-
Cuneo, Kyle C., James J. Vredenburgh, John H. Sampson, David A. Reardon, Annick Desjardins, Katherine B. Peters, Henry S. Friedman, Christopher G. Willett, and John P. Kirkpatrick. “Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.” Int J Radiat Oncol Biol Phys 82, no. 5 (April 1, 2012): 2018–24. https://doi.org/10.1016/j.ijrobp.2010.12.074.Full Text Link to Item
-
Paldino, M. J., A. Desjardins, H. S. Friedman, J. J. Vredenburgh, and D. P. Barboriak. “A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme.” Br J Radiol 85, no. 1012 (April 2012): 382–89. https://doi.org/10.1259/bjr/24774491.Full Text Link to Item
-
Desjardins, Annick, and Henry S. Friedman. “Neuro-oncology: Glioblastoma--community adjusts to new standard of care.” Nat Rev Neurol 8, no. 5 (March 20, 2012): 244–46. https://doi.org/10.1038/nrneurol.2012.42.Full Text Link to Item
-
Desjardins, Annick, David A. Reardon, April Coan, Jennifer Marcello, James E. Herndon, Leighann Bailey, Katherine B. Peters, Henry S. Friedman, and James J. Vredenburgh. “Bevacizumab and daily temozolomide for recurrent glioblastoma.” Cancer 118, no. 5 (March 1, 2012): 1302–12. https://doi.org/10.1002/cncr.26381.Full Text Link to Item
-
Reardon, David A., Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon, et al. “Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.” J Neurooncol 107, no. 1 (March 2012): 155–64. https://doi.org/10.1007/s11060-011-0722-2.Full Text Link to Item
-
Reardon, David A., James E. Herndon, Katherine Peters, Annick Desjardins, April Coan, Emil Lou, Ashley Sumrall, et al. “Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.” J Neurooncol 107, no. 1 (March 2012): 213–21. https://doi.org/10.1007/s11060-011-0740-0.Full Text Link to Item
-
Reardon, David A., Andrew D. Norden, Annick Desjardins, James J. Vredenburgh, James E. Herndon, April Coan, John H. Sampson, et al. “Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.” J Neurooncol 106, no. 2 (January 2012): 409–15. https://doi.org/10.1007/s11060-011-0687-1.Full Text Link to Item
-
Sampson, John H., Robert J. Schmittling, Gary E. Archer, Kendra L. Congdon, Smita K. Nair, Elizabeth A. Reap, Annick Desjardins, et al. “A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.” Plos One 7, no. 2 (2012): e31046. https://doi.org/10.1371/journal.pone.0031046.Full Text Open Access Copy Link to Item
-
Vredenburgh, James J., Annick Desjardins, John P. Kirkpatrick, David A. Reardon, Katherine B. Peters, James E. Herndon, Jennifer Marcello, et al. “Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.” Int J Radiat Oncol Biol Phys 82, no. 1 (January 1, 2012): 58–66. https://doi.org/10.1016/j.ijrobp.2010.08.058.Full Text Link to Item
-
Desjardins, Annick, David A. Reardon, Katherine B. Peters, Stevie Threatt, April D. Coan, James E. Herndon, Allan H. Friedman, Henry S. Friedman, and James J. Vredenburgh. “A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.” J Neurooncol 105, no. 3 (December 2011): 601–6. https://doi.org/10.1007/s11060-011-0627-0.Full Text Link to Item
-
Reardon, David A., Annick Desjardins, Katherine B. Peters, James J. Vredenburgh, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, et al. “Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.” Cancer 117, no. 23 (December 1, 2011): 5351–58. https://doi.org/10.1002/cncr.26188.Full Text Link to Item
-
Reardon, David A., James J. Vredenburgh, April Coan, Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, Sith Sathornsumetee, Jeremy N. Rich, James E. Herndon, and Henry S. Friedman. “Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.” J Neurooncol 105, no. 3 (December 2011): 621–27. https://doi.org/10.1007/s11060-011-0631-4.Full Text Link to Item
-
Desjardins, Annick, David A. Reardon, Katherine B. Peters, James E. Herndon, Sridharan Gururangan, Julie Norfleet, Henry S. Friedman, and James J. Vredenburgh. “PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH IRINOTECAN FOR MALIGNANT GLIOMA PATIENTS.” Neuro Oncology 13 (November 1, 2011): 90–90.Link to Item
-
Keir, Stephen T., David A. Reardon, Henry S. Friedman, and Darrel D. Bigner. “ACTIVITY OF THE PAN-HER INHIBITOR PF-00299804 AGAINST A PANEL OF BRAIN TUMOR XENOGRAFTS.” Neuro Oncology 13 (November 1, 2011): 164–164.Link to Item
-
Keir, Stephen T., David A. Reardon, Julia R. Saling, Lloyd S. Gray, Darell D. Bigner, and Henry S. Friedman. “MIBEFRADIL, A NOVEL THERAPY FOR GLIOBLATOMA MULTIFORME: INTERLACED THERAPY IN A MURINE MODEL.” Neuro Oncology 13 (November 1, 2011): 108–9.Link to Item
-
Mitchell, Duane A., Gary E. Archer, Henry S. Friedman, James E. Herndon, Darell D. Bigner, and John H. Sampson. “DENDRITIC CELL VACCINES TARGETING CYTOMEGALOVIRUS IN GLIOBLASTOMA.” Neuro Oncology 13 (November 1, 2011): 39–39.Link to Item
-
Peters, Katherine B., April D. Coan, Miranda J. West, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Henry S. Friedman, and Lee W. Jones. “PROGNOSTIC IMPORTANCE OF QUALITY OF LIFE AND FATIGUE IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA.” Neuro Oncology 13 (November 1, 2011): 123–123.Link to Item
-
Vredenburgh, James J., Annick Desjardins, David A. Reardon, Katherine B. Peters, John P. Kirkpatrick, James E. Herndon, April D. Coan, et al. “THE ADDITION OF BEVACIZUMAB TO TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE, AND ORAL TOPOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME.” Neuro Oncology 13 (November 1, 2011): 89–90.Link to Item
-
Lou, Emil, Scott Turner, Ashley Sumrall, David A. Reardon, Annick Desjardins, Katherine B. Peters, John H. Sampson, Henry S. Friedman, and James J. Vredenburgh. “Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.” J Clin Oncol 29, no. 28 (October 1, 2011): e739–42. https://doi.org/10.1200/JCO.2011.36.1865.Full Text Link to Item
-
Turner, Scott G., Katherine B. Peters, James J. Vredenburgh, Annick Desjardins, Henry S. Friedman, and David A. Reardon. “Everolimus tablets for patients with subependymal giant cell astrocytoma.” Expert Opin Pharmacother 12, no. 14 (October 2011): 2265–69. https://doi.org/10.1517/14656566.2011.601742.Full Text Link to Item
-
Mitchell, Duane A., Xiuyu Cui, Robert J. Schmittling, Luis Sanchez-Perez, David J. Snyder, Kendra L. Congdon, Gary E. Archer, et al. “Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.” Blood 118, no. 11 (September 15, 2011): 3003–12. https://doi.org/10.1182/blood-2011-02-334565.Full Text Link to Item
-
Ruden, Emily, David A. Reardon, April D. Coan, James E. Herndon, Whitney E. Hornsby, Miranda West, Diane R. Fels, et al. “Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma.” J Clin Oncol 29, no. 21 (July 20, 2011): 2918–23. https://doi.org/10.1200/JCO.2011.34.9852.Full Text Link to Item
-
Friedman, H. S. “Intensified temozolomide fails to hike glioblastoma survival: Commentary.” Oncology Report, no. JULY-AUGUST (July 1, 2011): 6.
-
Vredenburgh, James J., Annick Desjardins, David A. Reardon, Katherine B. Peters, James E. Herndon, Jennifer Marcello, John P. Kirkpatrick, et al. “The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.” Clin Cancer Res 17, no. 12 (June 15, 2011): 4119–24. https://doi.org/10.1158/1078-0432.CCR-11-0120.Full Text Link to Item
-
Wefel, Jeffrey S., Timothy Cloughesy, James L. Zazzali, Maoxia Zheng, Michael Prados, Patrick Y. Wen, Tom Mikkelsen, et al. “Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.” Neuro Oncol 13, no. 6 (June 2011): 660–68. https://doi.org/10.1093/neuonc/nor024.Full Text Link to Item
-
Reardon, David A., Annick Desjardins, Katherine Peters, Sridharan Gururangan, John Sampson, Jeremy N. Rich, Roger McLendon, et al. “Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.” J Neurooncol 103, no. 2 (June 2011): 371–79. https://doi.org/10.1007/s11060-010-0403-6.Full Text Link to Item
-
Bota, D. A., Z. Eroglu, D. A. Reardon, B. D. Fu, J. Norfleet, A. Desjardins, M. E. Linskey, K. Peters, H. S. Friedman, and J. J. Vredenburgh. “Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma.” Journal of Clinical Oncology 29, no. 15 (May 20, 2011).Link to Item
-
Bota, D. A., Z. Eroglu, D. A. Reardon, B. D. Fu, J. Norfleet, A. Desjardins, M. E. Linskey, K. Peters, H. S. Friedman, and J. J. Vredenburgh. “Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 2056.Link to Item
-
Desjardins, A., D. A. Reardon, J. J. Vredenburgh, K. Peters, M. Trikha, J. James, M. Gardner, A. Brickhouse, J. E. Herndon, and H. S. Friedman. “A pharmacokinetic (PK) study of AC480 administered twice daily in patients with surgically resectable, recurrent malignant glioma (MG) not on enzyme-inducing antiepileptic drug (EIAED).” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 2070.Link to Item
-
Lou, E., D. A. Reardon, K. Peters, A. Desjardins, J. E. Herndon, A. D. Coan, S. G. Turner, et al. “Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 2055.Link to Item
-
Reardon, D. A., J. J. Vredenburgh, A. Desjardins, K. Peters, A. D. Coan, J. E. Herndon, and H. S. Friedman. “Bevacizumab (BV) continuation following BV progression: Meta-analysis of five consecutive recurrent glioblastoma (GBM) trials.” Journal of Clinical Oncology 29, no. 15 (May 20, 2011).Link to Item
-
Reardon, D. A., J. J. Vredenburgh, A. Desjardins, K. Peters, A. D. Coan, J. E. Herndon, and H. S. Friedman. “Bevacizumab (BV) continuation following BV progression: Meta-analysis of five consecutive recurrent glioblastoma (GBM) trials.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 2030.Link to Item
-
Sumrall, A. L., D. A. Reardon, A. Desjardins, K. Peters, E. Lou, S. G. Turner, L. Bailey, H. S. Friedman, and J. J. Vredenburgh. “Venous thromboembolic complications in patients with malignant glioma treated on a bevacizumab clinical trial.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 9090.Link to Item
-
Vredenburgh, J. J., A. Desjardins, D. A. Reardon, K. Peters, J. Kirkpatrick, A. D. Coan, L. Bailey, D. Janney, C. Lu, and H. S. Friedman. “Bevacizumab, temozolomide, and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly-diagnosed glioblastoma multiforme (GBM).” Journal of Clinical Oncology 29, no. 15 (May 20, 2011).Link to Item
-
Vredenburgh, J. J., A. Desjardins, D. A. Reardon, K. Peters, J. Kirkpatrick, A. D. Coan, L. Bailey, D. Janney, C. Lu, and H. S. Friedman. “Bevacizumab, temozolomide, and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly-diagnosed glioblastoma multiforme (GBM).” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 2098.Link to Item
-
Desjardins, A., D. A. Reardon, J. J. Vredenburgh, K. Peters, M. Trikha, J. James, M. Gardner, A. Brickhouse, J. E. Herndon, and H. S. Friedman. “A pharmacokinetic (PK) study of AC480 administered twice daily in patients with surgically resectable, recurrent malignant glioma (MG) not on enzyme-inducing antiepileptic drug (EIAED).” Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 2070–2070. https://doi.org/10.1200/jco.2011.29.15_suppl.2070.Full Text
-
Lou, E., D. A. Reardon, K. Peters, A. Desjardins, J. E. Herndon, A. D. Coan, S. G. Turner, et al. “Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma.” Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 2055–2055. https://doi.org/10.1200/jco.2011.29.15_suppl.2055.Full Text
-
Paldino, M. J., T. Z. Wong, D. A. Reardon, H. S. Friedman, and D. P. Barboriak. “Prognostic significance of parameters derived from co-registered 18F-fluorodeoxyglucose PET and contrast-enhanced MRI in patients with high-grade glioma.” Br J Radiol 84, no. 1000 (April 2011): 327–33. https://doi.org/10.1259/bjr/48528504.Full Text Link to Item
-
Reardon, David A., Scott Turner, Katherine B. Peters, Annick Desjardins, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, et al. “A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.” J Natl Compr Canc Netw 9, no. 4 (April 2011): 414–27. https://doi.org/10.6004/jnccn.2011.0038.Full Text Link to Item
-
Sampson, John H., Kenneth D. Aldape, Gary E. Archer, April Coan, Annick Desjardins, Allan H. Friedman, Henry S. Friedman, et al. “Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.” Neuro Oncol 13, no. 3 (March 2011): 324–33. https://doi.org/10.1093/neuonc/noq157.Full Text Link to Item
-
Parsons, D Williams, Meng Li, Xiaosong Zhang, Siân Jones, Rebecca J. Leary, Jimmy Cheng-Ho Lin, Simina M. Boca, et al. “The genetic landscape of the childhood cancer medulloblastoma.” Science 331, no. 6016 (January 28, 2011): 435–39. https://doi.org/10.1126/science.1198056.Full Text Link to Item
-
Friedman, H. S. “Cediranib falls short in phase III recurrent glioblastoma study: Commentary.” Oncology Report, no. JANUARY (January 1, 2011): 11.
-
Friedman, H. S. “Frail elderly benefit from post-op temozolomide for glioblastoma: Commentary.” Oncology Report, no. JANUARY (January 1, 2011): 11.
-
Prados, Michael, Timothy Cloughesy, Meghna Samant, Liang Fang, Patrick Y. Wen, Tom Mikkelsen, David Schiff, et al. “Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.” Neuro Oncol 13, no. 1 (January 2011): 143–51. https://doi.org/10.1093/neuonc/noq151.Full Text Link to Item
-
Peters, Katherine B., Thomas E. Coyle, James J. Vredenburgh, Annick Desjardins, Henry S. Friedman, and David A. Reardon. “Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy.” J Neurooncol 101, no. 1 (January 2011): 155–59. https://doi.org/10.1007/s11060-010-0239-0.Full Text Link to Item
-
Reardon, David A., James J. Vredenburgh, Annick Desjardins, Katherine Peters, Sridharan Gururangan, John H. Sampson, Jennifer Marcello, et al. “Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.” J Neurooncol 101, no. 1 (January 2011): 57–66. https://doi.org/10.1007/s11060-010-0217-6.Full Text Link to Item
-
Gluckman, E., H. E. Broxmeyer, A. D. Auerbach, H. S. Friedman, G. W. Douglas, A. Devergie, H. Esperou, et al. “Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling.” Cellular Therapy and Transplantation 2, no. 7 (December 1, 2010). https://doi.org/10.3205/ctt-2010-en-000079.01.Full Text Open Access Copy
-
Sathornsumetee, Sith, Annick Desjardins, James J. Vredenburgh, Roger E. McLendon, Jennifer Marcello, James E. Herndon, Alyssa Mathe, et al. “Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.” Neuro Oncol 12, no. 12 (December 2010): 1300–1310. https://doi.org/10.1093/neuonc/noq099.Full Text Link to Item
-
Cui, Bo, Stewart P. Johnson, Nancy Bullock, Francis Ali-Osman, Darell D. Bigner, and Henry S. Friedman. “Decoupling of DNA damage response signaling from DNA damages underlies temozolomide resistance in glioblastoma cells.” J Biomed Res 24, no. 6 (November 2010): 424–35. https://doi.org/10.1016/S1674-8301(10)60057-7.Full Text Link to Item
-
Sampson, John H., Amy B. Heimberger, Gary E. Archer, Kenneth D. Aldape, Allan H. Friedman, Henry S. Friedman, Mark R. Gilbert, et al. “Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.” J Clin Oncol 28, no. 31 (November 1, 2010): 4722–29. https://doi.org/10.1200/JCO.2010.28.6963.Full Text Link to Item
-
Sampson, John H., Gary Archer, Christoph Pedain, Eva Wembacher-Schröder, Manfred Westphal, Sandeep Kunwar, Michael A. Vogelbaum, et al. “Poor drug distribution as a possible explanation for the results of the PRECISE trial.” J Neurosurg 113, no. 2 (August 2010): 301–9. https://doi.org/10.3171/2009.11.JNS091052.Full Text Link to Item
-
Toshimitsu, Hiroaki, Yasunori Yoshimoto, Christina K. Augustine, James C. Padussis, Jin S. Yoo, M. Angelica Selim, Scott K. Pruitt, Henry S. Friedman, Francis Ali-Osman, and Douglas S. Tyler. “Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma.” Ann Surg Oncol 17, no. 8 (August 2010): 2247–54. https://doi.org/10.1245/s10434-010-0971-x.Full Text Link to Item
-
Friedman, H. S. “Bevacizumab-irinotecan data hold up in recurrent GBM: Comment.” Oncology Report, no. JULY-AUGUST (July 1, 2010): 4.
-
Friedman, H. S. “Novel electric fields device may offer alternative to chemotherapy: Comment.” Oncology Report, no. JULY-AUGUST (July 1, 2010): 5.
-
Aliabadi, Hamidreza, James J. Vredenburgh, Richard G. Everson, Annick Desjardins, Henry S. Friedman, Roger E. McLendon, Debara L. Tucci, and John H. Sampson. “Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration.” J Neurooncol 98, no. 3 (July 2010): 427–30. https://doi.org/10.1007/s11060-009-0091-2.Full Text Link to Item
-
Gururangan, Sridharan, Susan N. Chi, Tina Young Poussaint, Arzu Onar-Thomas, Richard J. Gilbertson, Sridhar Vajapeyam, Henry S. Friedman, et al. “Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.” J Clin Oncol 28, no. 18 (June 20, 2010): 3069–75. https://doi.org/10.1200/JCO.2009.26.8789.Full Text Link to Item
-
Cloughesy, T., J. J. Vredenburgh, B. Day, A. Das, and H. S. Friedman. “Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study.” Journal of Clinical Oncology 28, no. 15 (May 20, 2010).Link to Item
-
Desjardins, A., J. J. Vredenburgh, D. A. Reardon, J. E. Herndon, J. Marcello, K. Peters, S. Gururangan, S. Sathornsumetee, J. N. Rich, and H. S. Friedman. “Long-term survival from the initial trial of bevacizumab and irinotecan.” Journal of Clinical Oncology 28, no. 15 (May 20, 2010).Link to Item
-
Brickhouse, A., J. J. Vredenburgh, S. Gururangan, D. A. Reardon, A. Desjardins, K. Peters, J. E. Herndon, J. Norfleet, J. Marcello, and H. S. Friedman. “Phase I trial of vandetanib and oral etoposide (VP-16) for recurrent malignant gliomas (MG).” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 2038–2038. https://doi.org/10.1200/jco.2010.28.15_suppl.2038.Full Text
-
Gururangan, S., J. J. Vredenburgh, A. Desjardins, K. Peters, J. E. Herndon, R. E. McLendon, D. Janney, H. S. Friedman, and D. A. Reardon. “CYP3A-inducing antiepileptics decrease sorafenib exposures: Results of a phase II study in adults with recurrent glioblastoma.” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 2089–2089. https://doi.org/10.1200/jco.2010.28.15_suppl.2089.Full Text
-
Kirkpatrick, J., J. J. Vredenburgh, D. A. Reardon, A. Desjardins, K. Peters, S. Gururangan, J. E. Herndon, J. Marcello, S. Woodring, and H. S. Friedman. “Phase I trial of the addition of oral topotecan to standard 5-day temozolomide for malignant gliomas.” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 2073–2073. https://doi.org/10.1200/jco.2010.28.15_suppl.2073.Full Text
-
Peters, K., A. Desjardins, J. J. Vredenburgh, B. Dryman, S. Gururangan, H. S. Friedman, and D. A. Reardon. “Imatinib mesylate plus hydroxyurea for adults with recurrent/progressive low-grade glioma: Final phase II study results.” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 2060–2060. https://doi.org/10.1200/jco.2010.28.15_suppl.2060.Full Text
-
Sathornsumetee, S., A. Desjardins, J. J. Vredenburgh, R. E. McLendon, J. Marcello, J. E. Herndon, J. Norfleet, S. Gururangan, H. S. Friedman, and D. A. Reardon. “Phase II trial of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: Final results.” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 2055–2055. https://doi.org/10.1200/jco.2010.28.15_suppl.2055.Full Text
-
Vredenburgh, J. J., A. Desjardins, D. A. Reardon, K. Peters, J. Kirkpatrick, J. E. Herndon, J. Marcello, L. Bailey, S. Threatt, and H. S. Friedman. “Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM).” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 2023–2023. https://doi.org/10.1200/jco.2010.28.15_suppl.2023.Full Text
-
Friedman, H. S., M. D. Prados, P. Y. Wen, T. Mikkelsen, D. Schiff, L. E. Abrey, W. K. A. Yung, et al. “Reply to W. Wick et al.” Journal of Clinical Oncology 28, no. 12 (April 20, 2010). https://doi.org/10.1200/JCO.2009.26.9472.Full Text
-
Augustine, Christina K., Sin-Ho Jung, Insuk Sohn, Jin Soo Yoo, Yasunori Yoshimoto, John A. Olson, Henry S. Friedman, Francis Ali-Osman, and Douglas S. Tyler. “Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma.” Mol Cancer Ther 9, no. 4 (April 2010): 779–90. https://doi.org/10.1158/1535-7163.MCT-09-0764.Full Text Link to Item
-
Jones, Lee W., Allan H. Friedman, Miranda J. West, Stephanie K. Mabe, Jennifer Fraser, William E. Kraus, Henry S. Friedman, Maura I. Tresch, Nancy Major, and David A. Reardon. “Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma.” Cancer 116, no. 3 (February 1, 2010): 695–704. https://doi.org/10.1002/cncr.24808.Full Text Link to Item
-
Jones, Lee W., Marina Mourtzakis, Katherine B. Peters, Allan H. Friedman, Miranda J. West, Stephanie K. Mabe, William E. Kraus, Henry S. Friedman, and David A. Reardon. “Changes in functional performance measures in adults undergoing chemoradiation for primary malignant glioma: a feasibility study.” Oncologist 15, no. 6 (2010): 636–47. https://doi.org/10.1634/theoncologist.2009-0265.Full Text Link to Item
-
Reardon, David A., Annick Desjardins, James J. Vredenburgh, Sridharan Gururangan, Allan H. Friedman, James E. Herndon, Jennifer Marcello, et al. “Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.” J Neurooncol 96, no. 2 (January 2010): 219–30. https://doi.org/10.1007/s11060-009-9950-0.Full Text Link to Item
-
Vredenburgh, James J., Timothy Cloughesy, Meghna Samant, Michael Prados, Patrick Y. Wen, Tom Mikkelsen, David Schiff, et al. “Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.” Oncologist 15, no. 12 (2010): 1329–34. https://doi.org/10.1634/theoncologist.2010-0105.Full Text Link to Item
-
Reardon, D. A., A. Desjardins, J. J. Vredenburgh, S. Gururangan, J. H. Sampson, S. Sathornsumetee, R. E. McLendon, et al. “Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.” Br J Cancer 101, no. 12 (December 15, 2009): 1986–94. https://doi.org/10.1038/sj.bjc.6605412.Full Text Open Access Copy Link to Item
-
Quinn, Jennifer A., Sara Xiaoyin Jiang, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Allan H. Friedman, John H. Sampson, Roger E. McLendon, James E. Herndon, and Henry S. Friedman. “Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.” J Neurooncol 95, no. 3 (December 2009): 393–400. https://doi.org/10.1007/s11060-009-9937-x.Full Text Link to Item
-
Sampson, John H., Gary E. Archer, Duane A. Mitchell, Amy B. Heimberger, James E. Herndon, Denise Lally-Goss, Sharon McGehee-Norman, et al. “An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.” Mol Cancer Ther 8, no. 10 (October 2009): 2773–79. https://doi.org/10.1158/1535-7163.MCT-09-0124.Full Text Link to Item
-
Bektas, Meryem, Stewart P. Johnson, William E. Poe, Darell D. Bigner, and Henry S. Friedman. “A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells.” Cancer Chemother Pharmacol 64, no. 5 (October 2009): 1053–58. https://doi.org/10.1007/s00280-009-1063-0.Full Text Link to Item
-
Friedman, Henry S., Michael D. Prados, Patrick Y. Wen, Tom Mikkelsen, David Schiff, Lauren E. Abrey, WK Alfred Yung, et al. “Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.” J Clin Oncol 27, no. 28 (October 1, 2009): 4733–40. https://doi.org/10.1200/JCO.2008.19.8721.Full Text Link to Item
-
Perry, Stephanie L., Cindy Bohlin, David A. Reardon, Annick Desjardins, Allan H. Friedman, Henry S. Friedman, and James J. Vredenburgh. “Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients.” J Neurooncol 95, no. 1 (October 2009): 129–34. https://doi.org/10.1007/s11060-009-9911-7.Full Text Link to Item
-
Quinn, Jennifer A., Sara Xiaoyin Jiang, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Jeremy N. Rich, Sridharan Gururangan, et al. “Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.” Neuro Oncol 11, no. 5 (October 2009): 556–61. https://doi.org/10.1215/15228517-2009-007.Full Text Link to Item
-
Friedman, H. S. “Bevacizumab, chemotherapy, and RT delay progression: Commentary.” Oncology Report, no. FALL (September 1, 2009): 6.
-
Affronti, Mary Lou, Christopher R. Heery, James E. Herndon, Jeremy N. Rich, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Allan H. Friedman, Darell D. Bigner, and Henry S. Friedman. “Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.” Cancer 115, no. 15 (August 1, 2009): 3501–11. https://doi.org/10.1002/cncr.24398.Full Text Link to Item
-
Jones, Lee W., Rachel-Rose Cohen, Stephanie K. Mabe, Miranda J. West, Annick Desjardins, James J. Vredenburgh, Allan H. Friedman, David A. Reardon, Emily Waner, and Henry S. Friedman. “Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing.” J Neurooncol 94, no. 1 (August 2009): 79–85. https://doi.org/10.1007/s11060-009-9803-x.Full Text Link to Item
-
Quinn, Jennifer A., Sara Xiaoyin Jiang, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon, and Henry S. Friedman. “Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.” Cancer 115, no. 13 (July 1, 2009): 2964–70. https://doi.org/10.1002/cncr.24336.Full Text Link to Item
-
Okamura, Tatsunori, Simendra Singh, John Buolamwini, Timothy Haystead, Henry Friedman, Darell Bigner, and Francis Ali-Osman. “Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor.” J Biol Chem 284, no. 25 (June 19, 2009): 16979–89. https://doi.org/10.1074/jbc.M808153200.Full Text Link to Item
-
Cui, B., S. P. Johnson, N. Bullock, F. Ali-Osman, D. D. Bigner, and H. S. Friedman. “Bifunctional DNA alkylator 1,3-bis(2-chloroethyl)-1-nitrosourea activates the ATR-Chk1 pathway independently of the mismatch repair pathway.” Mol Pharmacol 75, no. 6 (June 2009): 1356–63. https://doi.org/10.1124/mol.108.053124.Full Text Link to Item
-
Friedman, H. S., J. J. Vredenburgh, A. Desjardins, D. E. Janney, K. B. Peters, A. H. Friedman, S. Gururangan, and D. A. Reardon. “A phase I study of sunitinib plus irinotecan in the treatment of patients with recurrent malignant glioma.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): e13024.Link to Item
-
Heimberger, A. B., G. E. Archer, D. A. Mitchell, D. D. Bigner, R. J. Schmittling, J. E. Herndon, T. Davis, et al. “Epidermal growth factor receptor variant III (EGFRvIII) vaccine (CDX-110) in GBM.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 2021.Link to Item
-
Herndon, J., J. Vredenburgh, D. Reardon, A. Desjardins, K. Peters, S. Gururangan, J. Norfleet, A. Friedman, D. Bigner, and H. S. Friedman. “Phase I trial of vendetanib and oral etoposide for recurrent malignant gliomas.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): e13016.Link to Item
-
Kirkpatrick, J. P., J. J. Vredenburgh, A. Desjardins, S. Gururangan, K. B. Peters, S. T. Boulton, A. H. Friedman, H. S. Friedman, and D. A. Reardon. “Phase I study of vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): e13007.Link to Item
-
Paldino, M., A. Desjardins, H. S. Friedman, J. J. Vredenburgh, and D. P. Barboriak. “Prognostic significance of early changes in the apparent diffusion coefficient that occurs after treatment of patients with glioblastoma multiforme with bevacizumab.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 2058.Link to Item
-
Peters, K., A. Desjardins, D. A. Reardon, S. Perry, J. E. Herndon, L. Bailey, A. H. Friedman, H. S. Friedman, D. D. Bigner, and J. J. Vredenburgh. “Temozolomide (TMZ) and bevacizumab (BV) as initial treatment for unresectable or multifocal glioblastoma multiforme (GBM).” J Clin Oncol 27, no. 15_suppl (May 20, 2009): e13025.Link to Item
-
Sampson, J. H., G. E. Archer, D. D. Bigner, R. J. Schmittling, J. E. Herndon, T. Davis, H. S. Friedman, T. Keler, D. A. Reardon, and D. A. Mitchell. “Effect of daclizumab on TReg counts and EGFRvIII-specific immune responses in GBM.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 2034.Link to Item
-
Sathornsumetee, S., A. Desjardins, J. J. Vredenburgh, J. N. Rich, S. Gururangan, A. H. Friedman, H. S. Friedman, and D. A. Reardon. “Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 2045.Link to Item
-
Vredenburgh, J. J., A. Desjardins, D. A. Reardon, K. Peters, J. E. Herndon, J. Kirkpatrick, S. Gururangan, L. Bailey, A. H. Friedman, and H. S. Friedman. “Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM).” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 2015.Link to Item
-
Wefel, J. S., T. Cloughesy, J. Zazzali, J. Yi, H. S. Friedman, and H. S. BRAIN Investigators. “Neurocognitive function in patients with glioblastoma multiforme in first or second relapse treated with bevacizumab in the BRAIN study.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 2056.Link to Item
-
Reardon, David A., Merrill J. Egorin, Annick Desjardins, James J. Vredenburgh, Jan H. Beumer, Theodore F. Lagattuta, Sridharan Gururangan, James E. Herndon, August J. Salvado, and Henry S. Friedman. “Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.” Cancer 115, no. 10 (May 15, 2009): 2188–98. https://doi.org/10.1002/cncr.24213.Full Text Link to Item
-
Paldino, Michael J., Daniel Barboriak, Annick Desjardins, Henry S. Friedman, and James J. Vredenburgh. “Repeatability of quantitative parameters derived from diffusion tensor imaging in patients with glioblastoma multiforme.” J Magn Reson Imaging 29, no. 5 (May 2009): 1199–1205. https://doi.org/10.1002/jmri.21732.Full Text Link to Item
-
Archer, Gary E., Amy B. Heimberger, Darell D. Bigner, Tom Davis, Henry S. Friedman, Tibor Keler, Roger E. McLendon, et al. “INDUCTION OF IMMUNOLOGIC AND CLINICAL RESPONSES WITH EGFRVIII-TARGETED VACCINE (CDX-110) WITH CYCLES OF TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED EGFRVIII-POSITIVE GBM.” Neuro Oncology 11, no. 2 (April 1, 2009): 224–224.Link to Item
-
Okamura, Tatsunori, Simendrah Singh, John K. Buolamwini, Henry S. Friedman, Darell D. Bigner, and Francis Ali-Osman. “EGF RECEPTOR TYROSINE KINASE MEDIATES A NOVEL PATHWAY OF DRUG RESISTANCE IN MALIGNANT GLIOMAS VIA TYROSINE PHOSPHORYLATION AND FUNCTIONAL ACTIVATION OF GLUTATHIONE S-TRANSFERASE P1.” Neuro Oncology 11, no. 2 (April 1, 2009): 218–218.Link to Item
-
Reardon, David A., Sith Sathornsumetee, James J. Vredenburgh, Jeremy N. Rich, Annick Desjardins, Jennifer A. Quinn, Alyssa Mathe, Sridharan Gururangan, Allen H. Friedman, and Henry S. Friedman. “PHASE II STUDY OF BEVACIZUMAB AND ERLOTINIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME.” Neuro Oncology 11, no. 2 (April 1, 2009): 231–231.Link to Item
-
Ashley, D. M., C. D. Riffkin, M. M. Lovric, T. Mikeska, A. Dobrovic, J. A. Maxwell, H. S. Friedman, et al. “In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs (British Journal of Cancer (2008) 99, (294-304) DOI: 10.1038/sj.bjc.6604459).” British Journal of Cancer 100, no. 6 (March 24, 2009): 1012. https://doi.org/10.1038/sj.bjc.6604990.Full Text
-
Quinn, Jennifer A., Sara Xiaoyin Jiang, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Jeremy N. Rich, Sridharan Gururangan, et al. “Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.” J Clin Oncol 27, no. 8 (March 10, 2009): 1262–67. https://doi.org/10.1200/JCO.2008.18.8417.Full Text Link to Item
-
Bacolod, Manny D., Randy Fehdrau, Stewart P. Johnson, Nancy S. Bullock, Darell D. Bigner, Michael Colvin, and Henry S. Friedman. “BCNU-sequestration by metallothioneins may contribute to resistance in a medulloblastoma cell line.” Cancer Chemother Pharmacol 63, no. 4 (March 2009): 753–58. https://doi.org/10.1007/s00280-008-0792-9.Full Text Link to Item
-
Yan, Hai, D Williams Parsons, Genglin Jin, Roger McLendon, B Ahmed Rasheed, Weishi Yuan, Ivan Kos, et al. “IDH1 and IDH2 mutations in gliomas.” N Engl J Med 360, no. 8 (February 19, 2009): 765–73. https://doi.org/10.1056/NEJMoa0808710.Full Text Link to Item
-
Younis, Islam R., Samuel Malone, Henry S. Friedman, Larry J. Schaaf, and William P. Petros. “Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma.” Cancer Chemother Pharmacol 63, no. 3 (February 2009): 517–24. https://doi.org/10.1007/s00280-008-0769-8.Full Text Link to Item
-
Kieran, Mark W., Jeffrey G. Supko, Dana Wallace, Robert Fruscio, Tina Young Poussaint, Peter Phillips, Ian Pollack, et al. “Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors.” Pediatr Blood Cancer 52, no. 2 (February 2009): 169–76. https://doi.org/10.1002/pbc.21873.Full Text Link to Item
-
Quinn, Jennifer A., Sara Xiaoyin Jiang, James Carter, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Jeremy N. Rich, et al. “Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.” Clin Cancer Res 15, no. 3 (February 1, 2009): 1064–68. https://doi.org/10.1158/1078-0432.CCR-08-2130.Full Text Link to Item
-
Vredenburgh, James J., Annick Desjardins, David A. Reardon, and Henry S. Friedman. “Experience with irinotecan for the treatment of malignant glioma.” Neuro Oncol 11, no. 1 (February 2009): 80–91. https://doi.org/10.1215/15228517-2008-075.Full Text Link to Item
-
Augustine, Christina K., Jin Soo Yoo, Anil Potti, Yasunori Yoshimoto, Patricia A. Zipfel, Henry S. Friedman, Joseph R. Nevins, Francis Ali-Osman, and Douglas S. Tyler. “Genomic and molecular profiling predicts response to temozolomide in melanoma.” Clin Cancer Res 15, no. 2 (January 15, 2009): 502–10. https://doi.org/10.1158/1078-0432.CCR-08-1916.Full Text Link to Item
-
Keir, S. T., M. M. Farland, E. S. Lipp, and H. S. Friedman. “Family appraisal of caregiving in a brain cancer model.” Journal of Hospice and Palliative Nursing 11, no. 1 (January 1, 2009): 60–66. https://doi.org/10.1097/NJH.0b013e3181917e35.Full Text
-
Keir, Stephen T., Margaret M. Farland, Eric S. Lipp, and Henry S. Friedman. “Distress persists in long-term brain tumor survivors with glioblastoma multiforme.” J Cancer Surviv 2, no. 4 (December 2008): 269–74. https://doi.org/10.1007/s11764-008-0069-7.Full Text Link to Item
-
Schmittling, Robert J., Gary E. Archer, Duane A. Mitchell, Amy Heimberger, Charles Pegram, James E. Herndon, Henry S. Friedman, Darell D. Bigner, and John H. Sampson. “Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.” J Immunol Methods 339, no. 1 (November 30, 2008): 74–81. https://doi.org/10.1016/j.jim.2008.08.004.Full Text Link to Item
-
Vredenburgh, J. J., J. N. Rich, D. A. Reardon, A. Desjardins, and H. S. Friedman. “In reply.” Journal of Clinical Oncology 26, no. 32 (November 10, 2008): 5305. https://doi.org/10.1200/JCO.2008.18.0372.Full Text
-
Desjardins, Annick, David A. Reardon, James E. Herndon, Jennifer Marcello, Jennifer A. Quinn, Jeremy N. Rich, Sith Sathornsumetee, et al. “Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.” Clin Cancer Res 14, no. 21 (November 1, 2008): 7068–73. https://doi.org/10.1158/1078-0432.CCR-08-0260.Full Text Link to Item
-
Kadota, Richard P., Donald H. Mahoney, John Doyle, Reggie Duerst, Henry Friedman, Emi Holmes, Larry Kun, Tianni Zhou, and Ian F. Pollack. “Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma.” Pediatr Blood Cancer 51, no. 5 (November 2008): 675–78. https://doi.org/10.1002/pbc.21655.Full Text Link to Item
-
Gururangan, Sridharan, Jeanne Krauser, Melody A. Watral, Tim Driscoll, Nicole Larrier, David A. Reardon, Jeremy N. Rich, et al. “Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma.” Neuro Oncol 10, no. 5 (October 2008): 745–51. https://doi.org/10.1215/15228517-2008-044.Full Text Link to Item
-
Friedman, H. S. “Bevacizumab drove 6-month survival in glioblastoma: Commentary.” Oncology Report, no. FALL (September 1, 2008): 9.
-
Friedman, H. S. “Blocking p-STAT-3 restored in vitro T-cell function in glioblastoma: Commentary.” Oncology Report, no. FALL (September 1, 2008): 11.
-
Maxwell, Jill A., Stewart P. Johnson, Roger E. McLendon, David W. Lister, Krystle S. Horne, Ahmed Rasheed, Jennifer A. Quinn, et al. “Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.” Clin Cancer Res 14, no. 15 (August 1, 2008): 4859–68. https://doi.org/10.1158/1078-0432.CCR-07-4807.Full Text Link to Item
-
Ashley, D. M., C. D. Riffkin, M. M. Lovric, T. Mikeska, A. Dobrovic, J. A. Maxwell, H. S. Friedman, et al. “In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.” Br J Cancer 99, no. 2 (July 22, 2008): 294–304. https://doi.org/10.1038/sj.bjc.6604459.Full Text Link to Item
-
Neale, Geoffrey, Xiaoping Su, Christopher L. Morton, Doris Phelps, Richard Gorlick, Richard B. Lock, C Patrick Reynolds, et al. “Molecular characterization of the pediatric preclinical testing panel.” Clin Cancer Res 14, no. 14 (July 15, 2008): 4572–83. https://doi.org/10.1158/1078-0432.CCR-07-5090.Full Text Link to Item
-
Keir, Stephen T., Roberta D. Calhoun-Eagan, Jonas J. Swartz, Oussama A. Saleh, and Henry S. Friedman. “Screening for distress in patients with brain cancer using the NCCN's rapid screening measure.” Psychooncology 17, no. 6 (June 2008): 621–25. https://doi.org/10.1002/pon.1271.Full Text Link to Item
-
Reardon, David A., Annick Desjardins, James J. Vredenburgh, Sith Sathornsumetee, Jeremy N. Rich, Jennifer A. Quinn, Theodore F. Lagattuta, et al. “Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.” Neuro Oncol 10, no. 3 (June 2008): 330–40. https://doi.org/10.1215/15228517-2008-003.Full Text Link to Item
-
Sampson, John H., Gamal Akabani, Gerald E. Archer, Mitchel S. Berger, R Edward Coleman, Allan H. Friedman, Henry S. Friedman, et al. “Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.” Neuro Oncol 10, no. 3 (June 2008): 320–29. https://doi.org/10.1215/15228517-2008-012.Full Text Link to Item
-
Kirkpatrick, J. P., J. N. Rich, J. J. Vredenburgh, A. Desjardins, J. A. Quinn, S. Gururangan, S. Sathornsumetee, M. J. Egorin, H. S. Friedman, and D. A. Reardon. “Final report: Phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG).” J Clin Oncol 26, no. 15_suppl (May 20, 2008): 2057.Link to Item
-
Kirkpatrick, J. P., J. N. Rich, J. J. Vredenburgh, A. Desjardins, J. A. Quinn, S. Gururangan, S. Sathornsumetee, M. J. Egorin, H. S. Friedman, and D. A. Reardon. “Final report: Phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG).” Journal of Clinical Oncology 26, no. 15 (May 20, 2008).Link to Item
-
Mitchell, D., G. E. Archer, D. D. Bigner, H. S. Friedman, D. Lally-Goss, J. E. Herndon, S. McGehee, R. McLendon, D. A. Reardon, and J. H. Sampson. “Efficacy of a phase II vaccine targeting Cytomegalovirus antigens in newly diagnosed GBM.” Journal of Clinical Oncology 26, no. 15 (May 20, 2008).Link to Item
-
Rich, J. N., A. Desjardins, S. Sathornsumetee, J. J. Vredenburgh, J. A. Quinn, S. Gururangan, A. H. Friedman, H. S. Friedman, and D. A. Reardon. “Phase II study of bevacizumab and etoposide in patients with recurrent malignant glioma.” Journal of Clinical Oncology 26, no. 15 (May 20, 2008).Link to Item
-
Sathornsumetee, S., J. J. Vredenburgh, J. N. Rich, A. Desjardins, J. A. Quinn, A. E. Mathe, S. Gururangan, A. H. Friedman, H. S. Friedman, and D. A. Reardon. “Phase II study of bevacizumab and erlotinib in patients with recurrent glioblastoma multiforme.” Journal of Clinical Oncology 26, no. 15 (May 20, 2008).Link to Item
-
Cloughesy, T. F., M. D. Prados, P. Y. Wen, T. Mikkelsen, L. E. Abrey, D. Schiff, W. K. Yung, Z. Maoxia, I. Dimery, and H. S. Friedman. “A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM).” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 2010b-2010b. https://doi.org/10.1200/jco.2008.26.15_suppl.2010b.Full Text
-
Desjardins, A., D. P. Barboriak, J. E. Herndon, J. Marcello, D. A. Reardon, J. A. Quinn, J. N. Rich, S. Sathornsumetee, H. S. Friedman, and J. J. Vredenburgh. “Effect of bevacizumab (BEV) and irinotecan (CPT-11) on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in glioblastoma (GBM) patients.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 2026–2026. https://doi.org/10.1200/jco.2008.26.15_suppl.2026.Full Text
-
Friedman, H. S., A. Desjardins, J. J. Vredenburgh, J. N. Rich, S. Sathornsumetee, S. Gururangan, J. A. Quinn, and D. A. Reardon. “Phase II trial of erlotinib plus sirolimus for recurrent glioblastoma multiforme (GBM).” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 2062–2062. https://doi.org/10.1200/jco.2008.26.15_suppl.2062.Full Text
-
Maron, R., J. J. Vredenburgh, A. Desjardins, D. A. Reardon, J. A. Quinn, J. N. Rich, S. Gururangan, S. A. Wagner, M. E. Salacz, and H. S. Friedman. “Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM).” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 2074–2074. https://doi.org/10.1200/jco.2008.26.15_suppl.2074.Full Text
-
Quinn, J. A., X. S. Jiang, J. N. Rich, A. Desjardins, J. J. Vredenburgh, D. A. Reardon, S. Gururangan, et al. “Phase I trial of temozolomide plus O6-benzylguanine on three different 5-day temozolomide regimens for patients with progressive glioblastoma multiforme.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 2084–2084. https://doi.org/10.1200/jco.2008.26.15_suppl.2084.Full Text
-
Salacz, M. E., A. Desjardins, J. A. Quinn, J. N. Rich, J. J. Vredenburgh, S. Sathornsumetee, K. Goli, H. S. Friedman, and D. A. Reardon. “Treatment of adults with recurrent progressive low-grade glioma using imatinib mesylate and hydroxyurea.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 2071–2071. https://doi.org/10.1200/jco.2008.26.15_suppl.2071.Full Text
-
Sampson, J. H., G. E. Archer, D. D. Bigner, T. Davis, H. S. Friedman, T. Keler, D. A. Mitchell, D. A. Reardon, R. Sawaya, and A. B. Heimberger. “Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 2011–2011. https://doi.org/10.1200/jco.2008.26.15_suppl.2011.Full Text
-
Wagner, S. A., A. Desjardins, D. A. Reardon, J. Marcello, J. E. Herndon, J. A. Quinn, J. N. Rich, S. Sathornsumetee, H. S. Friedman, and J. J. Vredenburgh. “Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 2021–2021. https://doi.org/10.1200/jco.2008.26.15_suppl.2021.Full Text
-
Bacolod, M. D., S. M. Lin, S. P. Johnson, N. S. Bullock, M. Colvin, D. D. Bigner, and H. S. Friedman. “The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide.” Curr Cancer Drug Targets 8, no. 3 (May 2008): 172–79. https://doi.org/10.2174/156800908784293631.Full Text Link to Item
-
Everson, Richard G., Michael W. Graner, Matthias Gromeier, James J. Vredenburgh, Annick Desjardins, David A. Reardon, Henry S. Friedman, Allan H. Friedman, Darell D. Bigner, and John H. Sampson. “Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.” Expert Rev Anticancer Ther 8, no. 5 (May 2008): 717–32. https://doi.org/10.1586/14737140.8.5.717.Full Text Link to Item
-
Reardon, David A., Michael R. Zalutsky, Gamal Akabani, R Edward Coleman, Allan H. Friedman, James E. Herndon, Roger E. McLendon, et al. “A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.” Neuro Oncol 10, no. 2 (April 2008): 182–89. https://doi.org/10.1215/15228517-2007-053.Full Text Link to Item
-
Vredenburgh, J. J., A. Desjardins, D. A. Reardon, and H. S. Friedman. “In reply.” Journal of Clinical Oncology 26, no. 6 (February 20, 2008): 1013. https://doi.org/10.1200/JCO.2007.15.1746.Full Text
-
Gururangan, Sridharan, Christopher D. Turner, Clinton F. Stewart, Melinda O’Shaughnessy, Mehmet Kocak, Tina Young Poussaint, Peter C. Phillips, et al. “Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study.” Clin Cancer Res 14, no. 4 (February 15, 2008): 1124–30. https://doi.org/10.1158/1078-0432.CCR-07-4242.Full Text Link to Item
-
Gururangan, Sridharan, Wendy Frankel, Russell Broaddus, Mark Clendenning, Leigha Senter, Marie McDonald, James Eastwood, et al. “Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation.” Neuro Oncol 10, no. 1 (February 2008): 93–97. https://doi.org/10.1215/15228517-2007-037.Full Text Link to Item
-
Sathornsumetee, Sith, Yiting Cao, Jennifer E. Marcello, James E. Herndon, Roger E. McLendon, Annick Desjardins, Henry S. Friedman, Mark W. Dewhirst, James J. Vredenburgh, and Jeremy N. Rich. “Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.” J Clin Oncol 26, no. 2 (January 10, 2008): 271–78. https://doi.org/10.1200/JCO.2007.13.3652.Full Text Link to Item
-
Zalutsky, Michael R., David A. Reardon, Gamal Akabani, R Edward Coleman, Allan H. Friedman, Henry S. Friedman, Roger E. McLendon, Terence Z. Wong, and Darell D. Bigner. “Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.” J Nucl Med 49, no. 1 (January 2008): 30–38. https://doi.org/10.2967/jnumed.107.046938.Full Text Link to Item
-
Houghton, Peter J., John M. Maris, Henry S. Friedman, Stephen T. Keir, Richard B. Lock, Hernan Carol, Richard Gorlick, et al. “Pediatric preclinical testing program (PPTP) evaluation of the fully human anti-IGF-1R antibody SCH 717454.” Molecular Cancer Therapeutics 6, no. 12 (December 1, 2007): 3405S-3405S.Link to Item
-
Houghton, Peter J., John M. Maris, Joshua Courtright, Henry S. Friedman, Stephen T. Keir, Richard B. Lock, Hernan Carol, et al. “Pediatric preclinical testing program (PPTP) evaluation of the EGFR and ErbB2 inhibitor lapatinib.” Molecular Cancer Therapeutics 6, no. 12 (December 1, 2007): 3471S-3471S.Link to Item
-
Keir, Stephen T., Jonas J. Swartz, and Henry S. Friedman. “Stress and long-term survivors of brain cancer.” Support Care Cancer 15, no. 12 (December 2007): 1423–28. https://doi.org/10.1007/s00520-007-0292-1.Full Text Link to Item
-
Houghton, Peter J., Christopher L. Morton, Chandra Tucker, Debbie Payne, Edward Favours, Claire Cole, Richard Gorlick, et al. “The pediatric preclinical testing program: description of models and early testing results.” Pediatr Blood Cancer 49, no. 7 (December 2007): 928–40. https://doi.org/10.1002/pbc.21078.Full Text Link to Item
-
Broniscer, Alberto, Sridharan Gururangan, Tobey J. MacDonald, Stewart Goldman, Roger J. Packer, Clinton F. Stewart, Dana Wallace, et al. “Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report.” Clin Cancer Res 13, no. 22 Pt 1 (November 15, 2007): 6712–18. https://doi.org/10.1158/1078-0432.CCR-07-1016.Full Text Link to Item
-
Johnson, Stewart P., Barton A. Kamen, Darell D. Bigner, and Henry S. Friedman. “O (4)-benzylfolic acid inactivates O (6)-alkylguanine-DNA alkyltransferase in brain tumor cell lines.” Cancer Chemother Pharmacol 60, no. 6 (November 2007): 883–89. https://doi.org/10.1007/s00280-007-0435-6.Full Text Link to Item
-
Vredenburgh, James J., Annick Desjardins, James E. Herndon, Jennifer Marcello, David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, et al. “Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.” J Clin Oncol 25, no. 30 (October 20, 2007): 4722–29. https://doi.org/10.1200/JCO.2007.12.2440.Full Text Link to Item
-
Kadota, Richard, D. H. Mahoney, J. Doyle, R. Duerst, H. S. Friedman, E. J. Holmes, L. E. Kun, T. Zhou, and I. E. Pollack. “Cyclophosphamide (CPM) and melphalan (MEL) for recurrent medulloblastoma (MB) and intracranial germinoma (GCT) - A Children's Oncology Group (COG) study.” Pediatric Blood & Cancer 49, no. 4 (October 1, 2007): 422–422. https://doi.org/10.1002/pbc.Full Text Link to Item
-
Nicholson, H Stacy, Cynthia S. Kretschmar, Mark Krailo, Mark Bernstein, Richard Kadota, Daniel Fort, Henry Friedman, et al. “Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.” Cancer 110, no. 7 (October 1, 2007): 1542–50. https://doi.org/10.1002/cncr.22961.Full Text Link to Item
-
Bota, Daniela A., Annick Desjardins, Jennifer A. Quinn, Mary L. Affronti, and Henry S. Friedman. “Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas.” Ther Clin Risk Manag 3, no. 5 (October 2007): 707–15.Link to Item
-
Friedman, H. S. “Dendritic cell vaccine shows promise in glioblastoma: Commentary.” Oncology Report, no. FALL (September 1, 2007): 11.
-
Friedman, H. S. “Motexafin gadolinium delays progression in NSCLC brain metastases: Commentary.” Oncology Report, no. FALL (September 1, 2007): 10.
-
Friedman, H. S. “Bevacizumab plus irinotecan stalls recurrent gliomas: Commentary.” Oncology Report, no. FALL (September 1, 2007): 9.
-
Friedman, H. S. “VEGF inhibitor cediranib active in recurrent glioblastoma: Commentary.” Oncology Report, no. FALL (September 1, 2007): 10.
-
Friedman, H. S. “Temozolomide and vaccination can work together to treat GBM: Commentary.” Oncology Report, no. FALL (September 1, 2007): 11.
-
Hjelmeland, Anita B., Kathryn P. Lattimore, Brian E. Fee, Qing Shi, Sarah Wickman, Stephen T. Keir, Mark D. Hjelmeland, et al. “The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion.” Mol Cancer Ther 6, no. 9 (September 2007): 2449–57. https://doi.org/10.1158/1535-7163.MCT-07-0155.Full Text Link to Item
-
Keir, S. T., J. J. Swartz, and H. S. Friedman. “Stress levels and sources of stress in an adult brain tumor population.” Psycho Oncology 16, no. 9 (September 1, 2007): S140–41.Link to Item
-
Friedman, Henry S., and Jill Maxwell. “The fallacy of single-agent chemotherapy for cancer.” J Clin Oncol 25, no. 23 (August 10, 2007): 3550. https://doi.org/10.1200/JCO.2007.12.3596.Full Text Link to Item
-
Badruddoja, Michael A., Stephen T. Keir, Ivan King, Joseph Zeidner, James J. Vredenburgh, Lawrence H. Muhlbaier, Darell D. Bigner, and Henry S. Friedman. “Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice.” Neuro Oncol 9, no. 3 (July 2007): 240–44. https://doi.org/10.1215/15228517-2007-011.Full Text Link to Item
-
Shi, Qing, Anita B. Hjelmeland, Stephen T. Keir, Linhua Song, Sarah Wickman, Dowdy Jackson, Osamu Ohmori, Darell D. Bigner, Henry S. Friedman, and Jeremy N. Rich. “A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.” Mol Carcinog 46, no. 6 (June 2007): 488–96. https://doi.org/10.1002/mc.20297.Full Text Link to Item
-
Yoshimoto, Yasunori, Christina K. Augustine, Jin S. Yoo, Patricia A. Zipfel, M Angelica Selim, Scott K. Pruitt, Henry S. Friedman, Francis Ali-Osman, and Douglas S. Tyler. “Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents.” Mol Cancer Ther 6, no. 5 (May 2007): 1492–1500. https://doi.org/10.1158/1535-7163.MCT-06-0718.Full Text Link to Item
-
Desjardins, Annick, Jennifer A. Quinn, James J. Vredenburgh, Sith Sathornsumetee, Allan H. Friedman, James E. Herndon, Roger E. McLendon, et al. “Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.” J Neurooncol 83, no. 1 (May 2007): 53–60. https://doi.org/10.1007/s11060-006-9302-2.Full Text Link to Item
-
McLendon, Roger E., Gamal Akabani, Henry S. Friedman, David A. Reardon, Linda Cleveland, Ilkcan Cokgor, James E. Herndon, et al. “Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.” Nucl Med Biol 34, no. 4 (May 2007): 405–13. https://doi.org/10.1016/j.nucmedbio.2007.01.009.Full Text Link to Item
-
Pollack, Ian F., Regina I. Jakacki, Susan M. Blaney, Michael L. Hancock, Mark W. Kieran, Peter Phillips, Larry E. Kun, et al. “Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report.” Neuro Oncol 9, no. 2 (April 2007): 145–60. https://doi.org/10.1215/15228517-2006-031.Full Text Link to Item
-
Gururangan, Sridharan, Michael J. Fisher, Jeffrey C. Allen, James E. Herndon, Jennifer A. Quinn, David A. Reardon, James J. Vredenburgh, et al. “Temozolomide in children with progressive low-grade glioma.” Neuro Oncol 9, no. 2 (April 2007): 161–68. https://doi.org/10.1215/15228517-2006-030.Full Text Link to Item
-
Jones, Lee W., Bebe Guill, Stephen T. Keir, Karen Carter, Henry S. Friedman, Darell D. Bigner, and David A. Reardon. “Using the theory of planned behavior to understand the determinants of exercise intention in patients diagnosed with primary brain cancer.” Psychooncology 16, no. 3 (March 2007): 232–40. https://doi.org/10.1002/pon.1077.Full Text Link to Item
-
Vredenburgh, James J., Annick Desjardins, James E. Herndon, Jeannette M. Dowell, David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, et al. “Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.” Clin Cancer Res 13, no. 4 (February 15, 2007): 1253–59. https://doi.org/10.1158/1078-0432.CCR-06-2309.Full Text Link to Item
-
Sampson, John H., Martin L. Brady, Neil A. Petry, David Croteau, Allan H. Friedman, Henry S. Friedman, Terence Wong, et al. “Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning.” Neurosurgery 60, no. 2 Suppl 1 (February 2007): ONS89–98. https://doi.org/10.1227/01.NEU.0000249256.09289.5F.Full Text Link to Item
-
Jones, Lee W., Bebe Guill, Stephen T. Keir, Karen Carter, Henry S. Friedman, Darell D. Bigner, and David A. Reardon. “Exercise interest and preferences among patients diagnosed with primary brain cancer.” Support Care Cancer 15, no. 1 (January 2007): 47–55. https://doi.org/10.1007/s00520-006-0096-8.Full Text Link to Item
-
Badruddoja, Michael A., Kara Penne, Annick Desjardins, David A. Reardon, Jeremy N. Rich, Jennifer A. Quinn, Sith Sathornsumetee, et al. “Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.” Neuro Oncol 9, no. 1 (January 2007): 70–74. https://doi.org/10.1215/15228517-2006-022.Full Text Link to Item
-
Keir, Stephen T., Ann Bebe Guill, Karen E. Carter, and Henry S. Friedman. “Stress and intervention preferences of patients with brain tumors.” Support Care Cancer 14, no. 12 (December 2006): 1213–19. https://doi.org/10.1007/s00520-006-0087-9.Full Text Link to Item
-
Keir, Stephen T., Ann Bebe Guill, Karen E. Carter, Lindsay C. Boole, Lazaro Gonzales, and Henry S. Friedman. “Differential levels of stress in caregivers of brain tumor patients--observations from a pilot study.” Support Care Cancer 14, no. 12 (December 2006): 1258–61. https://doi.org/10.1007/s00520-006-0090-1.Full Text Link to Item
-
Houghton, P. J., J. M. Maris, H. S. Friedman, S. T. Keir, R. B. Lock, R. Gorlick, E. A. Kolb, C. P. Reynolds, C. Morton, and M. A. Smith. “313 POSTER Pediatric preclinical testing program (PPTP) evaluation of the KSP inhibitor Ispinesib (SB-715992).” European Journal of Cancer Supplements 4, no. 12 (November 2006): 98–98. https://doi.org/10.1016/s1359-6349(06)70318-4.Full Text
-
Smith, M. A., J. M. Maris, S. T. Keir, H. S. Friedman, R. B. Lock, E. A. Kolb, N. Keshelava, C. P. Reynolds, C. Morton, and P. J. Houghton. “322 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the Src-Abl inhibitor dasatinib (BMS-354825).” European Journal of Cancer Supplements 4, no. 12 (November 2006): 101–101. https://doi.org/10.1016/s1359-6349(06)70327-5.Full Text
-
Maxwell, Jill A., Stewart P. Johnson, Jennifer A. Quinn, Roger E. McLendon, Francis Ali-Osman, Allan H. Friedman, James E. Herndon, et al. “Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma.” Mol Cancer Ther 5, no. 10 (October 2006): 2531–39. https://doi.org/10.1158/1535-7163.MCT-06-0106.Full Text Link to Item
-
Ochiai, Hidenobu, Chris T. Pernell, Gary E. Archer, Tracy A. Chewning, Roger E. McLendon, Henry S. Friedman, and John H. Sampson. “Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin.” Neurol Med Chir (Tokyo) 46, no. 10 (October 2006): 485–89. https://doi.org/10.2176/nmc.46.485.Full Text Link to Item
-
Friedman, H. S. “Spontaneous necrosis influences the accuracy of glioma grading: Comment.” Oncology Report, no. FALL (September 1, 2006): 13–14.
-
Friedman, H. S. “Bevacizumab-irinotecan combination shows activity in recurrent glioma: Comment.” Oncology Report, no. FALL (September 1, 2006): 11.
-
Friedman, H. S. “Chromosomal translocation confers favorable prognosis in brain tumors: Comment.” Oncology Report, no. FALL (September 1, 2006): 12–13.
-
Friedman, H. S. “Age, resection status fail to define risk in glioma: Comment.” Oncology Report, no. FALL (September 1, 2006): 14.
-
Friedman, H. S. “Modafinil improves neurocognitive function in brain tumor patients: Comment.” Oncology Report, no. FALL (September 1, 2006): 11–12.
-
Reardon, D. A., M. R. Zalutsky, G. Akabani, R. E. Coleman, A. H. Friedman, R. E. McLendon, H. S. Friedman, J. E. Herndon, J. Kirkpatrick, and D. D. Bigner. “Radioimmunotherapy of patients with malignant brain tumors: patient-specific dosing of I-131-labeled anti-tenacin antibody to achieve 44 Gy boost dose to resection cavity margins.” European Journal of Nuclear Medicine and Molecular Imaging 33 (September 1, 2006): S194–S194.Link to Item
-
Sathornsumetee, Sith, Anita B. Hjelmeland, Stephen T. Keir, Roger E. McLendon, David Batt, Timothy Ramsey, Naeem Yusuff, et al. “AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma.” Cancer Res 66, no. 17 (September 1, 2006): 8722–30. https://doi.org/10.1158/0008-5472.CAN-06-0284.Full Text Link to Item
-
Zalutsky, M. R., D. A. Reardon, J. A. Quinn, R. E. Coleman, G. Akabani, A. H. Friedman, H. S. Friedman, et al. “Chimeric murine/human IgG(2) anti-tenascin 81C6 monoclonal antibody: phase I trial in patients with malignant glioma of a construct with improved stability.” European Journal of Nuclear Medicine and Molecular Imaging 33 (September 1, 2006): S194–S194.Link to Item
-
Desjardins, A., D. A. Reardon, J. A. Quinn, J. N. Rich, J. J. Vredenburgh, S. Sathornsumetee, A. Salvado, and H. S. Friedman. “Phase II trial of imatinib mesylate and hydroxyurea for grade III malignant gliomas.” J Clin Oncol 24, no. 18_suppl (June 20, 2006): 1573.Link to Item
-
Heery, C. R., A. Desjardins, J. A. Quinn, J. N. Rich, S. Gururangan, J. J. Vredenburgh, A. H. Friedman, D. A. Reardon, and H. S. Friedman. “Acute toxicity analysis of patients receiving surgery, Gliadel wafer implantation, and postoperative daily temozolomide with radiation therapy for primary high-grade glioma.” J Clin Oncol 24, no. 18_suppl (June 20, 2006): 11504.Link to Item
-
Kirkpatrick, J., A. Desjardins, J. J. Vredenburgh, J. A. Quinn, J. N. Rich, S. Sathornsumetee, S. Gururangan, A. H. Friedman, H. S. Friedman, and D. A. Reardon. “Combination of bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and temozolomide: Study of cases.” J Clin Oncol 24, no. 18_suppl (June 20, 2006): 11522.Link to Item
-
Korones, D. N., M. Benita-Weiss, T. Coyle, P. Bushunow, L. Mechtler, and H. S. Friedman. “A phase II study of temozolomide and oral VP-16 for adults with recurrent glioma-Final results.” J Clin Oncol 24, no. 18_suppl (June 20, 2006): 1565.Link to Item
-
Quinn, J. A., J. J. Vredenburgh, J. N. Rich, D. A. Reardon, A. Desjardins, S. Gururangan, A. H. Friedman, et al. “Phase II trial of Gliadel plus O(6)-benzylguanine (O(6)-BG) for patients with recurrent glioblastoma multiforme.” J Clin Oncol 24, no. 18_suppl (June 20, 2006): 1568.Link to Item
-
Reardon, D., J. A. Quinn, J. N. Rich, J. J. Vredenburgh, A. Desjardins, S. Sathornsumetee, S. Gururangan, M. J. Egorin, A. Salvado, and H. S. Friedman. “A phase I trial of imatinib, hydroxyurea and RAD001 for patients with recurrent malignant glioma.” J Clin Oncol 24, no. 18_suppl (June 20, 2006): 1580.Link to Item
-
Rich, J. N., Q. Shi, A. B. Hjelmeland, S. T. Keir, S. Wickman, G. Wu, D. Jackson, O. Ohmori, D. D. Bigner, and H. S. Friedman. “A novel low molecular weight inhibitor of focal adhesion kinase and insulin-like growth factor-1 receptor, TAE226, inhibits glioma growth.” J Clin Oncol 24, no. 18_suppl (June 20, 2006): 11505.Link to Item
-
Sathornsumetee, S., D. A. Reardon, J. A. Quinn, J. N. Rich, J. J. Vredenburgh, A. Desjardins, S. Gururangan, M. Egorin, A. Salvado, and H. S. Friedman. “An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma.” J Clin Oncol 24, no. 18_suppl (June 20, 2006): 1560.Link to Item
-
Vredenburgh, J. J., A. Desjardins, J. E. Herndon, J. Quinn, J. Rich, S. Sathornsumetee, H. S. Friedman, D. Reardon, S. Gururangan, and A. Friedman. “Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas.” J Clin Oncol 24, no. 18_suppl (June 20, 2006): 1506.Link to Item
-
Vredenburgh, J. J., C. Bohlin, D. A. Reardon, A. Desjardins, J. Quinn, J. Rich, S. Sathornsumetee, L. B. Marks, A. H. Friedman, and H. S. Friedman. “Tinzaparin prophylaxis against thromboembolic complications in brain tumor patients.” J Clin Oncol 24, no. 18_suppl (June 20, 2006): 1539.Link to Item
-
Reardon, David A., Jennifer A. Quinn, Gamal Akabani, R Edward Coleman, Allan H. Friedman, Henry S. Friedman, James E. Herndon, et al. “Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.” J Nucl Med 47, no. 6 (June 2006): 912–18.Link to Item
-
Jones, Lee W., Bebe Guill, Stephen T. Keir, Karen Carter B S, Henry S. Friedman, Darrell D. Bigner, and David A. Reardon. “Patterns of exercise across the cancer trajectory in brain tumor patients.” Cancer 106, no. 10 (May 15, 2006): 2224–32. https://doi.org/10.1002/cncr.21858.Full Text Link to Item
-
Miralbell, Raymond, T. J. Fitzgerald, Fran Laurie, Sandy Kessel, Arvin Glicksman, Henry S. Friedman, Marcia Urie, et al. “Radiotherapy in pediatric medulloblastoma: quality assessment of Pediatric Oncology Group Trial 9031.” Int J Radiat Oncol Biol Phys 64, no. 5 (April 1, 2006): 1325–30. https://doi.org/10.1016/j.ijrobp.2005.11.002.Full Text Link to Item
-
Chintagumpala, Murali M., Henry S. Friedman, Clinton F. Stewart, James Kepner, Roger E. McLendon, Paul L. Modrich, Charles McCluggage, et al. “A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group.” J Neurooncol 77, no. 2 (April 2006): 193–98. https://doi.org/10.1007/s11060-005-9024-x.Full Text Link to Item
-
Gururangan, Sridharan, Colleen A. McLaughlin, James Brashears, Melody A. Watral, James Provenzale, R Edward Coleman, Edward C. Halperin, et al. “Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma.” J Neurooncol 77, no. 2 (April 2006): 207–12. https://doi.org/10.1007/s11060-005-9029-5.Full Text Link to Item
-
Shankar, Sriram, Michael R. Zalutsky, Henry Friedman, and Ganesan Vaidyanathan. “Molecular imaging of alkylguanine-DNA alkyltransferase: further evaluation of radioiodinated derivatives of O6-benzylguanine.” Nucl Med Biol 33, no. 3 (April 2006): 399–407. https://doi.org/10.1016/j.nucmedbio.2005.12.015.Full Text Link to Item
-
Reardon, David A., Jeremy N. Rich, Henry S. Friedman, and Darell D. Bigner. “Recent advances in the treatment of malignant astrocytoma.” J Clin Oncol 24, no. 8 (March 10, 2006): 1253–65. https://doi.org/10.1200/JCO.2005.04.5302.Full Text Link to Item
-
Gururangan, Sridharan, William P. Petros, Tina Young Poussaint, Michael L. Hancock, Peter C. Phillips, Henry S. Friedman, Lisa Bomgaars, Susan M. Blaney, Larry E. Kun, and James M. Boyett. “Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).” Clin Cancer Res 12, no. 5 (March 1, 2006): 1540–46. https://doi.org/10.1158/1078-0432.CCR-05-2094.Full Text Link to Item
-
Ueno, Tomio, Sae Hee Ko, Elizabeth Grubbs, Yasunori Yoshimoto, Christi Augustine, Zeinab Abdel-Wahab, Tsung-Yen Cheng, et al. “Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.” Mol Cancer Ther 5, no. 3 (March 2006): 732–38. https://doi.org/10.1158/1535-7163.MCT-05-0098.Full Text Link to Item
-
Keir, S. T., A. B. Guill, K. E. Carter, and H. S. Friedman. “Caregivers of brain tumor patients: Stress and intervention preferences.” Psycho Oncology 15, no. 1 (February 1, 2006): S52–S52.Link to Item
-
Keir, S. T., A. B. Guill, K. E. Carter, and H. S. Friedman. “Brain tumor patients: Stress and intervention preferences.” Psycho Oncology 15, no. 1 (February 1, 2006): S77–78.Link to Item
-
Keating, K. N., H. S. Friedman, and E. M. Perfetto. “Moxifloxacin versus levofloxacin for treatment of acute rhinosinusitis: a retrospective database analysis of treatment duration, outcomes, and charges.” Current Medical Research and Opinion 22, no. 2 (February 2006): 327–33.
-
Reardon, David A., Jennifer A. Quinn, James J. Vredenburgh, Sridharan Gururangan, Allan H. Friedman, Annick Desjardins, Sith Sathornsumetee, et al. “Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.” Clin Cancer Res 12, no. 3 Pt 1 (February 1, 2006): 860–68. https://doi.org/10.1158/1078-0432.CCR-05-2215.Full Text Link to Item
-
Ko, Sae Hee, Tomio Ueno, Yasunori Yoshimoto, Jin Soo Yoo, Omar I. Abdel-Wahab, Zeinab Abdel-Wahab, Edward Chu, et al. “Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity.” Clin Cancer Res 12, no. 1 (January 1, 2006): 289–97. https://doi.org/10.1158/1078-0432.CCR-05-0210.Full Text Link to Item
-
Reardon, David A., Gamal Akabani, R Edward Coleman, Allan H. Friedman, Henry S. Friedman, James E. Herndon, Roger E. McLendon, et al. “Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.” J Clin Oncol 24, no. 1 (January 1, 2006): 115–22. https://doi.org/10.1200/JCO.2005.03.4082.Full Text Link to Item
-
Vaidyanathan, G., D. J. Affleck, M. Schottelius, H. Wester, H. S. Friedman, and M. R. Zalutsky. “Synthesis and evaluation of glycosylated octreotate analogues labeled with radioiodine and 211At via a tin precursor.” Bioconjug Chem 17, no. 1 (2006): 195–203. https://doi.org/10.1021/bc0502560.Full Text Link to Item
-
Reardon, David A., Merrill J. Egorin, Jennifer A. Quinn, Jeremy N. Rich, Sridharan Gururangan, James J. Vredenburgh, Annick Desjardins, et al. “Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.” J Clin Oncol 23, no. 36 (December 20, 2005): 9359–68. https://doi.org/10.1200/JCO.2005.03.2185.Full Text Link to Item
-
Friedman, A. H., R. E. McLendon, J. N. Provenzale, and H. S. Friedman. “Ependymoma,” December 1, 2005, 190–98. https://doi.org/10.1016/B978-0-7216-8148-1.50028-0.Full Text
-
Rich, Jeremy N., Sith Sathornsumetee, Stephen T. Keir, Mark W. Kieran, Andrea Laforme, Arja Kaipainen, Roger E. McLendon, et al. “ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors.” Clin Cancer Res 11, no. 22 (November 15, 2005): 8145–57. https://doi.org/10.1158/1078-0432.CCR-05-0319.Full Text Link to Item
-
Friedman, Henry S., and Darell D. Bigner. “Glioblastoma multiforme and the epidermal growth factor receptor.” N Engl J Med 353, no. 19 (November 10, 2005): 1997–99. https://doi.org/10.1056/NEJMp058186.Full Text Link to Item
-
Martin, L. R., H. S. Friedman, K. M. Clark, and J. S. Tucker. “Longevity following the experience of parental divorce.” Social Science & Medicine 61, no. 10 (November 2005): 2177–89.
-
Greenberg, Mark L., Paul G. Fisher, Carolyn Freeman, David N. Korones, Mark Bernstein, Henry Friedman, Susan Blaney, et al. “Etoposide, vincristine, and cyclosporin A with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brainstem gliomas: a pediatric oncology group phase I study.” Pediatr Blood Cancer 45, no. 5 (October 15, 2005): 644–48. https://doi.org/10.1002/pbc.20382.Full Text Link to Item
-
McLendon, Roger E., James E. Herndon, Bryan West, David Reardon, Rodney Wiltshire, BK Ahmed Rasheed, Jennifer Quinn, Henry S. Friedman, Allan H. Friedman, and Darell D. Bigner. “Survival analysis of presumptive prognostic markers among oligodendrogliomas.” Cancer 104, no. 8 (October 15, 2005): 1693–99. https://doi.org/10.1002/cncr.21362.Full Text Link to Item
-
Quinn, Jennifer A., Annick Desjardins, Jon Weingart, Henry Brem, M Eileen Dolan, Shannon M. Delaney, James Vredenburgh, et al. “Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.” J Clin Oncol 23, no. 28 (October 1, 2005): 7178–87. https://doi.org/10.1200/JCO.2005.06.502.Full Text Link to Item
-
Reardon, David A., Jennifer A. Quinn, Jeremy N. Rich, Annick Desjardins, James Vredenburgh, Sridharan Gururangan, Sith Sathornsumetee, et al. “Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.” Cancer 104, no. 7 (October 1, 2005): 1478–86. https://doi.org/10.1002/cncr.21316.Full Text Link to Item
-
Cheng, C Lynn, Stewart P. Johnson, Stephen T. Keir, Jennifer A. Quinn, Francis Ali-Osman, Csaba Szabo, Hongshan Li, et al. “Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft.” Mol Cancer Ther 4, no. 9 (September 2005): 1364–68. https://doi.org/10.1158/1535-7163.MCT-05-0128.Full Text Link to Item
-
Friedman, H. S. “Can PFS predict overall survival. Comment.” Oncology Report, no. FALL (September 1, 2005): 14.
-
Friedman, H. S. “Peritumoral administration best way to deliver ILI3PE. Comment.” Oncology Report, no. FALL (September 1, 2005): 12.
-
Friedman, H. S. “Thalidomide does not improve survival. Comment.” Oncology Report, no. FALL (September 1, 2005): 14–15.
-
Desjardins, Annick, Jeremy N. Rich, Jennifer A. Quinn, James Vredenburgh, Sridharan Gururangan, Sith Sathornsumetee, David A. Reardon, Allan H. Friedman, Darell D. Bigner, and Henry S. Friedman. “Chemotherapy and novel therapeutic approaches in malignant glioma.” Front Biosci 10 (September 1, 2005): 2645–68. https://doi.org/10.2741/1727.Full Text Link to Item
-
Akabani, Gamal, David A. Reardon, R Edward Coleman, Terence Z. Wong, Scott D. Metzler, James E. Bowsher, Daniel P. Barboriak, et al. “Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.” J Nucl Med 46, no. 6 (June 2005): 1042–51.Link to Item
-
Friedman, H. S. “Radiation sensitizer shows promise in breast cancer patients with brain metastases.” Oncology Report, no. SPRING (March 1, 2005): 14–16.
-
Friedman, H. S. “'Encouraging news': Vaccine increases survival in phase I brain cancer trial.” Oncology Report, no. SPRING (March 1, 2005): 13–14.
-
Friedman, H. S. “Promising results in overcoming temozolomide resistance.” Oncology Report, no. SPRING (March 1, 2005): 12–13.
-
Friedman, H. S. “Adding temozolomide to radiation improves survival in patients with glioblastoma.” Oncology Report, no. SPRING (March 1, 2005): 11–12.
-
Friedman, H. S. “Carotid-artery stenting versus endarterectomy.” The New England Journal of Medicine 352, no. 6 (February 2005): 624–27.
-
Blaney, Susan M., James Boyett, Henry Friedman, Amar Gajjar, Russ Geyer, Marc Horowtiz, Daniel Hunt, et al. “Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001).” J Clin Oncol 23, no. 3 (January 20, 2005): 525–31. https://doi.org/10.1200/JCO.2005.06.544.Full Text Link to Item
-
Reardon, David A., Jennifer A. Quinn, James Vredenburgh, Jeremy N. Rich, Sridharan Gururangan, Michael Badruddoja, James E. Herndon, Jeannette M. Dowell, Allan H. Friedman, and Henry S. Friedman. “Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.” Cancer 103, no. 2 (January 15, 2005): 329–38. https://doi.org/10.1002/cncr.20776.Full Text Link to Item
-
Sampson, John H., David A. Reardon, Allan H. Friedman, Henry S. Friedman, R Edward Coleman, Roger E. McLendon, Ira Pastan, and Darell D. Bigner. “Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study.” Neuro Oncol 7, no. 1 (January 2005): 90–96. https://doi.org/10.1215/S1152851703000589.Full Text Link to Item
-
Goudar, Ranjit K., Qing Shi, Mark D. Hjelmeland, Stephen T. Keir, Roger E. McLendon, Carol J. Wikstrand, Elizabeth D. Reese, et al. “Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.” Mol Cancer Ther 4, no. 1 (January 2005): 101–12.Link to Item
-
Jones, Richard F., Robert Sunheimer, Henry Friedman, David Miller, Ronald Ginsburg, Mary Jumbelic, Gregory Threatte, and Gabriel P. Haas. “Comparison of ante- and post-mortem PSA levels for epidemiological studies.” Anticancer Res 25, no. 2B (2005): 1263–67.Link to Item
-
Shi, Qing, Shideng Bao, Jill A. Maxwell, Elizabeth D. Reese, Henry S. Friedman, Darell D. Bigner, Xiao-Fan Wang, and Jeremy N. Rich. “Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation.” J Biol Chem 279, no. 50 (December 10, 2004): 52200–209. https://doi.org/10.1074/jbc.M409630200.Full Text Link to Item
-
Gururangan, Sri, and Henry S. Friedman. “Recent advances in the treatment of pediatric brain tumors.” Oncology (Williston Park) 18, no. 13 (November 2004): 1649–61.Link to Item
-
Ueno, Tomio, Sae Hee Ko, Elizabeth Grubbs, Scott K. Pruitt, Henry S. Friedman, and Douglas S. Tyler. “Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma.” Am J Surg 188, no. 5 (November 2004): 532–37. https://doi.org/10.1016/j.amjsurg.2004.07.014.Full Text Link to Item
-
Vaidyanathan, Ganesan, Philip C. Welsh, Katia C. Vitorello, Stacey Snyder, Henry S. Friedman, and Michael R. Zalutsky. “A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells.” Eur J Nucl Med Mol Imaging 31, no. 10 (October 2004): 1362–70. https://doi.org/10.1007/s00259-004-1596-8.Full Text Link to Item
-
Bacolod, Manny D., Stewart P. Johnson, Anthony E. Pegg, M Eileen Dolan, Robert C. Moschel, Nancy S. Bullock, Qingming Fang, et al. “Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations.” Mol Cancer Ther 3, no. 9 (September 2004): 1127–35.Link to Item
-
Grubbs, Elizabeth G., Omar Abdel-Wahab, Tsung-Yen Cheng, Zeinab Abdel-Wahab, Bercedis Peterson, Scott K. Pruitt, O Michael Colvin, Henry S. Friedman, and Douglas S. Tyler. “In-transit melanoma: the role of alkylating-agent resistance in regional therapy.” J Am Coll Surg 199, no. 3 (September 2004): 419–27. https://doi.org/10.1016/j.jamcollsurg.2004.05.271.Full Text Link to Item
-
Grubbs, Elizabeth G., Tomio Ueno, Omar Abdel-Wahab, Tsung-Yen Cheng, Scott K. Pruitt, O. Michael Colvin, Henry S. Friedman, and Douglas S. Tyler. “Modulation of resistance to regional chemotherapy in the extremity melanoma model.” Surgery 136, no. 2 (August 2004): 210–18. https://doi.org/10.1016/j.surg.2004.04.021.Full Text Link to Item
-
Wiltshire, Rodney N., James E. Herndon, Annie Lloyd, Henry S. Friedman, Darell D. Bigner, Sandra H. Bigner, and Roger E. McLendon. “Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications.” J Mol Diagn 6, no. 3 (August 2004): 166–79. https://doi.org/10.1016/S1525-1578(10)60507-7.Full Text Link to Item
-
Badruddoja, M. A., D. A. Reardon, G. Akabani, A. H. Friedman, H. S. Friedman, J. N. Rich, J. A. Quinn, K. Penne, J. J. Vredenburgh, and D. D. Bigner. “Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors.” J Clin Oncol 22, no. 14_suppl (July 15, 2004): 1569.Link to Item
-
Desjardins, A., J. A. Quinn, D. A. Reardon, J. N. Rich, J. J. Vredenburgh, C. Efird, and H. S. Friedman. “Phase II study of thalidomide and daily cyclophosphamide for adults with malignant glioma.” J Clin Oncol 22, no. 14_suppl (July 15, 2004): 1554.Link to Item
-
Hjelmeland, Mark D., Anita B. Hjelmeland, Sith Sathornsumetee, Elizabeth D. Reese, Michael H. Herbstreith, Nicholas J. Laping, Henry S. Friedman, Darell D. Bigner, Xiao-Fan Wang, and Jeremy N. Rich. “SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility.” Mol Cancer Ther 3, no. 6 (June 2004): 737–45.Link to Item
-
Learn, Chris A., Tristan L. Hartzell, Carol J. Wikstrand, Gary E. Archer, Jeremy N. Rich, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner, and John H. Sampson. “Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.” Clin Cancer Res 10, no. 9 (May 1, 2004): 3216–24. https://doi.org/10.1158/1078-0432.ccr-03-0521.Full Text Link to Item
-
Quinn, Jennifer A., David A. Reardon, Allan H. Friedman, Jeremy N. Rich, John H. Sampson, James Vredenburgh, Sridharan Gururangan, et al. “Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.” Neuro Oncol 6, no. 2 (April 2004): 145–53. https://doi.org/10.1215/S1152851703000498.Full Text Link to Item
-
Reardon, David A., Jennifer A. Quinn, Jeremy N. Rich, Sridharan Gururangan, James Vredenburgh, John H. Sampson, James M. Provenzale, et al. “Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.” Neuro Oncol 6, no. 2 (April 2004): 134–44. https://doi.org/10.1215/s1152851703000413.Full Text Link to Item
-
Friedman, H. S. “Conditions associated with ST-segment elevation.” The New England Journal of Medicine 350, no. 11 (March 2004): 1152–55.
-
Friedman, H. S. “Heart rate variability in atrial fibrillation related to left atrial size.” The American Journal of Cardiology 93, no. 6 (March 2004): 705–9.
-
Rich, J. N., H. S. Friedman, J. B. Powell, and J. E. Dancey. “In reply.” Journal of Clinical Oncology 22, no. 13 (January 1, 2004): 2756. https://doi.org/10.1200/JCO.2004.99.044.Full Text
-
Rich, Jeremy N., David A. Reardon, Terry Peery, Jeannette M. Dowell, Jennifer A. Quinn, Kara L. Penne, Carol J. Wikstrand, et al. “Phase II trial of gefitinib in recurrent glioblastoma.” J Clin Oncol 22, no. 1 (January 1, 2004): 133–42. https://doi.org/10.1200/JCO.2004.08.110.Full Text Link to Item
-
Vaidyanathan, Ganesan, Donna J. Affleck, Joseph Norman, Phil Welsh, Wenge Liu, Stewart P. Johnson, Henry S. Friedman, and Michael R. Zalutsky. “O6-3-[131I]iodobenzylguanine: improved synthesis and further evaluation of a potential agent for imaging of alkylguanine-DNA alkyltransferase.” Bioconjug Chem 15, no. 2 (2004): 402–8. https://doi.org/10.1021/bc0341977.Full Text Link to Item
-
Grossi, Peter M., Hidenobu Ochiai, Gary E. Archer, Roger E. McLendon, Michael R. Zalutsky, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner, and John H. Sampson. “Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer.” Clin Cancer Res 9, no. 15 (November 15, 2003): 5514–20.Link to Item
-
Cheng, Tsung-Yen, Elizabeth Grubbs, Omar Abdul-Wahab, Szu-Yun Leu, Chen-Fang Hung, William Petros, Thomas Aloia, et al. “Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion.” Am J Surg 186, no. 5 (November 2003): 460–67. https://doi.org/10.1016/j.amjsurg.2003.07.019.Full Text Link to Item
-
Dreyer, ZoAnn E., Richard P. Kadota, Clinton F. Stewart, Henry S. Friedman, Donald H. Mahoney, Larry E. Kun, Charles W. McCluggage, et al. “Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237.” Neuro Oncol 5, no. 4 (October 2003): 261–67. https://doi.org/10.1215/S115285170200056X.Full Text Link to Item
-
Sampson, John H., Gamal Akabani, Gary E. Archer, Darell D. Bigner, Mitchel S. Berger, Allan H. Friedman, Henry S. Friedman, et al. “Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.” J Neurooncol 65, no. 1 (October 2003): 27–35. https://doi.org/10.1023/a:1026290315809.Full Text Link to Item
-
Heimberger, Amy B., Laura E. Crotty, Gary E. Archer, Kenneth R. Hess, Carol J. Wikstrand, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner, and John H. Sampson. “Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors.” Clin Cancer Res 9, no. 11 (September 15, 2003): 4247–54.Link to Item
-
Flowers, James L., Robert M. Hoffman, Timothy A. Driscoll, Monroe E. Wall, Mansukh C. Wani, Govindarajan Manikumar, Henry S. Friedman, Mark Dewhirst, O Michael Colvin, and David J. Adams. “The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH.” Cancer Chemother Pharmacol 52, no. 3 (September 2003): 253–61. https://doi.org/10.1007/s00280-003-0635-7.Full Text Link to Item
-
Gururangan, Sridharan, Colleen McLaughlin, Jennifer Quinn, Jeremy Rich, David Reardon, Edward C. Halperin, James Herndon, et al. “High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas.” J Clin Oncol 21, no. 11 (June 1, 2003): 2187–91. https://doi.org/10.1200/JCO.2003.10.096.Full Text Link to Item
-
Friedman, H. S. “Introduction: Irinotecan in brain tumors.” Cancer 97, no. 9 SUPPL. (May 1, 2003): 2351. https://doi.org/10.1002/cncr.11303.Full Text
-
Reardon, David A., Henry S. Friedman, James B. Powell, Mark Gilbert, and W. K. Yung. “Irinotecan: promising activity in the treatment of malignant glioma.” Oncology (Williston Park) 17, no. 5 Suppl 5 (May 2003): 9–14.Link to Item
-
Vaidyanathan, Ganesan, Henry S. Friedman, Donna J. Affleck, Margaret Schottelius, Hans-Jürgen Wester, and Michael R. Zalutsky. “Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts.” Clin Cancer Res 9, no. 5 (May 2003): 1868–76.Link to Item
-
Cloughesy, Timothy F., Emese Filka, John Kuhn, Gillian Nelson, Fairooz Kabbinavar, Henry Friedman, Langdon L. Miller, and Gary L. Elfring. “Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.” Cancer 97, no. 9 Suppl (May 1, 2003): 2381–86. https://doi.org/10.1002/cncr.11306.Full Text Link to Item
-
Friedman, Henry S., Stephen T. Keir, and Peter J. Houghton. “The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.” Cancer 97, no. 9 Suppl (May 1, 2003): 2359–62. https://doi.org/10.1002/cncr.11305.Full Text Link to Item
-
Korones, David N., Michal Benita-Weiss, Thomas E. Coyle, Laszlo Mechtler, Peter Bushunow, Brandon Evans, David A. Reardon, Jennifer A. Quinn, and Henry Friedman. “Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.” Cancer 97, no. 8 (April 15, 2003): 1963–68. https://doi.org/10.1002/cncr.11260.Full Text Link to Item
-
Friedman, H. S., H. Zhou, and R. von der Heydt. “The coding of uniform colour figures in monkey visual cortex.” The Journal of Physiology 548, no. Pt 2 (April 2003): 593–613.
-
Quinn, Jennifer A., David A. Reardon, Allan H. Friedman, Jeremy N. Rich, John H. Sampson, James M. Provenzale, Roger E. McLendon, et al. “Phase II trial of temozolomide in patients with progressive low-grade glioma.” J Clin Oncol 21, no. 4 (February 15, 2003): 646–51. https://doi.org/10.1200/JCO.2003.01.009.Full Text Link to Item
-
McGirt, Matthew J., Ketan R. Bulsara, Thomas J. Cummings, Kent C. New, Kenneth M. Little, Henry S. Friedman, and Allan H. Friedman. “Prognostic value of magnetic resonance imaging-guided stereotactic biopsy in the evaluation of recurrent malignant astrocytoma compared with a lesion due to radiation effect.” J Neurosurg 98, no. 1 (January 2003): 14–20. https://doi.org/10.3171/jns.2003.98.1.0014.Full Text Link to Item
-
Gururangan, Sridharan, and Henry S. Friedman. “Innovations in design and delivery of chemotherapy for brain tumors.” Neuroimaging Clin N Am 12, no. 4 (November 2002): 583–97. https://doi.org/10.1016/s1052-5149(02)00031-x.Full Text Link to Item
-
Heimberger, Amy B., Chris A. Learn, Gary E. Archer, Roger E. McLendon, Tracy A. Chewning, Frank L. Tuck, John B. Pracyk, et al. “Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).” Clin Cancer Res 8, no. 11 (November 2002): 3496–3502.Link to Item
-
Cokgor, Ilkcan, Allan H. Friedman, and Henry S. Friedman. “Current options for the treatment of neoplastic meningitis.” J Neurooncol 60, no. 1 (October 2002): 79–88. https://doi.org/10.1023/a:1020200317464.Full Text Link to Item
-
Gilbert, Mark R., Henry S. Friedman, John F. Kuttesch, Michael D. Prados, Jeffrey J. Olson, Gregory H. Reaman, and Sara L. Zaknoen. “A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy.” Neuro Oncol 4, no. 4 (October 2002): 261–67. https://doi.org/10.1093/neuonc/4.4.261.Full Text Link to Item
-
Friedman, Henry S., Stephen Keir, Anthony E. Pegg, Peter J. Houghton, O Michael Colvin, Robert C. Moschel, Darell D. Bigner, and M Eileen Dolan. “O6-benzylguanine-mediated enhancement of chemotherapy.” Mol Cancer Ther 1, no. 11 (September 2002): 943–48.Link to Item
-
Leggas, Markos, Clinton F. Stewart, Michael H. Woo, Maryam Fouladi, Pamela J. Cheshire, Jennifer K. Peterson, Henry S. Friedman, Catherine Billups, and Peter J. Houghton. “Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.” Clin Cancer Res 8, no. 9 (September 2002): 3000–3007.Link to Item
-
Bacolod, Manny D., Stewart P. Johnson, Francis Ali-Osman, Paul Modrich, Nancy S. Bullock, O Michael Colvin, Darell D. Bigner, and Henry S. Friedman. “Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma.” Mol Cancer Ther 1, no. 9 (July 2002): 727–36.Link to Item
-
Gururangan, Sridharan, Christina M. Cavazos, David Ashley, James E. Herndon, Carol S. Bruggers, Albert Moghrabi, Deborah L. Scarcella, et al. “Phase II study of carboplatin in children with progressive low-grade gliomas.” J Clin Oncol 20, no. 13 (July 1, 2002): 2951–58. https://doi.org/10.1200/JCO.2002.12.008.Full Text Link to Item
-
Lal, Anita, Chad A. Glazer, Holly M. Martinson, Henry S. Friedman, Gary E. Archer, John H. Sampson, and Gregory J. Riggins. “Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion.” Cancer Res 62, no. 12 (June 15, 2002): 3335–39.Link to Item
-
Rasheed, Ahmed, James E. Herndon, Timothy T. Stenzel, Jacqueline G. M. Raetz, Jason Kendelhardt, Henry S. Friedman, Allan H. Friedman, Darell D. Bigner, Sandra H. Bigner, and Roger E. McLendon. “Molecular markers of prognosis in astrocytic tumors.” Cancer 94, no. 10 (May 15, 2002): 2688–97. https://doi.org/10.1002/cncr.10544.Full Text Link to Item
-
Aldosari, Naji, Sandra H. Bigner, Peter C. Burger, Laurence Becker, James L. Kepner, Henry S. Friedman, and Roger E. McLendon. “MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group.” Arch Pathol Lab Med 126, no. 5 (May 2002): 540–44. https://doi.org/10.5858/2002-126-0540-MAMOAI.Full Text Link to Item
-
McGirt, Matthew J., Alan T. Villavicencio, Ketan R. Bulsara, Henry S. Friedman, and Allan H. Friedman. “Management of tumor bed cysts after chemotherapeutic wafer implantation. Report of four cases.” J Neurosurg 96, no. 5 (May 2002): 941–45. https://doi.org/10.3171/jns.2002.96.5.0941.Full Text Link to Item
-
Quinn, Jennifer A., James Pluda, M Eileen Dolan, Shannon Delaney, Richard Kaplan, Jeremy N. Rich, Allan H. Friedman, et al. “Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.” J Clin Oncol 20, no. 9 (May 1, 2002): 2277–83. https://doi.org/10.1200/JCO.2002.09.084.Full Text Link to Item
-
Aldosari, Naji, Rodney N. Wiltshire, Amalia Dutra, Evelin Schrock, Roger E. McLendon, Henry S. Friedman, Darell D. Bigner, and Sandra H. Bigner. “Comprehensive molecular cytogenetic investigation of chromosomal abnormalities in human medulloblastoma cell lines and xenograft.” Neuro Oncol 4, no. 2 (April 2002): 75–85. https://doi.org/10.1093/neuonc/4.2.75.Full Text Link to Item
-
Cloughesy, Timothy F., Emese Filka, Gillian Nelson, Fairooz Kabbinavar, Henry Friedman, Langdon L. Miller, and Gary L. Elfring. “Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.” Am J Clin Oncol 25, no. 2 (April 2002): 204–8. https://doi.org/10.1097/00000421-200204000-00022.Full Text Link to Item
-
Turner, Christopher D., Sridharan Gururangan, James Eastwood, Krystal Bottom, Melody Watral, Rodney Beason, Roger E. McLendon, et al. “Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.” Neuro Oncol 4, no. 2 (April 2002): 102–8. https://doi.org/10.1093/neuonc/4.2.109.Full Text Link to Item
-
Reardon, David A., Gamal Akabani, R Edward Coleman, Allan H. Friedman, Henry S. Friedman, James E. Herndon, Ilkcan Cokgor, et al. “Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.” J Clin Oncol 20, no. 5 (March 1, 2002): 1389–97. https://doi.org/10.1200/JCO.2002.20.5.1389.Full Text Link to Item
-
Eberhart, Charles G., James L. Kepner, Patricia T. Goldthwaite, Larry E. Kun, Patricia K. Duffner, Henry S. Friedman, Douglas R. Strother, and Peter C. Burger. “Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study.” Cancer 94, no. 2 (January 15, 2002): 552–60. https://doi.org/10.1002/cncr.10189.Full Text Link to Item
-
Friedman, Henry S., Stewart P. Johnson, and O Michael Colvin. “Cellular mechanisms of cyclophosphamide resistance: model studies in human medulloblastoma cell lines.” Cancer Treat Res 112 (2002): 199–209. https://doi.org/10.1007/978-1-4615-1173-1_10.Full Text Link to Item
-
Heimberger, Amy B., Gary E. Archer, Laura E. Crotty, Roger E. McLendon, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner, and John H. Sampson. “Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma.” Neurosurgery 50, no. 1 (January 2002): 158–64. https://doi.org/10.1097/00006123-200201000-00024.Full Text Link to Item
-
DeGrado, T. R., S. W. Baldwin, S. Wang, M. D. Orr, R. P. Liao, H. S. Friedman, R. Reiman, D. T. Price, and R. E. Coleman. “Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers.” J Nucl Med 42, no. 12 (December 2001): 1805–14.Link to Item
-
Bacolod, M. D., N. H. Bullock, S. P. Johnson, O. M. Colvin, and H. S. Friedman. “Characterization of molecular mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea alone or in combination with O-6-benzylguanine in human medulloblastoma and rhabdomyosarcoma cell lines.” Clinical Cancer Research 7, no. 11 (November 1, 2001): 3739S-3739S.Link to Item
-
Friedman, H. S., W. A. Yung, E. Jackson, J. Provenzale, N. Leeds, C. Conrad, A. Walker, A. Henry, D. Laurent, and M. Dugan. “A phase I trial of PTK787/ZK 222584 (PTK/ZK), a novel oral VEGF-R TK inhibitor in patients with recurrent GBM.” Clinical Cancer Research 7, no. 11 (November 1, 2001): 3665S-3665S.Link to Item
-
Reid, J. M., S. Cha, J. C. Buckner, W. P. Petros, H. S. Friedman, S. Tourt-Uhlig, A. Walker, et al. “Pharmacokinetics of CPT-11 in glioma patients: Pooled analysis of data from 4 NCI-sponsored trials (Duke university, NABTC, NABTT, NCCTG).” Clinical Cancer Research 7, no. 11 (November 1, 2001): 3737S-3737S.Link to Item
-
Friedman, H. S., S. T. Keir, P. J. Houghton, A. A. Lawless, D. D. Bigner, and S. J. Waters. “Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice.” Cancer Chemother Pharmacol 48, no. 5 (November 2001): 413–16. https://doi.org/10.1007/s002800100358.Full Text Link to Item
-
Gururangan, S., L. Cokgor, J. N. Rich, S. Edwards, M. L. Affronti, J. A. Quinn, J. E. Herndon, et al. “Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.” Neuro Oncol 3, no. 4 (October 2001): 246–50. https://doi.org/10.1093/neuonc/3.4.246.Full Text Link to Item
-
Cavazos, C. M., S. T. Keir, T. Yoshinari, D. D. Bigner, and H. S. Friedman. “Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts.” Cancer Chemother Pharmacol 48, no. 3 (September 2001): 250–54. https://doi.org/10.1007/s002800100347.Full Text Link to Item
-
Keir, S. T., F. Hausheer, A. A. Lawless, D. D. Bigner, and H. S. Friedman. “Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice.” Cancer Chemother Pharmacol 48, no. 1 (July 2001): 83–87. https://doi.org/10.1007/s002800000274.Full Text Link to Item
-
Struck, R. F., A. Tiwari, H. S. Friedman, S. Keir, L. R. Morgan, and W. R. Waud. “Acyl derivatives of demethylpenclomedine, an antitumor-active, non-neurotoxic metabolites of penclomedine.” Cancer Chemother Pharmacol 48, no. 1 (July 2001): 47–52. https://doi.org/10.1007/s002800000255.Full Text Link to Item
-
Zalutsky, M. R., G. Akabani, H. S. Friedman, I. Cokgor, R. E. Coleman, A. H. Friedman, R. E. McLendon, X. G. Zhao, K. L. Alston, and D. D. Bigner. “Radioimmunotherapy of recurrent glioma patients using alpha-particle emitting astatine-211 labeled chimeric anti-tenascin monoclonal antibody.” Journal of Nuclear Medicine 42, no. 5 (May 1, 2001): 121P-122P.Link to Item
-
Cokgor, I., G. Akabani, H. S. Friedman, A. H. Friedman, M. R. Zalutsky, L. M. Zehngebot, J. M. Provenzale, C. D. Guy, C. J. Wikstrand, and D. D. Bigner. “Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case study.” Cancer 91, no. 9 (May 1, 2001): 1809–13.Link to Item
-
Friedman, H. S. “Serum homocysteine and stroke in atrial fibrillation.” Ann Intern Med 134, no. 3 (February 6, 2001): 253–54. https://doi.org/10.7326/0003-4819-134-3-200102060-00027.Full Text Link to Item
-
Ewesuedo, R. B., L. R. Wilson, H. S. Friedman, R. C. Moschel, and M. E. Dolan. “Inactivation of O6-alkylguanine-DNA alkyltransferase by 8-substituted O6-benzylguanine analogs in mice.” Cancer Chemother Pharmacol 47, no. 1 (2001): 63–69. https://doi.org/10.1007/s002800000202.Full Text Link to Item
-
Hurwitz, C. A., L. C. Strauss, J. Kepner, C. Kretschmar, M. B. Harris, H. Friedman, L. Kun, and R. Kadota. “Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study.” J Pediatr Hematol Oncol 23, no. 5 (2001): 277–81. https://doi.org/10.1097/00043426-200106000-00008.Full Text Link to Item
-
Friedman, H. S. “Long-term relations of personality and health: dynamisms, mechanisms, tropisms.” J Pers 68, no. 6 (December 2000): 1089–1107. https://doi.org/10.1111/1467-6494.00127.Full Text Link to Item
-
Schmid, M., M. Sen, M. D. Rosenbach, C. J. Carrera, H. Friedman, and D. A. Carson. “A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer.” Oncogene 19, no. 50 (November 23, 2000): 5747–54. https://doi.org/10.1038/sj.onc.1203942.Full Text Link to Item
-
Cokgor, I., G. Akabani, C. T. Kuan, H. S. Friedman, A. H. Friedman, R. E. Coleman, R. E. McLendon, et al. “Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.” J Clin Oncol 18, no. 22 (November 15, 2000): 3862–72. https://doi.org/10.1200/JCO.2000.18.22.3862.Full Text Link to Item
-
Barboriak, D. P., T. M. Holmes, C. G. Less, R. E. Coleman, H. S. Friedman, and J. M. Provenzale. “Effect of intracavitary radiation therapy for cerebral gliomas on relative cerebral blood volume in adjacent white matter: Assessment with perfusion MR imaging.” Radiology 217 (November 1, 2000): 297–98.Link to Item
-
Heimberger, A. B., G. E. Archer, R. E. McLendon, D. Price, A. H. Friedman, H. S. Friedman, D. D. Bigner, and J. H. Sampson. “Oral administration of the specific EGFR tyrosine kinase inhibitor, ZD1839 (Iressa (TM)), is active against EGFR-overexpressing intracranial tumors.” Clinical Cancer Research 6 (November 1, 2000): 4542S-4543S.Link to Item
-
Friedman, H. S. “Observational studies and randomized trials.” N Engl J Med 343, no. 16 (October 19, 2000): 1195–96.Link to Item
-
Friedman, H. S., J. Pluda, J. A. Quinn, R. B. Ewesuedo, L. Long, A. H. Friedman, I. Cokgor, et al. “Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.” J Clin Oncol 18, no. 20 (October 15, 2000): 3522–28. https://doi.org/10.1200/JCO.2000.18.20.3522.Full Text Link to Item
-
Friedman, H. S., M. Win, A. Hussain, and A. Sinha. “Effects of cardiac glycosides on atrial contractile dysfunction after short-term atrial fibrillation.” Chest 118, no. 4 (October 2000): 1116–26. https://doi.org/10.1378/chest.118.4.1116.Full Text Link to Item
-
Heimberger, A. B., G. E. Archer, R. E. McLendon, C. Hulette, A. H. Friedman, H. S. Friedman, D. D. Bigner, and J. H. Sampson. “Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats.” Clin Cancer Res 6, no. 10 (October 2000): 4148–53.Link to Item
-
Houghton, P. J., C. F. Stewart, P. J. Cheshire, L. B. Richmond, M. N. Kirstein, C. A. Poquette, M. Tan, H. S. Friedman, and T. P. Brent. “Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.” Clin Cancer Res 6, no. 10 (October 2000): 4110–18.Link to Item
-
Patel, V. J., G. B. Elion, P. J. Houghton, S. Keir, A. E. Pegg, S. P. Johnson, M. E. Dolan, D. D. Bigner, and H. S. Friedman. “Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft.” Clin Cancer Res 6, no. 10 (October 2000): 4154–57.Link to Item
-
Brown, H. G., J. L. Kepner, E. J. Perlman, H. S. Friedman, D. R. Strother, P. K. Duffner, L. E. Kun, P. T. Goldthwaite, and P. C. Burger. “"Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group Study.” J Neuropathol Exp Neurol 59, no. 10 (October 2000): 857–65. https://doi.org/10.1093/jnen/59.10.857.Full Text Link to Item
-
Mahoney, D. H., M. E. Cohen, H. S. Friedman, J. L. Kepner, L. Gemer, J. W. Langston, H. E. James, P. K. Duffner, and L. E. Kun. “Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study.” Neuro Oncol 2, no. 4 (October 2000): 213–20. https://doi.org/10.1093/neuonc/2.4.213.Full Text Link to Item
-
Yung, W. K., R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, et al. “A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.” Br J Cancer 83, no. 5 (September 2000): 588–93. https://doi.org/10.1054/bjoc.2000.1316.Full Text Link to Item
-
Zhou, H., H. S. Friedman, and R. von der Heydt. “Coding of border ownership in monkey visual cortex.” J Neurosci 20, no. 17 (September 1, 2000): 6594–6611. https://doi.org/10.1523/JNEUROSCI.20-17-06594.2000.Full Text Link to Item
-
Friedman, H. S. “Can O6-alkylguanine-DNA alkyltransferase depletion enhance alkylator activity in the clinic?” Clin Cancer Res 6, no. 8 (August 2000): 2967–68.Link to Item
-
Thomas, P. R., M. Deutsch, J. L. Kepner, J. M. Boyett, J. Krischer, P. Aronin, L. Albright, et al. “Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation.” J Clin Oncol 18, no. 16 (August 2000): 3004–11. https://doi.org/10.1200/JCO.2000.18.16.3004.Full Text Link to Item
-
Friedman, H. S., R. C. Castellino, G. B. Elion, S. T. Keir, P. J. Houghton, S. P. Johnson, and D. D. Bigner. “Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts (vol 45, pg 345, 1999).” Cancer Chemotherapy and Pharmacology 46, no. 1 (July 1, 2000): 84–84.Link to Item
-
Friedman, H. S., T. Kerby, and H. Calvert. “Temozolomide and treatment of malignant glioma.” Clin Cancer Res 6, no. 7 (July 2000): 2585–97.Link to Item
-
Wiltshire, R. N., B. K. Rasheed, H. S. Friedman, A. H. Friedman, and S. H. Bigner. “Comparative genetic patterns of glioblastoma multiforme: potential diagnostic tool for tumor classification.” Neuro Oncol 2, no. 3 (July 2000): 164–73. https://doi.org/10.1093/neuonc/2.3.164.Full Text Link to Item
-
Friedman, H. S. “Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.” Seminars in Oncology 27, no. 3 SUPPL. 6 (June 30, 2000): 35–40.
-
Sampson, J. H., L. E. Crotty, S. Lee, G. E. Archer, D. M. Ashley, C. J. Wikstrand, L. P. Hale, et al. “Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors.” Proc Natl Acad Sci U S A 97, no. 13 (June 20, 2000): 7503–8. https://doi.org/10.1073/pnas.130166597.Full Text Link to Item
-
Freeman, C. R., J. Kepner, L. E. Kun, R. A. Sanford, R. Kadota, L. Mandell, and H. Friedman. “A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas?” Int J Radiat Oncol Biol Phys 47, no. 3 (June 1, 2000): 561–64. https://doi.org/10.1016/s0360-3016(00)00471-5.Full Text Link to Item
-
Friedman, H. S. “Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.” Seminars in Oncology 27, no. 3 (June 1, 2000): S35–40.Link to Item
-
Friedman, H. S. “Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.” Semin Oncol 27, no. 3 Suppl 6 (June 2000): 35–40.Link to Item
-
Aldosari, N., B. K. Rasheed, R. E. McLendon, H. S. Friedman, D. D. Bigner, and S. H. Bigner. “Characterization of chromosome 17 abnormalities in medulloblastomas.” Acta Neuropathol 99, no. 4 (April 2000): 345–51. https://doi.org/10.1007/s004010051134.Full Text Link to Item
-
Middlemas, D. S., C. F. Stewart, M. N. Kirstein, C. Poquette, H. S. Friedman, P. J. Houghton, and T. P. Brent. “Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.” Clin Cancer Res 6, no. 3 (March 2000): 998–1007.Link to Item
-
Akabani, G., I. Cokgor, R. E. Coleman, D. González Trotter, T. Z. Wong, H. S. Friedman, A. H. Friedman, et al. “Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.” Int J Radiat Oncol Biol Phys 46, no. 4 (March 1, 2000): 947–58. https://doi.org/10.1016/s0360-3016(99)00500-3.Full Text Link to Item
-
Martin, L. R., and H. S. Friedman. “Comparing personality scales across time: an illustrative study of validity and consistency in life-span archival data.” J Pers 68, no. 1 (February 2000): 85–110. https://doi.org/10.1111/1467-6494.00092.Full Text Link to Item
-
Friedman, H. S. “Can O6-Alkylguanine-DNA alkyltransferase depletion enhance alkylator activity in the clinic?” Clinical Cancer Research 6, no. 8 (2000): 2967–68.
-
Friedman, H. S., N. Wattanasuwan, A. Sharafkhaneh, M. Win, D. Mallipeddi, I. A. Khan, and C. P. Dai. “The comparative effects of drive and test stimulus intensity on myocardial excitability and vulnerability.” Pacing Clin Electrophysiol 23, no. 1 (January 2000): 84–95. https://doi.org/10.1111/j.1540-8159.2000.tb00653.x.Full Text Link to Item
-
Friedman, H. S., R. C. Castellino, G. B. Elion, S. T. Keir, P. J. Houghton, S. P. Johnson, and D. D. Bigner. “Erratum: Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts (Cancer Chemotherapy and Pharmacology 45 (345- 349)).” Cancer Chemotherapy and Pharmacology 46, no. 1 (January 1, 2000): 84.
-
Heydt, R. von der, H. Zhou, and H. S. Friedman. “Representation of stereoscopic edges in monkey visual cortex.” Vision Res 40, no. 15 (2000): 1955–67. https://doi.org/10.1016/s0042-6989(00)00044-4.Full Text Link to Item
-
Keir, S. T., M. E. Dolan, A. E. Pegg, A. Lawless, R. C. Moschel, D. D. Bigner, and H. S. Friedman. “O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts - Implications for clinical trials.” Cancer Chemotherapy and Pharmacology 45, no. 6 (2000): 437–40.
-
Bottom, K. S., D. M. Ashley, H. S. Friedman, and D. C. Longee. “Evaluation of pre-radiotherapy cyclophosphamide in patients with newly diagnosed glioblastoma multiforme. Writing Committee for The Brain Tumor Center at Duke.” J Neurooncol 46, no. 2 (2000): 151–56. https://doi.org/10.1023/a:1006258026274.Full Text Link to Item
-
Castellino, R. C., G. B. Elion, S. T. Keir, P. J. Houghton, S. P. Johnson, D. D. Bigner, and H. S. Friedman. “Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.” Cancer Chemother Pharmacol 45, no. 4 (2000): 345–49. https://doi.org/10.1007/s002800050050.Full Text Link to Item
-
Keir, S. T., M. E. Dolan, A. E. Pegg, A. Lawless, R. C. Moschel, D. D. Bigner, and H. S. Friedman. “O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials.” Cancer Chemother Pharmacol 45, no. 6 (2000): 437–40. https://doi.org/10.1007/s002800051016.Full Text Link to Item
-
Mulne, A. F., J. M. Ducore, R. D. Elterman, H. S. Friedman, J. P. Krischer, L. E. Kun, J. J. Shuster, and R. P. Kadota. “Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study.” J Pediatr Hematol Oncol 22, no. 1 (2000): 41–44. https://doi.org/10.1097/00043426-200001000-00008.Full Text Link to Item
-
Vaidyanathan, G., D. J. Affleck, C. M. Cavazos, S. P. Johnson, S. Shankar, H. S. Friedman, M. O. Colvin, and M. R. Zalutsky. “Radiolabeled guanine derivatives for the in vivo mapping of O(6)-alkylguanine-DNA alkyltransferase: 6-(4-[(18)F]Fluoro-benzyloxy)-9H-purin-2-ylamine and 6-(3-[(131)I]Iodo-benzyloxy)-9H-purin-2-ylamine.” Bioconjug Chem 11, no. 6 (2000): 868–75. https://doi.org/10.1021/bc0000435.Full Text Link to Item
-
Tucker, Joan S., Joseph E. Schwartz, Kathleen M. Clark, and Howard S. Friedman. “Age-related changes in the associations of social network ties with mortality risk.” Psychol Aging 14, no. 4 (December 1999): 564–71. https://doi.org/10.1037/0882-7974.14.4.564.Full Text Link to Item
-
Archer, G. E., J. H. Sampson, I. A. Lorimer, R. E. McLendon, C. T. Kuan, A. H. Friedman, H. S. Friedman, I. H. Pastan, and D. D. Bigner. “Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1.” Clin Cancer Res 5, no. 9 (September 1999): 2646–52.Link to Item
-
Zalutsky, M. R., G. Akabani, I. Cokgor, H. S. Friedman, R. E. Coleman, A. H. Friedman, R. E. McLendon, and D. D. Bigner. “Astatine-211 labeled chimeric anti-tenascin antibody: Phase I trial in brain tumor resection cavity patients.” European Journal of Nuclear Medicine 26, no. 9 (September 1, 1999): 1215–1215.Link to Item
-
Yung, W. K., M. D. Prados, R. Yaya-Tur, S. S. Rosenfeld, M. Brada, H. S. Friedman, R. Albright, et al. “Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.” J Clin Oncol 17, no. 9 (September 1999): 2762–71. https://doi.org/10.1200/JCO.1999.17.9.2762.Full Text Link to Item
-
Bigner, S. H., M. R. Matthews, B. K. Rasheed, R. N. Wiltshire, H. S. Friedman, A. H. Friedman, T. T. Stenzel, D. M. Dawes, R. E. McLendon, and D. D. Bigner. “Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization.” Am J Pathol 155, no. 2 (August 1999): 375–86. https://doi.org/10.1016/S0002-9440(10)65134-6.Full Text Link to Item
-
Friedman, H. S., E. Rodney, B. Sinha, A. Sharafkhaneh, N. Wattanasuwan, M. Win, D. Mallipeddi, A. Sinha, A. Hussain, and C. P. Dai. “Verapamil prolongs atrial fibrillation by evoking an intense sympathetic neurohumoral effect.” J Investig Med 47, no. 6 (July 1999): 293–303.Link to Item
-
Sampson, J. H., G. E. Archer, A. T. Villavicencio, R. E. McLendon, A. H. Friedman, W. R. Bishop, D. D. Bigner, and H. S. Friedman. “Treatment of neoplastic meningitis with intrathecal temozolomide.” Clin Cancer Res 5, no. 5 (May 1999): 1183–88.Link to Item
-
Friedman, H. S., W. P. Petros, A. H. Friedman, L. J. Schaaf, T. Kerby, J. Lawyer, M. Parry, et al. “Irinotecan therapy in adults with recurrent or progressive malignant glioma.” J Clin Oncol 17, no. 5 (May 1999): 1516–25. https://doi.org/10.1200/JCO.1999.17.5.1516.Full Text Link to Item
-
Kadota, R. P., C. F. Stewart, M. Horn, J. F. Kuttesch, P. C. Burger, J. L. Kepner, L. E. Kun, H. S. Friedman, and R. L. Heideman. “Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study.” J Neurooncol 43, no. 1 (May 1999): 43–47. https://doi.org/10.1023/a:1006294102611.Full Text Link to Item
-
Akabani, G., C. J. Reist, I. Cokgor, A. H. Friedman, H. S. Friedman, R. E. Coleman, X. G. Zhao, D. D. Bigner, and M. R. Zalutsky. “Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors.” J Nucl Med 40, no. 4 (April 1999): 631–38.Link to Item
-
Duffner, P. K., M. E. Horowitz, J. P. Krischer, P. C. Burger, M. E. Cohen, R. A. Sanford, H. S. Friedman, and L. E. Kun. “The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience.” Neuro Oncol 1, no. 2 (April 1999): 152–61. https://doi.org/10.1093/neuonc/1.2.152.Full Text Link to Item
-
Mandell, L. R., R. Kadota, C. Freeman, E. C. Douglass, J. Fontanesi, M. E. Cohen, E. Kovnar, et al. “There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy.” Int J Radiat Oncol Biol Phys 43, no. 5 (March 15, 1999): 959–64. https://doi.org/10.1016/s0360-3016(98)00501-x.Full Text Link to Item
-
Friedman, H. S., T. Kerby, S. Fields, J. E. Zilisch, D. Graden, R. E. McLendon, P. J. Houghton, S. Arbuck, I. Cokgor, and A. H. Friedman. “Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke.” Cancer 85, no. 5 (March 1, 1999): 1160–65.Link to Item
-
Friedman, H. S., and C. E. Priebe. “Smoothing bandwidth selection for response latency estimation.” J Neurosci Methods 87, no. 1 (February 1, 1999): 13–16. https://doi.org/10.1016/s0165-0270(98)00144-7.Full Text Link to Item
-
McLendon, R. E., H. S. Friedman, H. E. Fuchs, L. E. Kun, and S. H. Bigner. “Diagnostic markers in paediatric medulloblastoma: a Paediatric Oncology Group Study.” Histopathology 34, no. 2 (February 1999): 154–62. https://doi.org/10.1046/j.1365-2559.1999.00577.x.Full Text Link to Item
-
Cokgor, I., H. S. Friedman, and A. H. Friedman. “Chemotherapy for adults with malignant glioma.” Cancer Invest 17, no. 4 (1999): 264–72. https://doi.org/10.3109/07357909909040596.Full Text Link to Item
-
Cummings, T. J., J. Provenzale, S. Hunter, H. S. Friedman, G. Klintworth, S. H. Bigner, and R. E. McLendon. “Gliomas of the optic nerve in children and adults.” Laboratory Investigation 79, no. 1 (January 1, 1999): 170A-170A.Link to Item
-
Friedman, H. S. “Temozolomide.” Cns Drugs 12, no. 3 (January 1, 1999): 244. https://doi.org/10.2165/00023210-199912030-00007.Full Text
-
Friedman, H. S., H. Zhou, and R. von der Heydt. “Color filling-in under steady fixation: behavioral demonstration in monkeys and humans.” Perception 28, no. 11 (1999): 1383–95. https://doi.org/10.1068/p2831.Full Text Link to Item
-
Wu, M. H., K. E. Lohrbach, O. I. Olopade, D. M. Kokkinakis, H. S. Friedman, and M. E. Dolan. “Lack of evidence for a polymorphism at codon 160 of human O6-alkylguanine-DNA alkyltransferase gene in normal tissue and cancer.” Clin Cancer Res 5, no. 1 (January 1999): 209–13.Link to Item
-
Archer, G. E., J. H. Sampson, R. E. McLendon, A. H. Friedman, O. M. Colvin, M. Rose, H. Sands, et al. “Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats.” J Neurooncol 44, no. 3 (1999): 233–41. https://doi.org/10.1023/a:1006304424346.Full Text Link to Item
-
Dong, Q., S. P. Johnson, O. M. Colvin, N. Bullock, C. Kilborn, G. Runyon, D. M. Sullivan, et al. “Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR).” Cancer Chemother Pharmacol 43, no. 1 (1999): 73–79. https://doi.org/10.1007/s002800050865.Full Text Link to Item
-
Friedman, H. S., A. E. Pegg, S. P. Johnson, N. A. Loktionova, M. E. Dolan, P. Modrich, R. C. Moschel, et al. “Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase.” Cancer Chemother Pharmacol 43, no. 1 (1999): 80–85. https://doi.org/10.1007/s002800050866.Full Text Link to Item
-
Kadota, R. P., L. E. Kun, J. W. Langston, P. C. Burger, M. E. Cohen, D. H. Mahoney, A. W. Walter, et al. “Cyclophosphamide for the treatment of progressive low-grade astrocytoma: a Pediatric Oncology Group phase II Study.” J Pediatr Hematol Oncol 21, no. 3 (1999): 198–202. https://doi.org/10.1097/00043426-199905000-00007.Full Text Link to Item
-
Singh, A., R. F. Jones, H. Friedman, S. Hathir, G. Soos, A. Zabo, and G. P. Haas. “Expression of p53 and pRb in bladder and prostate cancers of patients having both cancers.” Anticancer Res 19, no. 6B (1999): 5415–17.Link to Item
-
Friedman, H. S., R. E. McLendon, T. Kerby, M. Dugan, S. H. Bigner, A. J. Henry, D. M. Ashley, et al. “DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.” J Clin Oncol 16, no. 12 (December 1998): 3851–57. https://doi.org/10.1200/JCO.1998.16.12.3851.Full Text Link to Item
-
Houghton, P. J., C. F. Stewart, J. Thompson, V. M. Santana, W. L. Furman, and H. S. Friedman. “Preclinical and clinical results with irinotecan: Extending principles learned in model systems to clinical trials design.” Oncology 12, no. 8 SUPPL. (November 24, 1998): 84–93.
-
Cokgor, I., A. H. Friedman, and H. S. Friedman. “Gliomas.” Eur J Cancer 34, no. 12 (November 1998): 1910–15. https://doi.org/10.1016/s0959-8049(98)00307-4.Full Text Link to Item
-
Friedman, H. S., D. M. Kokkinakis, J. Pluda, A. H. Friedman, I. Cokgor, M. M. Haglund, D. M. Ashley, et al. “Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.” J Clin Oncol 16, no. 11 (November 1998): 3570–75. https://doi.org/10.1200/JCO.1998.16.11.3570.Full Text Link to Item
-
Friedman, H. S., and C. E. Priebe. “Estimating stimulus response latency.” J Neurosci Methods 83, no. 2 (September 1, 1998): 185–94. https://doi.org/10.1016/s0165-0270(98)00075-2.Full Text Link to Item
-
Burger, P. C., I. T. Yu, T. Tihan, H. S. Friedman, D. R. Strother, J. L. Kepner, P. K. Duffner, L. E. Kun, and E. J. Perlman. “Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study.” Am J Surg Pathol 22, no. 9 (September 1998): 1083–92. https://doi.org/10.1097/00000478-199809000-00007.Full Text Link to Item
-
Duffner, P. K., J. P. Krischer, M. E. Horowitz, M. E. Cohen, P. C. Burger, H. S. Friedman, and L. E. Kun. “Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study.” Ann Neurol 44, no. 3 (September 1998): 313–16. https://doi.org/10.1002/ana.410440305.Full Text Link to Item
-
Houghton, P. J., C. F. Stewart, J. Thompson, V. M. Santana, W. L. Furman, and H. S. Friedman. “Extending principles learned in model systems to clinical trials design.” Oncology (Williston Park) 12, no. 8 Suppl 6 (August 1998): 84–93.Link to Item
-
Houghton, P. J., C. F. Stewart, J. Thompson, V. M. Santana, W. L. Furman, and H. S. Friedman. “Preclinical and clinical results with irinotecan - Extending principles learned in model systems to clinical trials design.” Oncology New York 12, no. 8 (August 1, 1998): 84–93.Link to Item
-
Friedman, H. S., S. Lovell, K. Rasheed, and A. H. Friedman. “Treatment of adults with progressive oligodendroglioma with carboplatin (CBDCA): preliminary results. Writing Committee for The Brain Tumor Center at Duke.” Med Pediatr Oncol 31, no. 1 (July 1998): 16–18. https://doi.org/10.1002/(sici)1096-911x(199807)31:1<16::aid-mpo3>3.0.co;2-2.Full Text Link to Item
-
Lee, S. E., S. P. Johnson, L. P. Hale, J. Li, N. Bullock, H. Fuchs, A. Friedman, et al. “Analysis of DNA mismatch repair proteins in human medulloblastoma.” Clin Cancer Res 4, no. 6 (June 1998): 1415–19.Link to Item
-
Bigner, D. D., M. T. Brown, A. H. Friedman, R. E. Coleman, G. Akabani, H. S. Friedman, W. L. Thorstad, et al. “Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.” J Clin Oncol 16, no. 6 (June 1998): 2202–12. https://doi.org/10.1200/JCO.1998.16.6.2202.Full Text Link to Item
-
McLendon, R. E., L. Cleveland, C. Pegram, S. H. Bigner, D. D. Bigner, and H. S. Friedman. “Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas.” Lab Invest 78, no. 5 (May 1998): 643–44.Link to Item
-
Mulhern, R. K., J. L. Kepner, P. R. Thomas, F. D. Armstrong, H. S. Friedman, and L. E. Kun. “Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group study.” J Clin Oncol 16, no. 5 (May 1998): 1723–28. https://doi.org/10.1200/JCO.1998.16.5.1723.Full Text Link to Item
-
Valdyanathan, G., H. S. Friedman, and M. R. Zalutsky. “N.C.A. 5-Iodo-1(2-deoxy,2-fluoro-beta-D-arabinofuranosyl)uracil (FIAU): Tissue uptake in D-54 glioma xenograft mouse model and cytotoxicity to D-247 glioma cells in vitro.” Journal of Nuclear Medicine 39, no. 5 (May 1, 1998): 104P-105P.Link to Item
-
Moghrabi, A., H. S. Friedman, D. M. Ashley, K. S. Bottom, T. Kerby, E. Stewart, C. Bruggers, et al. “Phase II study of carboplatin (CBDCA) in progressive low-grade gliomas.” Neurosurg Focus 4, no. 4 (April 15, 1998): e3. https://doi.org/10.3171/foc.1998.4.4.6.Full Text Link to Item
-
Duffner, P. K., J. P. Krischer, R. A. Sanford, M. E. Horowitz, P. C. Burger, M. E. Cohen, H. S. Friedman, and L. E. Kun. “Prognostic factors in infants and very young children with intracranial ependymomas.” Pediatr Neurosurg 28, no. 4 (April 1998): 215–22. https://doi.org/10.1159/000028654.Full Text Link to Item
-
McCowage, G. B., H. S. Friedman, A. Moghrabi, T. Kerby, L. Ferrell, E. Stewart, M. Duncan-Brown, et al. “Activity of high-dose cyclophosphamide in the treatment of childhood malignant gliomas.” Med Pediatr Oncol 30, no. 2 (February 1998): 75–80. https://doi.org/10.1002/(sici)1096-911x(199802)30:2<75::aid-mpo1>3.0.co;2-x.Full Text Link to Item
-
McLendon, R. E., H. S. Friedman, S. H. Bigner, and P. L. Modrich. “DNA mismatch repair enzyme detection in adult glioblastoma (GBM) by immunohistochemistry.” Modern Pathology 11, no. 1 (January 1, 1998): 160A-160A.Link to Item
-
Coggins, C. A., G. B. Elion, P. J. Houghton, C. B. Hare, S. Keir, O. M. Colvin, D. D. Bigner, and H. S. Friedman. “Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.” Cancer Chemother Pharmacol 41, no. 6 (1998): 485–90. https://doi.org/10.1007/s002800050771.Full Text Link to Item
-
Hanley, M. L., G. B. Elion, O. M. Colvin, P. L. Modrich, S. Keir, D. J. Adams, D. D. Bigner, and H. S. Friedman. “Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors.” Cancer Chemother Pharmacol 42, no. 6 (1998): 479–82. https://doi.org/10.1007/s002800050848.Full Text Link to Item
-
Friedman, H. S. “Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multi forme xenograft (vol 57, pg 2933, 1997).” Cancer Research 57, no. 21 (November 1, 1997): 4973–4973.Link to Item
-
Stenzel, T. T., B. K. A. Rasheed, R. E. McLendon, R. Parsons, A. H. Friedman, H. S. Friedman, and S. H. Bigner. “Pten gene mutations are seen in high grade, but not in low grade gliomas.” Clinical Chemistry 43, no. 11 (November 1, 1997): 25–25.Link to Item
-
Rasheed, B. K., T. T. Stenzel, R. E. McLendon, R. Parsons, A. H. Friedman, H. S. Friedman, D. D. Bigner, and S. H. Bigner. “PTEN gene mutations are seen in high-grade but not in low-grade gliomas.” Cancer Res 57, no. 19 (October 1, 1997): 4187–90.Link to Item
-
Bigner, S. H., R. E. McLendon, H. Fuchs, P. E. McKeever, and H. S. Friedman. “Chromosomal characteristics of childhood brain tumors.” Cancer Genet Cytogenet 97, no. 2 (September 1997): 125–34. https://doi.org/10.1016/s0165-4608(96)00404-9.Full Text Link to Item
-
Tucker, J. S., H. S. Friedman, J. E. Schwartz, M. H. Criqui, C. Tomlinson-Keasey, D. L. Wingard, and L. R. Martin. “Parental divorce: effects on individual behavior and longevity.” J Pers Soc Psychol 73, no. 2 (August 1997): 381–91. https://doi.org/10.1037//0022-3514.73.2.381.Full Text Link to Item
-
Friedman, H. S., S. P. Johnson, Q. Dong, S. C. Schold, B. K. Rasheed, S. H. Bigner, F. Ali-Osman, et al. “Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft.” Cancer Res 57, no. 14 (July 15, 1997): 2933–36.Link to Item
-
Ashley, D. M., R. E. Coleman, H. Fuchs, G. Dear, B. Ginsberg, F. M. Zalduondo, H. S. Friedman, and D. Longee. “Chronic CSF leak into the peritoneal cavity shown by radionuclide cisternography. Successful treatment with an epidural blood patch.” Clin Nucl Med 22, no. 6 (June 1997): 390–92. https://doi.org/10.1097/00003072-199706000-00010.Full Text Link to Item
-
Kupczyk-Subotkowska, L., T. J. Siahaan, A. S. Basile, H. S. Friedman, P. E. Higgins, D. Song, and J. M. Gallo. “Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate.” J Med Chem 40, no. 11 (May 23, 1997): 1726–30. https://doi.org/10.1021/jm960592p.Full Text Link to Item
-
McLendon, R. E., R. C. Bentley, J. E. Parisi, R. D. Tien, J. C. Harrison, N. J. Tarbell, A. L. Billitt, R. J. Gualtieri, and H. S. Friedman. “Malignant supratentorial glial-neuronal neoplasms: report of two cases and review of the literature.” Arch Pathol Lab Med 121, no. 5 (May 1997): 485–92.Link to Item
-
Graham, M. L., J. E. Herndon, J. R. Casey, S. Chaffee, G. H. Ciocci, J. P. Krischer, J. Kurtzberg, et al. “High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors.” J Clin Oncol 15, no. 5 (May 1997): 1814–23. https://doi.org/10.1200/JCO.1997.15.5.1814.Full Text Link to Item
-
Moghrabi, A., R. Tien, H. Fuchs, D. Longee, R. McLendon, and H. S. Friedman. “False positive images in the follow-up of patients with brain tumors.” Med Pediatr Oncol 28, no. 2 (February 1997): 127–31. https://doi.org/10.1002/(sici)1096-911x(199702)28:2<127::aid-mpo6>3.0.co;2-m.Full Text Link to Item
-
Friedman, H. S. “Effectiveness of right heart catheterization: time for a randomized trial.” Jama 277, no. 2 (January 8, 1997): 111. https://doi.org/10.1001/jama.277.2.111b.Full Text Link to Item
-
Friedman, H. S. “Erratum: (Cancer Research (July 15, 1997) (2933-2936)).” Cancer Research 57, no. 21 (January 1, 1997): 4973.
-
Hare, C. B., G. B. Elion, O. M. Colvin, F. Ali-Osman, O. W. Griffith, W. P. Petros, S. Keir, S. L. Marcelli, D. D. Bigner, and H. S. Friedman. “Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft.” Cancer Chemother Pharmacol 40, no. 5 (1997): 409–14. https://doi.org/10.1007/s002800050678.Full Text Link to Item
-
Hare, C. B., G. B. Elion, P. J. Houghton, J. A. Houghton, S. Keir, S. L. Marcelli, D. D. Bigner, and H. S. Friedman. “Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.” Cancer Chemother Pharmacol 39, no. 3 (1997): 187–91. https://doi.org/10.1007/s002800050558.Full Text Link to Item
-
Kurpad, S. N., M. E. Dolan, R. E. McLendon, G. E. Archer, R. C. Moschel, A. E. Pegg, D. D. Bigner, and H. S. Friedman. “Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea.” Cancer Chemother Pharmacol 39, no. 4 (1997): 307–16. https://doi.org/10.1007/s002800050577.Full Text Link to Item
-
Moynihan, K., G. B. Elion, C. Pegram, C. J. Reist, D. Wellner, D. D. Bigner, O. W. Griffith, and H. S. Friedman. “L-amino acid oxidase (LOX) modulation of melphalan activity against intracranial glioma.” Cancer Chemother Pharmacol 39, no. 3 (1997): 179–86. https://doi.org/10.1007/s002800050557.Full Text Link to Item
-
Friedman, H. S., and P. J. Houghton. “Treatment of central nervous system xenografts with camptothecins.” Ann N Y Acad Sci 803 (December 13, 1996): 210–12. https://doi.org/10.1111/j.1749-6632.1996.tb26390.x.Full Text Link to Item
-
Friedman, H. S., B. Sinha, A. Tun, R. Pasha, A. Sharafkhaneh, and A. Bharadwaj. “Zones of atrial vulnerability. Relationships to basic cycle length.” Circulation 94, no. 6 (September 15, 1996): 1456–64. https://doi.org/10.1161/01.cir.94.6.1456.Full Text Link to Item
-
Jones, D. N., G. B. McCowage, H. D. Sostman, D. M. Brizel, L. Layfield, H. C. Charles, M. W. Dewhirst, et al. “Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET.” J Nucl Med 37, no. 9 (September 1996): 1438–44.Link to Item
-
Halperin, E. C., and H. S. Friedman. “Is there a correlation between duration of presenting symptoms and stage of medulloblastoma at the time of diagnosis?” Cancer 78, no. 4 (August 15, 1996): 874–80. https://doi.org/10.1002/(SICI)1097-0142(19960815)78:4<874::AID-CNCR26>3.0.CO;2-R.Full Text Link to Item
-
Friedman, H. S. “Streptokinase versus alteplase in acute myocardial infarction.” J R Soc Med 89, no. 8 (August 1996): 427–30. https://doi.org/10.1177/014107689608900804.Full Text Link to Item
-
Vaidyanathan, G., H. S. Friedman, S. T. Keir, and M. R. Zalutsky. “Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model.” Nucl Med Biol 23, no. 6 (August 1996): 851–56. https://doi.org/10.1016/0969-8051(96)00115-1.Full Text Link to Item
-
McCowage, G., R. Tien, R. McLendon, G. Felsberg, H. Fuchs, M. L. Graham, J. Kurtzberg, et al. “Successful treatment of childhood pilocytic astrocytomas metastatic to the leptomeninges with high-dose cyclophosphamide.” Med Pediatr Oncol 27, no. 1 (July 1996): 32–39. https://doi.org/10.1002/(SICI)1096-911X(199607)27:1<32::AID-MPO7>3.0.CO;2-V.Full Text Link to Item
-
Ashley, D. M., D. Longee, R. Tien, H. Fuchs, M. L. Graham, J. Kurtzberg, J. Casey, et al. “Treatment of patients with pineoblastoma with high dose cyclophosphamide.” Med Pediatr Oncol 26, no. 6 (June 1996): 387–92. https://doi.org/10.1002/(SICI)1096-911X(199606)26:6<387::AID-MPO3>3.0.CO;2-D.Full Text Link to Item
-
Ashley, D. M., L. Meier, T. Kerby, F. M. Zalduondo, H. S. Friedman, A. Gajjar, L. Kun, P. K. Duffner, S. Smith, and D. Longee. “Response of recurrent medulloblastoma to low-dose oral etoposide.” J Clin Oncol 14, no. 6 (June 1996): 1922–27. https://doi.org/10.1200/JCO.1996.14.6.1922.Full Text Link to Item
-
Brown, M. T., R. E. Coleman, A. H. Friedman, H. S. Friedman, R. E. McLendon, R. Reiman, G. J. Felsberg, et al. “Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.” Clin Cancer Res 2, no. 6 (June 1996): 963–72.Link to Item
-
Friedman, H. S. “Tissue plasminogen activator for acute ischemic stroke.” N Engl J Med 334, no. 21 (May 23, 1996): 1405. https://doi.org/10.1056/NEJM199605233342114.Full Text Link to Item
-
McLendon, R. E., K. M. Fung, R. C. Bentley, B. K. Ahmed Rasheed, J. Q. Trojanowski, S. H. Bigner, D. D. Bigner, and H. S. Friedman. “Production and characterization of two ependymoma xenografts.” J Neuropathol Exp Neurol 55, no. 5 (May 1996): 540–48. https://doi.org/10.1097/00005072-199605000-00007.Full Text Link to Item
-
Vaidyanathan, G., H. S. Friedman, S. T. Keir, and M. R. Zalutsky. “Meta-[At-211]astatobenzylguanidine (MABG): In vivo evaluation in an athymic mouse human neuroblastoma xenograft model.” Journal of Nuclear Medicine 37, no. 5 (May 1, 1996): 236–236.Link to Item
-
Vaidyanathan, G., H. S. Friedman, S. T. Keir, and M. R. Zalutsky. “Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity.” Br J Cancer 73, no. 10 (May 1996): 1171–77. https://doi.org/10.1038/bjc.1996.226.Full Text Open Access Copy Link to Item
-
Tucker, J. S., H. S. Friedman, D. L. Wingard, and J. E. Schwartz. “Marital history at midlife as a predictor of longevity: alternative explanations to the protective effect of marriage.” Health Psychol 15, no. 2 (March 1996): 94–101. https://doi.org/10.1037//0278-6133.15.2.94.Full Text Link to Item
-
Kuyper, L. F., D. P. Baccanari, M. L. Jones, R. N. Hunter, R. L. Tansik, S. S. Joyner, C. M. Boytos, et al. “High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.” J Med Chem 39, no. 4 (February 16, 1996): 892–903. https://doi.org/10.1021/jm9505122.Full Text Link to Item
-
Barsky, D., Q. Dong, M. E. Colvin, C. F. Melius, S. M. Ludeman, O. M. Colvin, D. D. Bigner, P. Modrich, and H. S. Friedman. “A structural basis for a phosphoramide mustard-induced DNA interstrand cross-link at 5'd(GAC).” Biophysical Journal 70, no. 2 (February 1, 1996): MP447–MP447.Link to Item
-
Broome, C. B., R. I. Schiff, and H. S. Friedman. “Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions.” Med Pediatr Oncol 26, no. 2 (February 1996): 105–10. https://doi.org/10.1002/(SICI)1096-911X(199602)26:2<105::AID-MPO7>3.0.CO;2-P.Full Text Link to Item
-
Mahoney, D. H., D. Strother, B. Camitta, T. Bowen, T. Ghim, T. Pick, D. Wall, L. Yu, J. J. Shuster, and H. Friedman. “High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study.” J Clin Oncol 14, no. 2 (February 1996): 382–88. https://doi.org/10.1200/JCO.1996.14.2.382.Full Text Link to Item
-
Freeman, C. R., P. M. Bourgouin, R. A. Sanford, M. E. Cohen, H. S. Friedman, and L. E. Kun. “Long term survivors of childhood brain stem gliomas treated with hyperfractionated radiotherapy. Clinical characteristics and treatment related toxicities. The Pediatric Oncology Group.” Cancer 77, no. 3 (February 1, 1996): 555–62. https://doi.org/10.1002/(SICI)1097-0142(19960201)77:3<555::AID-CNCR19>3.0.CO;2-3.Full Text Link to Item
-
Srivenugopal, K. S., X. H. Yuan, H. S. Friedman, and F. Ali-Osman. “Ubiquitination-dependent proteolysis of O6-methylguanine-DNA methyltransferase in human and murine tumor cells following inactivation with O6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea.” Biochemistry 35, no. 4 (January 30, 1996): 1328–34. https://doi.org/10.1021/bi9518205.Full Text Link to Item
-
Blaeker, H., B. K. Rasheed, R. E. McLendon, H. S. Friedman, S. K. Batra, H. E. Fuchs, and S. H. Bigner. “Microsatellite analysis of childhood brain tumors.” Genes Chromosomes Cancer 15, no. 1 (January 1996): 54–63. https://doi.org/10.1002/(SICI)1098-2264(199601)15:1<54::AID-GCC8>3.0.CO;2-3.Full Text Link to Item
-
O’Leary, S. R., D. L. Wingard, S. L. Edelstein, M. H. Criqui, J. S. Tucker, and H. S. Friedman. “Is birth order associated with adult mortality?” Ann Epidemiol 6, no. 1 (January 1996): 34–40. https://doi.org/10.1016/1047-2797(95)00098-4.Full Text Link to Item
-
Dong, Q., N. Bullock, F. Ali-Osman, O. M. Colvin, D. D. Bigner, and H. S. Friedman. “Repair analysis of 4-hydroperoxycyclophosphamide-induced DNA interstrand crosslinking in the c-myc gene in 4-hydroperoxycyclophosphamide-sensitive and -resistant medulloblastoma cell lines.” Cancer Chemother Pharmacol 37, no. 3 (1996): 242–46. https://doi.org/10.1007/BF00688323.Full Text Link to Item
-
Duffner, P. K., J. P. Krischer, P. C. Burger, M. E. Cohen, J. W. Backstrom, M. E. Horowitz, R. A. Sanford, H. S. Friedman, and L. E. Kun. “Treatment of infants with malignant gliomas: the Pediatric Oncology Group experience.” J Neurooncol 28, no. 2–3 (1996): 245–56. https://doi.org/10.1007/BF00250203.Full Text Link to Item
-
Halperin, E. C., T. Samulski, W. J. Oakes, and H. S. Friedman. “Fabrication and testing of a device capable of reducing the incidence of ventricular shunt promoted metastasis.” J Neurooncol 27, no. 1 (January 1996): 39–46. https://doi.org/10.1007/BF00146082.Full Text Link to Item
-
Moynihan, K., G. B. Elion, F. Ali-Osman, S. Marcelli, S. Keir, D. D. Bigner, and H. S. Friedman. “Enhancement of melphalan activity by inhibition of DNA polymerase-alpha and DNA polymerase-beta.” Cancer Chemother Pharmacol 38, no. 4 (1996): 349–54. https://doi.org/10.1007/s002800050494.Full Text Link to Item
-
Tonda, M. E., R. L. Heideman, W. P. Petros, H. S. Friedman, D. J. Murry, and J. H. Rodman. “Carboplatin pharmacokinetics in young children with brain tumors.” Cancer Chemother Pharmacol 38, no. 5 (1996): 395–400. https://doi.org/10.1007/s002800050502.Full Text Link to Item
-
Dong, Q., D. Barsky, M. E. Colvin, C. F. Melius, S. M. Ludeman, J. F. Moravek, O. M. Colvin, D. D. Bigner, P. Modrich, and H. S. Friedman. “A structural basis for a phosphoramide mustard-induced DNA interstrand cross-link at 5'-d(GAC).” Proc Natl Acad Sci U S A 92, no. 26 (December 19, 1995): 12170–74. https://doi.org/10.1073/pnas.92.26.12170.Full Text Link to Item
-
Bigner, D. D., G. E. Archer, R. E. McLendon, H. S. Friedman, H. E. Fuchs, L. H. Pai, J. E. Herndon, and I. H. Pastan. “Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis.” Clin Cancer Res 1, no. 12 (December 1995): 1545–55.Link to Item
-
Lirng, J. F., D. S. Enterline, R. D. Tien, H. Fuchs, H. S. Friedman, K. S. Ellington, and R. P. McLendon. “MRI of papillary meningiomas in children.” Pediatr Radiol 25 Suppl 1 (November 1995): S9-13.Link to Item
-
Batra, S. K., S. Castelino-Prabhu, C. J. Wikstrand, X. Zhu, P. A. Humphrey, H. S. Friedman, and D. D. Bigner. “Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene.” Cell Growth Differ 6, no. 10 (October 1995): 1251–59.Link to Item
-
Kurpad, S. N., H. S. Friedman, G. E. Archer, R. E. McLendon, W. M. Petros, H. E. Fuchs, A. Guaspari, and D. D. Bigner. “Intraarterial administration of melphalan for treatment of intracranial human glioma xenografts in athymic rats.” Cancer Res 55, no. 17 (September 1, 1995): 3803–9.Link to Item
-
Schwartz, J. E., H. S. Friedman, J. S. Tucker, C. Tomlinson-Keasey, D. L. Wingard, and M. H. Criqui. “Sociodemographic and psychosocial factors in childhood as predictors of adult mortality.” Am J Public Health 85, no. 9 (September 1995): 1237–45. https://doi.org/10.2105/ajph.85.9.1237.Full Text Link to Item
-
Martin, L. R., H. S. Friedman, J. S. Tucker, J. E. Schwartz, M. H. Criqui, D. L. Wingard, and C. Tomlinson-Keasey. “An archival prospective study of mental health and longevity.” Health Psychol 14, no. 5 (September 1995): 381–87. https://doi.org/10.1037//0278-6133.14.5.381.Full Text Link to Item
-
Moghrabi, A., H. Fuchs, M. Brown, S. C. Schold, M. Graham, J. Kurtzberg, R. Tien, G. Felsberg, D. H. Lachance, and O. M. Colvin. “Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma.” Med Pediatr Oncol 25, no. 3 (September 1995): 190–96. https://doi.org/10.1002/mpo.2950250306.Full Text Link to Item
-
Friedman, H. S., M. E. Dolan, A. E. Pegg, S. Marcelli, S. Keir, J. J. Catino, D. D. Bigner, and S. C. Schold. “Activity of temozolomide in the treatment of central nervous system tumor xenografts.” Cancer Res 55, no. 13 (July 1, 1995): 2853–57.Link to Item
-
Duffner, P. K., M. E. Cohen, R. A. Sanford, M. E. Horowitz, J. P. Krischer, P. C. Burger, H. S. Friedman, and L. E. Kun. “Lack of efficacy of postoperative chemotherapy and delayed radiation in very young children with pineoblastoma. Pediatric Oncology Group.” Med Pediatr Oncol 25, no. 1 (July 1995): 38–44. https://doi.org/10.1002/mpo.2950250109.Full Text Link to Item
-
Marks, L. B., D. Cuthbertson, and H. S. Friedman. “Hematologic toxicity during craniospinal irradiation: the impact of prior chemotherapy.” Med Pediatr Oncol 25, no. 1 (July 1995): 45–51. https://doi.org/10.1002/mpo.2950250110.Full Text Link to Item
-
Castellino, S. M., H. S. Friedman, G. B. Elion, E. T. Ong, S. L. Marcelli, R. Page, D. D. Bigner, and M. W. Dewhirst. “Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma.” Br J Cancer 71, no. 6 (June 1995): 1181–87. https://doi.org/10.1038/bjc.1995.230.Full Text Link to Item
-
Razzouk, B. I., R. L. Heideman, H. S. Friedman, J. J. Jenkins, L. E. Kun, D. L. Fairclough, and M. E. Horowitz. “A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors.” Cancer 75, no. 11 (June 1, 1995): 2762–67. https://doi.org/10.1002/1097-0142(19950601)75:11<2762::aid-cncr2820751121>3.0.co;2-2.Full Text Link to Item
-
Heinz, R., D. Wiener, H. Friedman, and R. Tien. “Detection of cerebrospinal fluid metastasis: CT myelography or MR?” Ajnr Am J Neuroradiol 16, no. 5 (May 1995): 1147–51.Link to Item
-
Foltz, R. M., R. E. McLendon, H. S. Friedman, R. K. Dodge, D. D. Bigner, and M. W. Dewhirst. “A pial window model for the intracranial study of human glioma microvascular function.” Neurosurgery 36, no. 5 (May 1995): 976–84. https://doi.org/10.1227/00006123-199505000-00014.Full Text Link to Item
-
Friedman, H. S., J. S. Tucker, J. E. Schwartz, L. R. Martin, C. Tomlinson-Keasey, D. L. Wingard, and M. H. Criqui. “Childhood conscientiousness and longevity: health behaviors and cause of death.” J Pers Soc Psychol 68, no. 4 (April 1995): 696–703. https://doi.org/10.1037//0022-3514.68.4.696.Full Text Link to Item
-
Lachance, D. H., D. Oette, S. C. Schold, M. Brown, J. Kurtzberg, M. L. Graham, R. Tien, G. Felsberg, O. M. Colvin, and A. Moghrabi. “Dose escalation trial of cyclophosphamide with Sargramostim in the treatment of central nervous system (CNS) neoplasms.” Med Pediatr Oncol 24, no. 4 (April 1995): 241–47. https://doi.org/10.1002/mpo.2950240406.Full Text Link to Item
-
Pastan, I. H., G. E. Archer, R. E. McLendon, H. S. Friedman, H. E. Fuchs, Q. C. Wang, L. H. Pai, J. Herndon, and D. D. Bigner. “Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model.” Proc Natl Acad Sci U S A 92, no. 7 (March 28, 1995): 2765–69. https://doi.org/10.1073/pnas.92.7.2765.Full Text Link to Item
-
Tucker, J. S., H. S. Friedman, C. M. Tsai, and L. R. Martin. “Playing with pets and longevity among older people.” Psychol Aging 10, no. 1 (March 1995): 3–7. https://doi.org/10.1037//0882-7974.10.1.3.Full Text Link to Item
-
Friedman, H. S., J. S. Tucker, J. E. Schwartz, C. Tomlinson-Keasey, L. R. Martin, D. L. Wingard, and M. H. Criqui. “Psychosocial and behavioral predictors of longevity. The aging and death of the "termites".” Am Psychol 50, no. 2 (February 1995): 69–78. https://doi.org/10.1037//0003-066x.50.2.69.Full Text Link to Item
-
Friedman, H. S., N. Cirillo, F. Schiano, P. Nathan, S. Khan, H. Rosero, M. Vaseghi, T. Sacchi, B. Vasavada, and L. Bjornson. “Vasodilatory state of decompensated cirrhosis: relation to hepatic dysfunction, ascites, and vasoactive substances.” Alcohol Clin Exp Res 19, no. 1 (February 1995): 123–29. https://doi.org/10.1111/j.1530-0277.1995.tb01479.x.Full Text Link to Item
-
Friedman, H. S., and L. E. Kun. “More on surveillance of children with medulloblastoma.” N Engl J Med 332, no. 3 (January 19, 1995): 191. https://doi.org/10.1056/NEJM199501193320316.Full Text Link to Item
-
Duffner, P. K., L. E. Kun, P. C. Burger, M. E. Horowitz, M. E. Cohen, R. A. Sanford, J. P. Krischer, R. K. Mulhern, H. E. James, and H. L. Rekate. “Postoperative chemotherapy and delayed radiation in infants and very young children with choroid plexus carcinomas. The Pediatric Oncology Group.” Pediatr Neurosurg 22, no. 4 (1995): 189–96. https://doi.org/10.1159/000120900.Full Text Link to Item
-
Moghrabi, A., T. Kerby, R. D. Tien, and H. S. Friedman. “Prognostic value of contrast-enhanced magnetic resonance imaging in brainstem gliomas.” Pediatr Neurosurg 23, no. 6 (1995): 293–98. https://doi.org/10.1159/000120974.Full Text Link to Item
-
Batra, S. K., R. E. McLendon, J. S. Koo, S. Castelino-Prabhu, H. E. Fuchs, J. P. Krischer, H. S. Friedman, D. D. Bigner, and S. H. Bigner. “Prognostic implications of chromosome 17p deletions in human medulloblastomas.” J Neurooncol 24, no. 1 (1995): 39–45. https://doi.org/10.1007/BF01052657.Full Text Link to Item
-
Bigner, D. D., M. Brown, R. E. Coleman, A. H. Friedman, H. S. Friedman, R. E. McLendon, S. H. Bigner, X. G. Zhao, C. J. Wikstrand, and C. N. Pegram. “Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report.” J Neurooncol 24, no. 1 (1995): 109–22. https://doi.org/10.1007/BF01052668.Full Text Link to Item
-
Friedman, H. S., S. H. Bigner, and D. D. Bigner. “Cyclophosphamide therapy of medulloblastoma: from the laboratory to the clinic and back again (and again and again).” J Neurooncol 24, no. 1 (1995): 103–8. https://doi.org/10.1007/BF01052667.Full Text Link to Item
-
Heideman, R. L., E. C. Douglass, J. A. Langston, J. P. Krischer, P. C. Burger, E. H. Kovnar, L. E. Kun, H. S. Friedman, and R. Kadota. “A phase II study of every other day high-dose ifosfamide in pediatric brain tumors: a Pediatric Oncology Group Study.” J Neurooncol 25, no. 1 (1995): 77–84. https://doi.org/10.1007/BF01054726.Full Text Link to Item
-
Houghton, P. J., P. J. Cheshire, J. D. Hallman, L. Lutz, H. S. Friedman, M. K. Danks, and J. A. Houghton. “Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.” Cancer Chemother Pharmacol 36, no. 5 (1995): 393–403. https://doi.org/10.1007/BF00686188.Full Text Link to Item
-
Rich, J. N., G. B. Elion, D. Wellner, O. M. Colvin, D. R. Groothuis, J. H. Hilton, K. E. Schlageter, D. D. Bigner, O. W. Griffith, and H. S. Friedman. “The effect of L-amino acid oxidase on activity of melphalan against an intracranial xenograft.” Cancer Chemother Pharmacol 36, no. 5 (1995): 379–84. https://doi.org/10.1007/BF00686186.Full Text Link to Item
-
Schuster, J. M., M. R. Zalutsky, M. A. Noska, R. Dodge, H. S. Friedman, D. D. Bigner, and M. W. Dewhirst. “Hyperthermic modulation of radiolabelled antibody uptake in a human glioma xenograft and normal tissues.” Int J Hyperthermia 11, no. 1 (1995): 59–72. https://doi.org/10.3109/02656739509004948.Full Text Link to Item
-
Strickland, D. K., G. Vaidyanathan, H. S. Friedman, and M. R. Zalutsky. “Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines.” J Neurooncol 25, no. 1 (1995): 9–17. https://doi.org/10.1007/BF01054718.Full Text Link to Item
-
Friedman, H. S. “Effect of coronary artery bypass graft surgery on survival.” Lancet 344, no. 8931 (October 29, 1994): 1223.Link to Item
-
Dolan, M. E., M. Y. Chae, A. E. Pegg, J. H. Mullen, H. S. Friedman, and R. C. Moschel. “Metabolism of O6-benzylguanine, an inactivator of O6-alkylguanine-DNA alkyltransferase.” Cancer Res 54, no. 19 (October 1, 1994): 5123–30.Link to Item
-
Nelson, C. A., H. S. Friedman, S. Goozovat, J. A. Klein, L. R. Kneller, W. J. Perry, and S. A. Ustin. “Stage-two spin-correlation functions: Tests for non-CKM-type leptonic CP violation in tau --> rho nu decay.” Phys Rev D Part Fields 50, no. 7 (October 1, 1994): 4544–57. https://doi.org/10.1103/physrevd.50.4544.Full Text Link to Item
-
Friedman, H. S., G. E. Archer, R. E. McLendon, J. M. Schuster, O. M. Colvin, A. Guaspari, R. Blum, P. A. Savina, H. E. Fuchs, and D. D. Bigner. “Intrathecal melphalan therapy of human neoplastic meningitis in athymic nude rats.” Cancer Res 54, no. 17 (September 1, 1994): 4710–14.Link to Item
-
Wingard, D. L., M. H. Criqui, S. L. Edelstein, J. Tucker, C. Tomlinson-Keasey, J. E. Schwartz, and H. S. Friedman. “Is breast-feeding in infancy associated with adult longevity?” Am J Public Health 84, no. 9 (September 1994): 1458–62. https://doi.org/10.2105/ajph.84.9.1458.Full Text Link to Item
-
Friedman, H. S., M. E. Dolan, and R. C. Moschel. “Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.” Journal of the National Cancer Institute 86, no. 13 (July 6, 1994): 1027. https://doi.org/10.1093/jnci/86.13.1027.Full Text
-
Friedman, H. S., M. E. Dolan, S. H. Kaufmann, O. M. Colvin, O. W. Griffith, R. C. Moschel, S. C. Schold, D. D. Bigner, and F. Ali-Osman. “Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.” Cancer Res 54, no. 13 (July 1, 1994): 3487–93.Link to Item
-
Friedman, H. S., G. Archer, and D. D. Bigner. “Re: Toxicity of intrathecal melphalan.” J Natl Cancer Inst 86, no. 11 (June 1, 1994): 870–71. https://doi.org/10.1093/jnci/86.11.870.Full Text Link to Item
-
HOFFMAN, J. M., V. J. LOWE, H. S. FRIEDMAN, L. HARRIS, and R. E. COLEMAN. “METABOLIC CHARACTERIZATION OF PEDIATRIC PRIMARY BRAIN-TUMORS USING FDG-PET.” Journal of Nuclear Medicine 35, no. 5 (May 1, 1994): P44–P44.Link to Item
-
JONES, D. N., D. M. BRIZEL, H. C. CHARLES, M. W. DEWHIRST, H. S. FRIEDMAN, G. MCCOWAGE, D. M. PRESCOTT, H. D. SOSTMAN, and R. E. COLEMAN. “MONITORING OF RESPONSE TO NEOADJUVANT THERAPY OF SOFT-TISSUE AND MUSCULOSKELETAL SARCOMAS USING F-18-FDG PET.” Journal of Nuclear Medicine 35, no. 5 (May 1, 1994): P38–P38.Link to Item
-
Bandu, I., H. S. Friedman, P. Raggi, S. Fishman, S. Prasada, T. Sacchi, and B. Chandramouly. “Symptoms of patients with silent ischemia as detected by thallium stress testing.” Chest 105, no. 4 (April 1994): 1009–12. https://doi.org/10.1378/chest.105.4.1009.Full Text Link to Item
-
Schumacher, D. J., R. D. Tien, and H. Friedman. “Gadolinium enhancement of the leptomeninges caused by hydrocephalus: a potential mimic of leptomeningeal metastasis.” Ajnr Am J Neuroradiol 15, no. 4 (April 1994): 639–41.Link to Item
-
Rasheed, B. K., R. E. McLendon, J. E. Herndon, H. S. Friedman, A. H. Friedman, D. D. Bigner, and S. H. Bigner. “Alterations of the TP53 gene in human gliomas.” Cancer Res 54, no. 5 (March 1, 1994): 1324–30.Link to Item
-
Tien, R. D., G. J. Felsberg, H. Friedman, M. Brown, and J. MacFall. “MR imaging of high-grade cerebral gliomas: value of diffusion-weighted echoplanar pulse sequences.” Ajr Am J Roentgenol 162, no. 3 (March 1994): 671–77. https://doi.org/10.2214/ajr.162.3.8109520.Full Text Link to Item
-
Friedman, H. S. “Thrombolytic therapy for acute myocardial infarction: GUSTO criticized.” N Engl J Med 330, no. 7 (February 17, 1994): 504. https://doi.org/10.1056/NEJM199402173300715.Full Text Link to Item
-
Friedman, H. S., J. S. Tucker, L. R. Martin, C. Tomlinson-Keasey, J. E. Schwartz, D. L. Wingard, and M. H. Criqui. “Do non-scientists really live longer?” Lancet 343, no. 8892 (January 29, 1994): 296. https://doi.org/10.1016/s0140-6736(94)91143-6.Full Text Link to Item
-
Friedman, H. S., M. E. Dolan, and R. C. Moschel. “Erratum: Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme (Journal of the National Cancer Institute (1992) 84 (1926-1931)).” Journal of the National Cancer Institute 86, no. 13 (January 1, 1994): 1027.
-
Kadota, R. P., L. R. Mandell, J. Fontanesi, E. H. Kovnar, J. Krischer, L. E. Kun, and H. S. Friedman. “Hyperfractionated irradiation and concurrent cisplatin in brain stem tumors: a Pediatric Oncology Group pilot study (9139).” Pediatr Neurosurg 20, no. 4 (1994): 221–25. https://doi.org/10.1159/000120794.Full Text Link to Item
-
MCLENDON, R. E., A. BRADLEY, J. E. PARISI, B. W. SCHEITHAUER, G. FELSBERG, and H. S. FRIEDMAN. “COMPOSITE NEUROBLASTOMA MALIGNANT GLIOMA.” Laboratory Investigation 70, no. 1 (January 1, 1994): A139–A139.Link to Item
-
Aaron, R. H., G. B. Elion, O. M. Colvin, M. Graham, S. Keir, D. D. Bigner, and H. S. Friedman. “Busulfan therapy of central nervous system xenografts in athymic mice.” Cancer Chemother Pharmacol 35, no. 2 (1994): 127–31. https://doi.org/10.1007/BF00686634.Full Text Link to Item
-
Bruggers, C. S., H. S. Friedman, R. Tien, and R. Delong. “Cerebral atrophy in an infant following treatment with ifosfamide.” Med Pediatr Oncol 23, no. 4 (1994): 380–83. https://doi.org/10.1002/mpo.2950230412.Full Text Link to Item
-
Dolan, M. E., A. E. Pegg, R. C. Moschel, B. R. Vishnuvajjala, K. P. Flora, M. R. Grever, and H. S. Friedman. “Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL.” Cancer Chemother Pharmacol 35, no. 2 (1994): 121–26. https://doi.org/10.1007/BF00686633.Full Text Link to Item
-
Friedman, H. S., P. J. Houghton, S. C. Schold, S. Keir, and D. D. Bigner. “Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts.” Cancer Chemother Pharmacol 34, no. 2 (1994): 171–74. https://doi.org/10.1007/BF00685936.Full Text Link to Item
-
Kline, N. E., H. S. Friedman, R. H. Pitts, M. Barry, M. K. Foley, and K. L. Lindsley. “Ellen, a 12-year-old girl, was given a diagnosis of a primitive neuroectodermal tumor.” Cancer Pract 2, no. 6 (1994): 400–404.Link to Item
-
Krishna, M. C., M. W. Dewhirst, H. S. Friedman, J. A. Cook, W. DeGraff, A. Samuni, A. Russo, and J. B. Mitchell. “Hyperthermic sensitization by the radical initiator 2,2'-azobis (2-amidinopropane) dihydrochloride (AAPH). I. In vitro studies.” Int J Hyperthermia 10, no. 2 (1994): 271–81. https://doi.org/10.3109/02656739409009348.Full Text Link to Item
-
Moghrabi, A., H. S. Friedman, R. McLendon, B. Hockenberger, R. D. Tien, E. C. Halperin, and W. J. Oakes. “Arteriovenous malformation mimicking recurrent medulloblastoma.” Med Pediatr Oncol 22, no. 2 (1994): 140–43. https://doi.org/10.1002/mpo.2950220216.Full Text Link to Item
-
Nashold, J. R., W. J. Oakes, H. S. Friedman, E. C. Halperin, M. Soo, B. Hockenberger, G. N. Fuller, and R. Tien. “Management of pineal non-germinoma germ cell tumor with residual teratoma and normal alpha-fetoprotein.” Med Pediatr Oncol 22, no. 2 (1994): 137–39. https://doi.org/10.1002/mpo.2950220215.Full Text Link to Item
-
Osumi, A. K., R. E. Mclendon, R. D. Tien, H. S. Friedman, M. Graham, B. Hockenberger, E. C. Halperin, and W. J. Oakes. “Well differentiated astrocytoma occurring nine years after radiation therapy for medulloblastoma.” Clin Neuropathol 13, no. 5 (1994): 281–85.Link to Item
-
Mosijczuk, A. D., M. A. Nigro, P. R. Thomas, P. C. Burger, J. P. Krischer, R. A. Morantz, B. Kurdunowicz, A. F. Mulne, R. B. Towbin, and A. I. Freeman. “Preradiation chemotherapy in advanced medulloblastoma. A Pediatric Oncology Group pilot study.” Cancer 72, no. 9 (November 1, 1993): 2755–62. https://doi.org/10.1002/1097-0142(19931101)72:9<2755::aid-cncr2820720937>3.0.co;2-v.Full Text Link to Item
-
Halperin, E. C., H. S. Friedman, S. C. Schold, H. E. Fuchs, W. J. Oakes, B. Hockenberger, and P. C. Burger. “Surgery, hyperfractionated craniospinal irradiation, and adjuvant chemotherapy in the management of supratentorial embryonal neuroepithelial neoplasms in children.” Surg Neurol 40, no. 4 (October 1993): 278–83. https://doi.org/10.1016/0090-3019(93)90138-q.Full Text Link to Item
-
Garg, S., P. K. Garg, X. G. Zhao, H. S. Friedman, D. D. Bigner, and M. R. Zalutsky. “Radioiodination of a monoclonal antibody using N-succinimidyl 5-iodo-3-pyridinecarboxylate.” Nucl Med Biol 20, no. 7 (October 1993): 835–42. https://doi.org/10.1016/0969-8051(93)90149-o.Full Text Link to Item
-
Freeman, C. R., J. P. Krischer, R. A. Sanford, M. E. Cohen, P. C. Burger, R. del Carpio, E. C. Halperin, L. Munoz, H. S. Friedman, and L. E. Kun. “Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study.” Int J Radiat Oncol Biol Phys 27, no. 2 (September 30, 1993): 197–206. https://doi.org/10.1016/0360-3016(93)90228-n.Full Text Link to Item
-
Beauchamp, C., E. C. Westman, and J. A. Govert. “Treatment of acute myocardial infarction.” N Engl J Med 329, no. 6 (August 5, 1993): 430. https://doi.org/10.1056/NEJM199308053290613.Full Text Link to Item
-
Nelson, S. C., C. S. Bruggers, J. Kurtzberg, and H. S. Friedman. “Management of leukemic hyperleukocytosis with hydration, urinary alkalinization, and allopurinol. Are cranial irradiation and invasive cytoreduction necessary?” Am J Pediatr Hematol Oncol 15, no. 3 (August 1993): 351–55.Link to Item
-
Strong, J. A., H. P. Hatten, M. T. Brown, J. F. Debatin, H. S. Friedman, W. J. Oakes, and R. Tien. “Pilocytic astrocytoma: correlation between the initial imaging features and clinical aggressiveness.” Ajr Am J Roentgenol 161, no. 2 (August 1993): 369–72. https://doi.org/10.2214/ajr.161.2.8333380.Full Text Link to Item
-
Gravatt, L. C., S. Chaffee, M. E. Hebert, E. C. Halperin, H. S. Friedman, and J. Kurtzberg. “Efficacy and toxicity of 9-beta-D-arabinofuranosylguanine (araG) as an agent to purge malignant T cells from murine bone marrow: application to an in vivo T-leukemia model.” Leukemia 7, no. 8 (August 1993): 1261–67.Link to Item
-
Moghrabi, A., H. S. Friedman, P. C. Burger, R. Tien, and W. J. Oakes. “Carboplatin treatment of progressive optic pathway gliomas to delay radiotherapy.” J Neurosurg 79, no. 2 (August 1993): 223–27. https://doi.org/10.3171/jns.1993.79.2.0223.Full Text Link to Item
-
Levine, E. S., H. S. Friedman, O. W. Griffith, O. M. Colvin, J. H. Raynor, and M. Lieberman. “Cardiac cell toxicity induced by 4-hydroperoxycyclophosphamide is modulated by glutathione.” Cardiovasc Res 27, no. 7 (July 1993): 1248–53. https://doi.org/10.1093/cvr/27.7.1248.Full Text Link to Item
-
Friedman, H. S., J. S. Tucker, C. Tomlinson-Keasey, J. E. Schwartz, D. L. Wingard, and M. H. Criqui. “Does childhood personality predict longevity?” J Pers Soc Psychol 65, no. 1 (July 1993): 176–85. https://doi.org/10.1037//0022-3514.65.1.176.Full Text Link to Item
-
Duffner, P. K., M. E. Horowitz, J. P. Krischer, H. S. Friedman, P. C. Burger, M. E. Cohen, R. A. Sanford, R. K. Mulhern, H. E. James, and C. R. Freeman. “Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors.” N Engl J Med 328, no. 24 (June 17, 1993): 1725–31. https://doi.org/10.1056/NEJM199306173282401.Full Text Link to Item
-
Schuster, J. M., H. S. Friedman, G. E. Archer, H. E. Fuchs, R. E. McLendon, O. M. Colvin, and D. D. Bigner. “Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide.” Cancer Res 53, no. 10 Suppl (May 15, 1993): 2338–43.Link to Item
-
Brown, M. T., H. S. Friedman, W. J. Oakes, O. B. Boyko, B. Hockenberger, and S. C. Schold. “Chemotherapy for pilocytic astrocytomas.” Cancer 71, no. 10 (May 15, 1993): 3165–72. https://doi.org/10.1002/1097-0142(19930515)71:10<3165::aid-cncr2820711044>3.0.co;2-n.Full Text Link to Item
-
McLENDON, R. E., S. K. BATRA, H. S. FRIEDMAN, B. K. A. RASHEED, D. D. BIGNER, and S. H. BIGNER. “EXPRESSION OF C-MYC IN MEDULLOBLASTOMA XENOGRAFTS.” Journal of Neuropathology and Experimental Neurology 52, no. 3 (May 1993): 267–267. https://doi.org/10.1097/00005072-199305000-00030.Full Text
-
Soo, M. S., R. D. Tien, L. Gray, P. I. Andrews, and H. Friedman. “Mesenrhombencephalitis: MR findings in nine patients.” Ajr Am J Roentgenol 160, no. 5 (May 1993): 1089–93. https://doi.org/10.2214/ajr.160.5.8470582.Full Text Link to Item
-
Friedman, H. S., B. Babb, I. B. Shim, G. Sotomora, S. M. Farrer, and B. C. Vasavada. “Demonstration of a relation between urinary digoxin-like immunoreactive substance and cardiac performance.” Chest 103, no. 3 (March 1993): 878–81. https://doi.org/10.1378/chest.103.3.878.Full Text Link to Item
-
Castellino, S., G. B. Elion, O. W. Griffith, M. Dewhirst, J. Kurtzberg, R. C. Cattley, P. Scott, D. D. Bigner, and H. S. Friedman. “Development of a model of melphalan-induced gastrointestinal toxicity in mice.” Cancer Chemother Pharmacol 31, no. 5 (1993): 376–80. https://doi.org/10.1007/BF00686151.Full Text Link to Item
-
Wikstrand, C. J., D. C. Longee, R. E. McLendon, G. N. Fuller, H. S. Friedman, P. Fredman, L. Svennerholm, and D. D. Bigner. “Lactotetraose series ganglioside 3',6'-isoLD1 in tumors of central nervous and other systems in vitro and in vivo.” Cancer Res 53, no. 1 (January 1, 1993): 120–26.Link to Item
-
Ashdown, B. C., O. B. Boyko, J. P. Uglietta, H. S. Friedman, B. Hockenberger, W. J. Oakes, and G. N. Fuller. “Postradiation cerebellar necrosis mimicking tumor: MR appearance.” J Comput Assist Tomogr 17, no. 1 (1993): 124–26. https://doi.org/10.1097/00004728-199301000-00022.Full Text Link to Item
-
Bruggers, C. S., H. S. Friedman, G. N. Fuller, R. D. Tien, L. B. Marks, E. C. Halperin, B. Hockenberger, W. J. Oakes, and J. M. Hoffman. “Comparison of serial PET and MRI scans in a pediatric patient with a brainstem glioma.” Med Pediatr Oncol 21, no. 4 (1993): 301–6. https://doi.org/10.1002/mpo.2950210414.Full Text Link to Item
-
Colvin, O. M., H. S. Friedman, M. P. Gamcsik, C. Fenselau, and J. Hilton. “Role of glutathione in cellular resistance to alkylating agents.” Adv Enzyme Regul 33 (1993): 19–26. https://doi.org/10.1016/0065-2571(93)90006-y.Full Text Link to Item
-
Felker, G. M., H. S. Friedman, M. E. Dolan, R. C. Moschel, and C. Schold. “Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.” Cancer Chemother Pharmacol 32, no. 6 (1993): 471–76. https://doi.org/10.1007/BF00685892.Full Text Link to Item
-
Nelson, S. C., H. S. Friedman, B. Hockenberger, J. J. Vandersteenhoven, L. Gray, S. L. Touri, and W. J. Oakes. “False-positive MRI detection of recurrent or metastatic pediatric infratentorial tumors.” Med Pediatr Oncol 21, no. 5 (1993): 350–55. https://doi.org/10.1002/mpo.2950210508.Full Text Link to Item
-
Schuster, J. M., H. S. Friedman, G. E. Archer, H. E. Fuchs, R. E. McLendon, and D. D. Bigner. “Intraarterial Therapy of Human Glioma Xenografts in Athymic Rats Using 4-Hydroperoxycyclophosphamide.” Cancer Research 53, no. 10 (January 1, 1993): 2338–43.
-
Friedman, H. S., M. E. Dolan, R. C. Moschel, A. E. Pegg, G. M. Felker, J. Rich, D. D. Bigner, and S. C. Schold. “Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.” J Natl Cancer Inst 84, no. 24 (December 16, 1992): 1926–31. https://doi.org/10.1093/jnci/84.24.1926.Full Text Link to Item
-
Friedman, H. S., and G. R. VandenBos. “Disease-prone and self-healing personalities.” Hosp Community Psychiatry 43, no. 12 (December 1992): 1177–79. https://doi.org/10.1176/ps.43.12.1177.Full Text Link to Item
-
Groothuis, D. R., B. E. Lippitz, I. Fekete, K. E. Schlageter, P. Molnar, O. M. Colvin, C. R. Roe, D. D. Bigner, and H. S. Friedman. “The effect of an amino acid-lowering diet on the rate of melphalan entry into brain and xenotransplanted glioma.” Cancer Res 52, no. 20 (October 15, 1992): 5590–96.Link to Item
-
DeLong, R., H. Friedman, N. Friedman, K. Gustafson, and J. Oakes. “Methylphenidate in neuropsychological sequelae of radiotherapy and chemotherapy of childhood brain tumors and leukemia.” J Child Neurol 7, no. 4 (October 1992): 462–63. https://doi.org/10.1177/088307389200700425.Full Text Link to Item
-
Friedman, H. S., O. M. Colvin, S. H. Kaufmann, S. M. Ludeman, N. Bullock, D. D. Bigner, and O. W. Griffith. “Cyclophosphamide resistance in medulloblastoma.” Cancer Res 52, no. 19 (October 1, 1992): 5373–78.Link to Item
-
Friedman, H. S., and H. Fernando. “Ascites as a marker for the hyperdynamic heart of Laennec's cirrhosis.” Alcohol Clin Exp Res 16, no. 5 (October 1992): 968–70. https://doi.org/10.1111/j.1530-0277.1992.tb01902.x.Full Text Link to Item
-
Malik, R. K., G. N. Fuller, W. J. Oakes, R. Tien, B. Hockenberger, H. S. Friedman, and E. C. Halperin. “Back pain and paraplegia in a fifteen-year-old boy.” J Pediatr 121, no. 4 (October 1992): 652–58. https://doi.org/10.1016/s0022-3476(05)81166-7.Full Text Link to Item
-
Mulligan, K., S. Nelson, H. S. Friedman, and P. I. Andrews. “Shigellosis-associated encephalopathy.” Pediatr Infect Dis J 11, no. 10 (October 1992): 889–90. https://doi.org/10.1097/00006454-199210000-00017.Full Text Link to Item
-
Nelson, S. C., H. S. Friedman, W. J. Oakes, E. C. Halperin, R. Tien, G. N. Fuller, B. Hockenberger, M. W. Scroggs, M. Moncino, and J. Kurtzberg. “Successful therapy for trilateral retinoblastoma.” Am J Ophthalmol 114, no. 1 (July 15, 1992): 23–29. https://doi.org/10.1016/s0002-9394(14)77408-2.Full Text Link to Item
-
Friedman, H. S., and W. J. Oakes. “New therapeutic options in the management of childhood brain tumors.” Oncology (Williston Park) 6, no. 5 (May 1992): 27–36.Link to Item
-
He, X. M., L. E. Ostrowski, M. A. von Wronski, H. S. Friedman, C. J. Wikstrand, S. H. Bigner, A. Rasheed, S. K. Batra, S. Mitra, and T. P. Brent. “Expression of O6-methylguanine-DNA methyltransferase in six human medulloblastoma cell lines.” Cancer Res 52, no. 5 (March 1, 1992): 1144–48.Link to Item
-
Dunsmore, K. P., H. S. Friedman, and J. Kurtzberg. “The uses of intravenous immunoglobulin in pediatrics. An update.” Crit Rev Oncol Hematol 12, no. 2 (March 1992): 67–90. https://doi.org/10.1016/1040-8428(92)90085-5.Full Text Link to Item
-
Friedman, H. S. “Is there sex bias in the management of coronary artery disease?” N Engl J Med 326, no. 8 (February 20, 1992): 571.Link to Item
-
Friedman, H. S., J. P. Krischer, P. Burger, W. J. Oakes, B. Hockenberger, M. D. Weiner, J. M. Falletta, D. Norris, A. H. Ragab, and D. H. Mahoney. “Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study.” J Clin Oncol 10, no. 2 (February 1992): 249–56. https://doi.org/10.1200/JCO.1992.10.2.249.Full Text Link to Item
-
Laskowitz, D. T., G. B. Elion, M. W. Dewhirst, O. W. Griffith, P. M. Savina, M. R. Blum, D. M. Prescott, D. D. Bigner, and H. S. Friedman. “Hyperthermia-induced enhancement of melphalan activity against a melphalan-resistant human rhabdomyosarcoma xenograft.” Radiat Res 129, no. 2 (February 1992): 218–23.Link to Item
-
Halperin, E. C., D. M. Brizel, G. Honore, M. R. Sontag, O. W. Griffith, D. D. Bigner, and H. S. Friedman. “The radiation dose-response relationship in a human glioma xenograft and an evaluation of the influence of glutathione depletion by buthionine sulfoximine.” Int J Radiat Oncol Biol Phys 24, no. 1 (1992): 103–9. https://doi.org/10.1016/0360-3016(92)91028-l.Full Text Link to Item
-
Halperin, E. C., D. M. Brizel, G. Honore, M. R. Sontag, O. W. Griffith, D. D. Bigner, and H. S. Friedman. “The radiation dose-response relationship in a human glioma xenograft and an evaluation of the influence of glutathione depletion by buthionine sulfoximine.” International Journal of Radiation Oncology, Biology, Physics 24, no. 1 (1992): 103–9.
-
Debatin, J. F., S. N. Nadel, L. Gray, H. S. Friedman, P. Trotter, B. Hockenberger, and W. J. Oakes. “Phase III clinical evaluation of gadoteridol injection: experience in pediatric neuro-oncologic MR imaging.” Pediatr Radiol 22, no. 2 (1992): 93–98. https://doi.org/10.1007/BF02011303.Full Text Link to Item
-
Donnal, J., E. C. Halperin, H. S. Friedman, and O. B. Boyko. “Subfrontal recurrence of medulloblastoma.” Ajnr Am J Neuroradiol 13, no. 6 (1992): 1617–18.Link to Item
-
Hoffman, J. M., M. W. Hanson, H. S. Friedman, B. M. Hockenberger, W. J. Oakes, E. C. Halperin, and R. E. Coleman. “FDG-PET in pediatric posterior fossa brain tumors.” J Comput Assist Tomogr 16, no. 1 (1992): 62–68. https://doi.org/10.1097/00004728-199201000-00011.Full Text Link to Item
-
Laskowitz, D. T., G. B. Elion, M. W. Dewhirst, O. W. Griffith, R. A. Casero, P. A. Scott, N. Bullock, D. D. Bigner, and H. S. Friedman. “Effects of glutathione or polyamine depletion on in vivo thermosensitization.” Int J Hyperthermia 8, no. 2 (1992): 199–208. https://doi.org/10.3109/02656739209021775.Full Text Link to Item
-
Laskowitz, D. T., G. B. Elion, M. W. Dewhirst, O. W. Griffith, R. C. Cattley, D. D. Bigner, and H. S. Friedman. “Enhancement of melphalan-induced gastrointestinal toxicity in mice treated with regional hyperthermia and BSO-mediated glutathione depletion.” Int J Hyperthermia 8, no. 1 (1992): 111–20. https://doi.org/10.3109/02656739209052883.Full Text Link to Item
-
Marks, L. B., H. S. Friedman, J. Kurtzberg, W. J. Oakes, and B. M. Hockenberger. “Reversal of radiation-induced neutropenia by granulocyte colony-stimulating factor.” Med Pediatr Oncol 20, no. 3 (1992): 240–42. https://doi.org/10.1002/mpo.2950200312.Full Text Link to Item
-
Smith, D. C., N. A. Vick, D. L. Trump, H. S. Friedman, A. H. Friedman, J. Purvis, A. Gauspari, and S. C. Schold. “Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas.” Cancer Chemother Pharmacol 30, no. 4 (1992): 272–76. https://doi.org/10.1007/BF00686294.Full Text Link to Item
-
Friedman, H. S., and T. Miller-Herringer. “Nonverbal display of emotion in public and in private: self-monitoring, personality, and expressive cues.” J Pers Soc Psychol 61, no. 5 (November 1991): 766–75. https://doi.org/10.1037//0022-3514.61.5.766.Full Text Link to Item
-
Friedman, H. S., S. L. Tuori, H. P. Hatten, B. Hockenberger, J. J. Vandersteenhoven, and W. J. Oakes. “Inflammatory lesion mimicking a metastatic ependymoma.” Neurosurgery 29, no. 4 (October 1991): 617–20. https://doi.org/10.1097/00006123-199110000-00025.Full Text Link to Item
-
Saylors, R. L., D. Sidransky, H. S. Friedman, S. H. Bigner, D. D. Bigner, B. Vogelstein, and G. M. Brodeur. “Infrequent p53 gene mutations in medulloblastomas.” Cancer Res 51, no. 17 (September 1, 1991): 4721–23.Link to Item
-
Humphrey, P. A., L. M. Gangarosa, A. J. Wong, G. E. Archer, M. Lund-Johansen, R. Bjerkvig, O. D. Laerum, H. S. Friedman, and D. D. Bigner. “Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function.” Biochem Biophys Res Commun 178, no. 3 (August 15, 1991): 1413–20. https://doi.org/10.1016/0006-291x(91)91051-d.Full Text Link to Item
-
Lilley, E. R., G. B. Elion, M. W. Dewhirst, S. C. Schold, M. R. Blum, P. M. Savina, D. T. Laskowitz, D. D. Bigner, and H. S. Friedman. “Therapeutic analysis of melphalan-resistant human rhabdomyosarcoma xenograft TE-671 MR.” Cancer Res 51, no. 15 (August 1, 1991): 3906–9.Link to Item
-
Friedman, H. S., W. J. Oakes, S. H. Bigner, C. J. Wikstrand, and D. D. Bigner. “Medulloblastoma: tumor biological and clinical perspectives.” J Neurooncol 11, no. 1 (August 1991): 1–15. https://doi.org/10.1007/BF00166992.Full Text Link to Item
-
Bruggers, C. S., H. S. Friedman, P. C. Phillips, M. D. Wiener, B. Hockenberger, W. J. Oakes, and E. G. Buckley. “Leptomeningeal dissemination of optic pathway gliomas in three children.” Am J Ophthalmol 111, no. 6 (June 15, 1991): 719–23. https://doi.org/10.1016/s0002-9394(14)76778-9.Full Text Link to Item
-
Bittar, G., and H. S. Friedman. “The arrhythmogenicity of theophylline. A multivariate analysis of clinical determinants.” Chest 99, no. 6 (June 1991): 1415–20. https://doi.org/10.1378/chest.99.6.1415.Full Text Link to Item
-
He, X. M., C. J. Wikstrand, H. S. Friedman, S. H. Bigner, S. Pleasure, J. Q. Trojanowski, and D. D. Bigner. “Differentiation characteristics of newly established medulloblastoma cell lines (D384 Med, D425 Med, and D458 Med) and their transplantable xenografts.” Lab Invest 64, no. 6 (June 1991): 833–43.Link to Item
-
Schuster, J. M., H. S. Friedman, and D. D. Bigner. “Therapeutic analysis of in vitro and in vivo brain tumor models.” Neurol Clin 9, no. 2 (May 1991): 375–82.Link to Item
-
Bittar, G., H. S. Friedman, A. Dominguez, and V. Vorperian. “Theophylline produces an adverse effect on myocardial lactate metabolism at a therapeutic serum concentration: an effect blocked by verapamil.” J Pharmacol Exp Ther 257, no. 1 (April 1991): 214–18.Link to Item
-
Friedman, H. S., M. Horowitz, and W. J. Oakes. “Tumors of the central nervous system. Improvement in outcome through a multimodality approach.” Pediatr Clin North Am 38, no. 2 (April 1991): 381–91. https://doi.org/10.1016/s0031-3955(16)38083-x.Full Text Link to Item
-
Friedman, H. S. “Medical appropriateness of coronary angiograms.” N Engl J Med 324, no. 10 (March 7, 1991): 700. https://doi.org/10.1056/NEJM199103073241017.Full Text Link to Item
-
Brown, M. T., H. S. Friedman, W. J. Oakes, O. B. Boyko, and S. C. Schold. “Sagittal sinus thrombosis and leptomeningeal medulloblastoma.” Neurology 41, no. 3 (March 1991): 455–56. https://doi.org/10.1212/wnl.41.3.455.Full Text Link to Item
-
Gottfries, J., A. K. Percy, J. E. Månsson, P. Fredman, C. J. Wikstrand, H. S. Friedman, D. D. Bigner, and L. Svennerholm. “Glycolipids and glycosyltransferases in permanent cell lines established from human medulloblastomas.” Biochim Biophys Acta 1081, no. 3 (February 5, 1991): 253–61. https://doi.org/10.1016/0005-2760(91)90279-q.Full Text Link to Item
-
Bruggers, C. S., J. Kurtzberg, and H. S. Friedman. “Vincristine therapy for severe platelet alloimmunization.” Am J Pediatr Hematol Oncol 13, no. 3 (1991): 300–304. https://doi.org/10.1097/00043426-199123000-00009.Full Text Link to Item
-
Wikstrand, C. J., H. S. Friedman, and D. D. Bigner. “Medulloblastoma cell-substrate interaction in vitro.” Invasion Metastasis 11, no. 6 (1991): 310–24.Link to Item
-
Griebel, M., H. S. Friedman, E. C. Halperin, M. D. Wiener, L. Marks, W. J. Oakes, J. M. Hoffman, G. R. DeLong, S. C. Schold, and B. Hockenberger. “Reversible neurotoxicity following hyperfractionated radiation therapy of brain stem glioma.” Med Pediatr Oncol 19, no. 3 (1991): 182–86. https://doi.org/10.1002/mpo.2950190307.Full Text Link to Item
-
Longee, D. C., H. S. Friedman, P. C. Phillips, P. C. Burger, W. J. Oakes, D. Heffez, M. Wharam, L. Strauss, G. N. Fuller, and S. C. Schold. “Osteoblastic metastases from astrocytomas: a report of two cases.” Med Pediatr Oncol 19, no. 4 (1991): 318–24. https://doi.org/10.1002/mpo.2950190419.Full Text Link to Item
-
Rhodes, R. E., H. S. Friedman, H. P. Hatten, B. Hockenberger, W. J. Oakes, and T. Tomita. “Contrast-enhanced MR imaging of neurocutaneous melanosis.” Ajnr Am J Neuroradiol 12, no. 2 (1991): 380–82.Link to Item
-
Skapek, S. X., A. F. VanDellen, D. P. McMahon, D. G. Postels, O. W. Griffith, D. D. Bigner, and H. S. Friedman. “Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine.” Cancer Chemother Pharmacol 28, no. 1 (1991): 15–21. https://doi.org/10.1007/BF00684950.Full Text Link to Item
-
Wang, A. M., G. B. Elion, H. S. Friedman, W. J. Bodell, D. D. Bigner, and S. C. Schold. “Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts.” Cancer Chemother Pharmacol 27, no. 4 (1991): 278–84. https://doi.org/10.1007/BF00685112.Full Text Link to Item
-
Bigner, S. H., P. A. Humphrey, A. J. Wong, B. Vogelstein, J. Mark, H. S. Friedman, and D. D. Bigner. “Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts.” Cancer Res 50, no. 24 (December 15, 1990): 8017–22.Link to Item
-
Fishbein, J. D., H. S. Friedman, B. B. Bennett, and J. M. Falletta. “Catheter-related sepsis refractory to antibiotics treated successfully with adjunctive urokinase infusion.” Pediatr Infect Dis J 9, no. 9 (September 1990): 676–78.Link to Item
-
Friedman, H. S., and G. Bittar. “Aminophylline for angina pectoris. Boon or bust?” Chest 98, no. 1 (July 1990): 5–7. https://doi.org/10.1378/chest.98.1.5b.Full Text Link to Item
-
Humphrey, P. A., A. J. Wong, B. Vogelstein, M. R. Zalutsky, G. N. Fuller, G. E. Archer, H. S. Friedman, M. M. Kwatra, S. H. Bigner, and D. D. Bigner. “Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma.” Proc Natl Acad Sci U S A 87, no. 11 (June 1990): 4207–11. https://doi.org/10.1073/pnas.87.11.4207.Full Text Link to Item
-
Wasson, J. C., R. L. Saylors, P. Zeltzer, H. S. Friedman, S. H. Bigner, P. C. Burger, D. D. Bigner, A. T. Look, E. C. Douglass, and G. M. Brodeur. “Oncogene amplification in pediatric brain tumors.” Cancer Res 50, no. 10 (May 15, 1990): 2987–90.Link to Item
-
Oakes, W. J., H. S. Friedman, S. H. Bigner, N. H. Bullock, and D. D. Bigner. “Successful laboratory growth and analysis of CUSA-obtained medulloblastoma samples. Technical note.” J Neurosurg 72, no. 5 (May 1990): 821–23. https://doi.org/10.3171/jns.1990.72.5.0821.Full Text Link to Item
-
Lopes, M. B. S., A. Frankfurter, G. M. Zientek, C. D. Katsetos, H. S. Friedman, D. D. Biqner, and M. M. Herman. “NEURON-ASSOCIATED MICROTUBULE PROTEINS IN THE U-251 MALIGNANT GLIOMA CELL LINE.” Journal of Neuropathology and Experimental Neurology 49, no. 3 (May 1990): 272–272. https://doi.org/10.1097/00005072-199005000-00041.Full Text
-
Bigner, S. H., H. S. Friedman, B. Vogelstein, W. J. Oakes, and D. D. Bigner. “Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts.” Cancer Res 50, no. 8 (April 15, 1990): 2347–50.Link to Item
-
Friedman, H. S., O. M. Colvin, K. Aisaka, J. Popp, E. H. Bossen, K. A. Reimer, J. B. Powell, J. Hilton, S. S. Gross, and R. Levi. “Glutathione protects cardiac and skeletal muscle from cyclophosphamide-induced toxicity.” Cancer Res 50, no. 8 (April 15, 1990): 2455–62.Link to Item
-
Longee, D. C., H. S. Friedman, R. E. Albright, P. C. Burger, W. J. Oakes, J. O. Moore, and S. C. Schold. “Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine.” J Neurosurg 72, no. 4 (April 1990): 583–88. https://doi.org/10.3171/jns.1990.72.4.0583.Full Text Link to Item
-
Fuchs, H. E., G. E. Archer, O. M. Colvin, S. H. Bigner, J. M. Schuster, G. N. Fuller, L. H. Muhlbaier, S. C. Schold, H. S. Friedman, and D. D. Bigner. “Activity of intrathecal 4-hydroperoxycyclophosphamide in a nude rat model of human neoplastic meningitis.” Cancer Res 50, no. 6 (March 15, 1990): 1954–59.Link to Item
-
Colapinto, E. V., M. R. Zalutsky, G. E. Archer, M. A. Noska, H. S. Friedman, S. Carrel, and D. D. Bigner. “Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14.” Cancer Res 50, no. 6 (March 15, 1990): 1822–27.Link to Item
-
Cope, D. A., M. W. Dewhirst, H. S. Friedman, D. D. Bigner, and M. R. Zalutsky. “Enhanced delivery of a monoclonal antibody F(ab')2 fragment to subcutaneous human glioma xenografts using local hyperthermia.” Cancer Res 50, no. 6 (March 15, 1990): 1803–9.Link to Item
-
Fekete, I., O. W. Griffith, K. E. Schlageter, D. D. Bigner, H. S. Friedman, and D. R. Groothuis. “Rate of buthionine sulfoximine entry into brain and xenotransplanted human gliomas.” Cancer Res 50, no. 4 (February 15, 1990): 1251–56.Link to Item
-
Ibayashi, N., M. M. Herman, J. C. Boyd, D. V. Caccamo, H. S. Friedman, D. D. Bigner, and L. J. Rubinstein. “Kinetics and glial fibrillary acidic (GFA) protein production in a transplantable human giant cell glioblastoma (D-212 MG) of near haploid karyotype maintained in an organ culture system. An immunohistochemistry study.” Neuropathol Appl Neurobiol 16, no. 1 (February 1990): 27–37. https://doi.org/10.1111/j.1365-2990.1990.tb00929.x.Full Text Link to Item
-
Lippitz, B. E., E. C. Halperin, O. W. Griffith, O. M. Colvin, G. Honore, C. B. Ostertag, D. D. Bigner, and H. S. Friedman. “L-buthionine-sulfoximine-mediated radiosensitization in experimental interstitial radiotherapy of intracerebral D-54 MG glioma xenografts in athymic mice.” Neurosurgery 26, no. 2 (February 1990): 255–60. https://doi.org/10.1097/00006123-199002000-00012.Full Text Link to Item
-
Lilley, E. R., M. C. Rosenberg, G. B. Elion, O. M. Colvin, D. D. Bigner, and H. S. Friedman. “Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft.” Cancer Res 50, no. 2 (January 15, 1990): 284–87.Link to Item
-
Bigner, S. H., B. Vogelstein, J. Mark, H. S. Friedman, and D. D. Bigner. “Cytogenetics and molecular genetics: their status and role in understanding the behavior of central nervous system neoplasms.” Monogr Pathol, no. 32 (1990): 30–40.Link to Item
-
Broxmeyer, H. E., E. Gluckman, A. Auerbach, G. W. Douglas, H. Friedman, S. Cooper, G. Hangoc, J. Kurtzberg, J. Bard, and E. A. Boyse. “Human umbilical cord blood: a clinically useful source of transplantable hematopoietic stem/progenitor cells.” Int J Cell Cloning 8 Suppl 1 (January 1990): 76–89. https://doi.org/10.1002/stem.5530080708.Full Text Link to Item
-
Friedman, H. S. “Coronary bypass graft surgery: reexamining the assumptions.” J Gen Intern Med 5, no. 1 (1990): 80–83. https://doi.org/10.1007/BF02602313.Full Text Link to Item
-
Mobarhan, S., P. Bowen, B. Andersen, M. Evans, M. Stacewicz-Sapuntzakis, S. Sugerman, P. Simms, D. Lucchesi, and H. Friedman. “Effects of beta-carotene repletion on beta-carotene absorption, lipid peroxidation, and neutrophil superoxide formation in young men.” Nutr Cancer 14, no. 3–4 (1990): 195–206. https://doi.org/10.1080/01635589009514094.Full Text Link to Item
-
Moncino, M. D., H. S. Friedman, J. Kurtzberg, and S. V. Pizzo. “Papillary adenocarcinoma of the renal pelvis in a child: case report and brief review of the literature.” Med Pediatr Oncol 18, no. 1 (1990): 81–86. https://doi.org/10.1002/mpo.2950180118.Full Text Link to Item
-
Rippe, D. J., O. B. Boyko, G. N. Fuller, H. S. Friedman, W. J. Oakes, and S. C. Schold. “Gadopentetate-dimeglumine-enhanced MR imaging of gliomatosis cerebri: appearance mimicking leptomeningeal tumor dissemination.” Ajnr Am J Neuroradiol 11, no. 4 (1990): 800–801.Link to Item
-
Rippe, D. J., O. B. Boyko, H. S. Friedman, W. J. Oakes, S. C. Schold, G. R. DeLong, and W. J. Meisler. “Gd-DTPA-enhanced MR imaging of leptomeningeal spread of primary intracranial CNS tumor in children.” Ajnr Am J Neuroradiol 11, no. 2 (1990): 329–32.Link to Item
-
Ware, R., H. S. Friedman, T. R. Kinney, J. Kurtzberg, S. Chaffee, and J. M. Falletta. “Familial erythrophagocytic lymphohistiocytosis: late relapse despite continuous high-dose VP-16 chemotherapy.” Med Pediatr Oncol 18, no. 1 (1990): 27–29. https://doi.org/10.1002/mpo.2950180106.Full Text Link to Item
-
Wiener, M. D., O. B. Boyko, H. S. Friedman, B. Hockenberger, and W. J. Oakes. “False-positive spinal MR findings for subarachnoid spread of primary CNS tumor in postoperative pediatric patients.” Ajnr Am J Neuroradiol 11, no. 6 (1990): 1100–1103.Link to Item
-
ROSENBERG, M. C., O. M. COLVIN, O. W. GRIFFITH, S. H. BIGNER, G. B. ELION, J. K. HORTON, E. LILLEY, D. D. BIGNER, and H. S. FRIEDMAN. “ESTABLISHMENT OF A MELPHALAN-RESISTANT RHABDOMYOSARCOMA XENOGRAFT WITH CROSS-RESISTANCE TO VINCRISTINE AND ENHANCED SENSITIVITY FOLLOWING BUTHIONINE SULFOXIMINE-MEDIATED GLUTATHIONE DEPLETION.” Cancer Research 49, no. 24 (December 15, 1989): 6917–22.Link to Item
-
Rosenberg, M. C., E. Lilley, H. S. Friedman, S. H. Bigner, D. D. Bigner, G. B. Elion, O. M. Colvin, O. W. Griffith, and J. K. Horton. “Establishment of a Melphalan-Resistant Rhabdomyosarcoma Xenograft with Cross-Resistance to Vincristine and Enhanced Sensitivity Following Buthionine Sulfoximine-Mediated Glutathione Depletion.” Cancer Research 49 (December 15, 1989): 6917–22.
-
Rosenberg, M. C., O. M. Colvin, O. W. Griffith, S. H. Bigner, G. B. Elion, J. K. Horton, E. Lilley, D. D. Bigner, and H. S. Friedman. “Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion.” Cancer Res 49, no. 24 Pt 1 (December 15, 1989): 6917–22.Link to Item
-
Shah, S., and H. S. Friedman. “The relation of quinidine-induced elevation of serum digoxin concentration to the conversion of atrial fibrillation-flutter: a pilot study.” Cardiovasc Drugs Ther 3, no. 6 (December 1989): 929–30. https://doi.org/10.1007/BF01869583.Full Text Link to Item
-
Gluckman, E., H. A. Broxmeyer, A. D. Auerbach, H. S. Friedman, G. W. Douglas, A. Devergie, H. Esperou, D. Thierry, G. Socie, and P. Lehn. “Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling.” N Engl J Med 321, no. 17 (October 26, 1989): 1174–78. https://doi.org/10.1056/NEJM198910263211707.Full Text Link to Item
-
Friedman, H. S., J. Kurtzberg, S. C. Schold, and W. J. Oakes. “Cerebrospinal fluid protein elevation secondary to a subdural fluid collection in a child receiving multiple lumbar punctures.” J Pediatr 115, no. 3 (September 1989): 439–41. https://doi.org/10.1016/s0022-3476(89)80851-0.Full Text Link to Item
-
Ibayashi, N., M. M. Herman, J. C. Boyd, D. D. Bigner, H. S. Friedman, V. P. Collins, L. A. Donoso, and L. J. Rubinstein. “Relationship of the demonstration of intermediate filament protein to kinetics of three human neuroepithelial tumor cell lines. Lack of neural-related proteins in most cells in S phase: a double-labeled immunohistochemical study on matrix cultures.” Lab Invest 61, no. 3 (September 1989): 310–18.Link to Item
-
Zalutsky, M. R., P. K. Garg, H. S. Friedman, and D. D. Bigner. “Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity.” Proc Natl Acad Sci U S A 86, no. 18 (September 1989): 7149–53. https://doi.org/10.1073/pnas.86.18.7149.Full Text Link to Item
-
Bigner, S. H., S. C. Schold, H. S. Friedman, J. Mark, and D. D. Bigner. “Chromosomal composition of malignant human gliomas through serial subcutaneous transplantation in athymic mice.” Cancer Genet Cytogenet 40, no. 1 (July 1, 1989): 111–20. https://doi.org/10.1016/0165-4608(89)90152-0.Full Text Link to Item
-
Friedman, H. S., S. C. Schold, M. S. Mahaley, O. M. Colvin, W. J. Oakes, N. A. Vick, P. C. Burger, S. H. Bigner, M. Borowitz, and E. C. Halperin. “Phase II treatment of medulloblastoma and pineoblastoma with melphalan: clinical therapy based on experimental models of human medulloblastoma.” J Clin Oncol 7, no. 7 (July 1989): 904–11. https://doi.org/10.1200/JCO.1989.7.7.904.Full Text Link to Item
-
Stine, K. C., H. S. Friedman, J. Kurtzberg, H. C. Filston, M. E. Baker, J. Lowe, and J. M. Falletta. “Pulmonary septic emboli mimicking metastatic rhabdomyosarcoma.” J Pediatr Surg 24, no. 5 (May 1989): 491–93. https://doi.org/10.1016/s0022-3468(89)80410-5.Full Text Link to Item
-
Friedman, H. S., O. M. Colvin, O. W. Griffith, B. Lippitz, G. B. Elion, S. C. Schold, J. Hilton, and D. D. Bigner. “Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion.” J Natl Cancer Inst 81, no. 7 (April 5, 1989): 524–27. https://doi.org/10.1093/jnci/81.7.524.Full Text Link to Item
-
Berger, M., H. S. Friedman, L. M. Gerber, M. Greenberg, B. Levine, M. B. Mirsky, C. H. Nacht, and C. Sheppard. “Coronary care in New York City hospitals.” N Y State J Med 89, no. 4 (April 1989): 199–205.Link to Item
-
Schold, S. C., T. P. Brent, E. von Hofe, H. S. Friedman, S. Mitra, D. D. Bigner, J. A. Swenberg, and P. Kleihues. “O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts.” J Neurosurg 70, no. 4 (April 1989): 573–77. https://doi.org/10.3171/jns.1989.70.4.0573.Full Text Link to Item
-
Friedman, H. S. “Sudden death and pacemakers.” Chest 95, no. 1 (January 1989): 251. https://doi.org/10.1378/chest.95.1.251a.Full Text Link to Item
-
Friedman, H. S., S. C. Schold, W. T. Djang, J. Kurtzberg, D. C. Longee, E. C. Halperin, J. M. Falletta, R. E. Coleman, and W. J. Oakes. “Criteria for termination of phase II chemotherapy for patients with progressive or recurrent brain tumor.” Neurology 39, no. 1 (January 1989): 62–66. https://doi.org/10.1212/wnl.39.1.62.Full Text Link to Item
-
He, X. M., S. X. Skapek, C. J. Wikstrand, H. S. Friedman, J. Q. Trojanowski, J. T. Kemshead, H. B. Coakham, S. H. Bigner, and D. D. Bigner. “Phenotypic analysis of four human medulloblastoma cell lines and transplantable xenografts.” J Neuropathol Exp Neurol 48, no. 1 (January 1989): 48–68. https://doi.org/10.1097/00005072-198901000-00005.Full Text Link to Item
-
Jr, S. C. S., T. P. Brent, E. V. Hofe, H. S. Friedman, S. Mitra, D. D. Bigner, J. A. Swenberg, and P. Kleihues. “O6-Alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts.” Journal of Neurosurgery 70, no. 4 (1989): 573–77.
-
Gottfries, J., J. E. Mansson, P. Fredman, C. J. Wikstrand, H. S. Friedman, D. D. Bigner, and L. Svennerholm. “Ganglioside mapping of a human medulloblastoma xenograft.” Acta Neuropathol 77, no. 3 (1989): 283–88. https://doi.org/10.1007/BF00687580.Full Text Link to Item
-
Halperin, E. C., S. M. Wehn, J. W. Scott, W. Djang, W. J. Oakes, and H. S. Friedman. “Selection of a management strategy for pediatric brainstem tumors.” Med Pediatr Oncol 17, no. 2 (1989): 117–26. https://doi.org/10.1002/mpo.2950170209.Full Text Link to Item
-
Skapek, S. X., O. M. Colvin, O. W. Griffith, D. R. Groothuis, E. V. Colapinto, Y. Lee, J. Hilton, G. B. Elion, D. D. Bigner, and H. S. Friedman. “Buthionine sulfoximine-mediated depletion of glutathione in intracranial human glioma-derived xenografts.” Biochem Pharmacol 37, no. 22 (November 15, 1988): 4313–17. https://doi.org/10.1016/0006-2952(88)90612-0.Full Text Link to Item
-
Friedman, H. S., W. F. Heneghan, M. Stern, S. M. Farrer, and B. Babb. “Digoxin-like immunoreactivity.” Chest 94, no. 5 (November 1988): 1116–17.Link to Item
-
Friedman, Howard S., and Stephanie Booth-Kewley. “Validity of the type A construct: a reprise.” Psychol Bull 104, no. 3 (November 1988): 381–84. https://doi.org/10.1037/0033-2909.104.3.381.Full Text Link to Item
-
Mokraoui, A. M., H. S. Friedman, L. A. Melniker, and T. N. Nguyen. “Effects of acetyl strophanthidin on duration of atrial fibrillation in the neurally-intact and blockaded dog.” Cardiovasc Drugs Ther 2, no. 4 (November 1988): 569–77. https://doi.org/10.1007/BF00051197.Full Text Link to Item
-
Colapinto, E. V., P. A. Humphrey, M. R. Zalutsky, D. R. Groothuis, H. S. Friedman, N. de Tribolet, S. Carrel, and D. D. Bigner. “Comparative localization of murine monoclonal antibody Me1-14 F(ab')2 fragment and whole IgG2a in human glioma xenografts.” Cancer Res 48, no. 20 (October 15, 1988): 5701–7.Link to Item
-
Friedman, H. S., S. X. Skapek, O. M. Colvin, G. B. Elion, M. R. Blum, P. M. Savina, J. Hilton, S. C. Schold, J. Kurtzberg, and D. D. Bigner. “Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma.” Cancer Res 48, no. 19 (October 1, 1988): 5397–5402.Link to Item
-
BOYKO, O. B., W. T. DJANG, R. E. COLEMAN, P. C. BURGER, S. C. SCHOLD, and H. S. FRIEDMAN. “TUMOR VERSUS EDEMA - TL-201 AND SPECT IMAGING IN COMPARISON TO MR IN THE FOLLOW-UP OF INTRACRANIAL GLIOMAS.” American Journal of Neuroradiology 9, no. 5 (September 1, 1988): 1012–1012.Link to Item
-
Ware, R., H. S. Friedman, L. T. Gutman, M. H. Rourk, N. A. Shorter, and H. C. Filston. “Combined medical and surgical management of severe pseudomembranous colitis.” Pediatr Infect Dis J 7, no. 8 (August 1988): 602–4.Link to Item
-
Friedman, H. S., O. M. Colvin, S. X. Skapek, S. M. Ludeman, G. B. Elion, S. C. Schold, P. F. Jacobsen, L. H. Muhlbaier, and D. D. Bigner. “Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents.” Cancer Res 48, no. 15 (August 1, 1988): 4189–95.Link to Item
-
Longee, D. C., H. S. Friedman, W. T. Djang, E. Halperin, S. C. Schold, and W. J. Oakes. “Transient late magnetic resonance imaging changes suggesting progression of brain stem glioma: implications for entry criteria for phase II trials.” Neurosurgery 23, no. 2 (August 1988): 248–53. https://doi.org/10.1227/00006123-198808000-00024.Full Text
-
Skapek, S. X., O. M. Colvin, O. W. Griffith, G. B. Elion, D. D. Bigner, and H. S. Friedman. “Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice.” Cancer Res 48, no. 10 (May 15, 1988): 2764–67.Link to Item
-
Lee, Y., D. E. Bullard, P. A. Humphrey, E. V. Colapinto, H. S. Friedman, M. R. Zalutsky, R. E. Coleman, and D. D. Bigner. “Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6.” Cancer Res 48, no. 10 (May 15, 1988): 2904–10.Link to Item
-
HE, X., C. J. WIKSTRAND, H. S. FRIEDMAN, J. Q. TROJANOWSKI, S. H. BIGNER, and D. D. BIGNER. “ANTIGENIC PHENOTYPES OF 4 HUMAN MEDULLOBLASTOMA CELL-LINES AND XENOGRAFTS.” Journal of Neuropathology and Experimental Neurology 47, no. 3 (May 1, 1988): 374–374.Link to Item
-
IBAYASHI, N., M. M. HERMAN, L. J. RUBINSTEIN, D. D. BIGNER, H. S. FRIEDMAN, V. P. COLLINS, and L. A. DONOSO. “INTERMEDIATE FILAMENT EXPRESSION OF 3 CULTURED HUMAN NEUROEPITHELIAL TUMOR-CELL LINES (MEDULLOBLASTOMA, RETINOBLASTOMA AND MALIGNANT ASTROCYTOMA) IN S-PHASE.” Journal of Neuropathology and Experimental Neurology 47, no. 3 (May 1, 1988): 349–349.Link to Item
-
Ware, R., J. Kurtzberg, H. S. Friedman, J. M. Falletta, and T. R. Kinney. “Chronic immune-mediated thrombocytopenia after varicella infection.” J Pediatr 112, no. 5 (May 1988): 742–44. https://doi.org/10.1016/s0022-3476(88)80693-0.Full Text Link to Item
-
Humphrey, P. A., A. J. Wong, B. Vogelstein, H. S. Friedman, M. H. Werner, D. D. Bigner, and S. H. Bigner. “Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts.” Cancer Res 48, no. 8 (April 15, 1988): 2231–38.Link to Item
-
Friedman, H. S., P. C. Burger, S. H. Bigner, J. Q. Trojanowski, G. M. Brodeur, X. M. He, C. J. Wikstrand, J. Kurtzberg, M. E. Berens, and E. C. Halperin. “Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of c-myc.” Am J Pathol 130, no. 3 (March 1988): 472–84.Link to Item
-
HUMPHREY, P. A., A. J. WONG, B. VOGELSTEIN, H. S. FRIEDMAN, D. D. BIGNER, and S. H. BIGNER. “LOSS OF EPIDERMAL GROWTH-FACTOR RECEPTOR GENE AMPLIFICATION AS MALIGNANT HUMAN GLIOMAS ESTABLISH IN CULTURE.” Proceedings of the American Association for Cancer Research 29 (March 1, 1988): 78–78.Link to Item
-
SKAPEK, S. X., O. M. COLVIN, O. W. GRIFFITH, D. R. GROOTHUIS, J. HILTON, G. B. ELION, D. D. BIGNER, and H. S. FRIEDMAN. “SELECTIVE BUTHIONINE SULFOXIMINE (BSO)-MEDIATED DEPLETION OF GLUTATHIONE (GSH) IN AN INTRACRANIAL HUMAN GLIOMA-DERIVED XENOGRAFT.” Proceedings of the American Association for Cancer Research 29 (March 1, 1988): 357–357.Link to Item
-
Friedman, H. S. “Rational for "eight-in-one" chemotherapy.” J Clin Oncol 6, no. 2 (February 1988): 393–95. https://doi.org/10.1200/JCO.1988.6.2.393.Full Text Link to Item
-
Lee, Y. S., D. E. Bullard, M. R. Zalutsky, R. E. Coleman, C. J. Wikstrand, H. S. Friedman, E. V. Colapinto, and D. D. Bigner. “Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model.” Cancer Res 48, no. 3 (February 1, 1988): 559–66.Link to Item
-
Bigner, S. H., J. Mark, H. S. Friedman, J. A. Biegel, and D. D. Bigner. “Structural chromosomal abnormalities in human medulloblastoma.” Cancer Genet Cytogenet 30, no. 1 (January 1988): 91–101. https://doi.org/10.1016/0165-4608(88)90096-9.Full Text Link to Item
-
Lee, Y. S., D. E. Bullard, M. R. Zalutsky, R. E. Coleman, C. J. Wikstrand, H. S. Friedman, E. V. Colapinto, and D. Bigner. “Therapeutic Efficacy of Antiglioma Mesenchymal Extracellular Matrix 131I-Radiolabeled Murine Monoclonal Antibody in a Human Glioma Xenograft Model.” Cancer Research 48, no. 3 (January 1, 1988): 584–88.
-
Colapinto, E. V., Y. S. Lee, P. A. Humphrey, M. R. Zalutsky, H. S. Friedman, D. E. Bullard, and D. D. Bigner. “The localisation of radiolabelled murine monoclonal antibody 81C6 and its Fab fragment in human glioma xenografts in athymic mice.” Br J Neurosurg 2, no. 2 (1988): 179–91. https://doi.org/10.3109/02688698808992668.Full Text Link to Item
-
Friedman, H. S., L. A. Trivelli, T. Nguyen, R. Benamor, and M. Dorsa. “Hematologic changes occurring with cardiac catheterization.” Cathet Cardiovasc Diagn 15, no. 2 (1988): 89–91. https://doi.org/10.1002/ccd.1810150205.Full Text Link to Item
-
Ware, R., H. S. Friedman, H. C. Filston, S. Chaffee, J. Kurtzberg, T. R. Kinney, and J. M. Falletta. “Childhood hepatic mesenchymoma: successful treatment with surgery and multiple-agent chemotherapy.” Med Pediatr Oncol 16, no. 1 (1988): 62–65. https://doi.org/10.1002/mpo.2950160114.Full Text Link to Item
-
Kurtzberg, J., H. S. Friedman, S. Chaffee, J. M. Falletta, T. R. Kinney, R. Kurlander, T. J. Matthews, and R. S. Schwartz. “Efficacy of intravenous gamma globulin in autoimmune-mediated pediatric blood dyscrasias.” Am J Med 83, no. 4A (October 23, 1987): 4–9. https://doi.org/10.1016/0002-9343(87)90544-4.Full Text Link to Item
-
Kurtzberg, J., H. S. Friedman, T. R. Kinney, S. Chaffee, and J. M. Falletta. “Treatment of platelet alloimmunization with intravenous immunoglobulin. Two case reports and review of the literature.” Am J Med 83, no. 4A (October 23, 1987): 30–33. https://doi.org/10.1016/0002-9343(87)90548-1.Full Text Link to Item
-
Friedman, H. S., and S. Booth-Kewley. “Personality, type A behavior, and coronary heart disease: the role of emotional expression.” J Pers Soc Psychol 53, no. 4 (October 1987): 783–92. https://doi.org/10.1037//0022-3514.53.4.783.Full Text Link to Item
-
Nguyen, T. N., H. S. Friedman, and A. M. Mokraoui. “Effects of alcohol on experimental atrial fibrillation.” Alcohol Clin Exp Res 11, no. 5 (October 1987): 474–76. https://doi.org/10.1111/j.1530-0277.1987.tb01926.x.Full Text Link to Item
-
Schold, S. C., H. S. Friedman, and D. D. Bigner. “Therapeutic profile of the human glioma line D-54 MG in athymic mice.” Cancer Treat Rep 71, no. 9 (September 1987): 849–50.Link to Item
-
Woodside, J. R., G. F. Stevens, and H. S. Friedman. “Visual internal urethrotome for incision of dense perirenal scar tissue during percutaneous stone removal.” Urology 30, no. 3 (September 1987): 272. https://doi.org/10.1016/0090-4295(87)90254-8.Full Text Link to Item
-
Friedman, H. S., I. Abramowitz, T. Nguyen, B. Babb, M. Stern, S. M. Farrer, and V. Tricomi. “Urinary digoxin-like immunoreactive substance in pregnancy. Relation to urinary electrolytes.” Am J Med 83, no. 2 (August 1987): 261–64. https://doi.org/10.1016/0002-9343(87)90695-4.Full Text Link to Item
-
Friedman, H. S., and S. Booth-Kewley. “The "disease-prone personality". A meta-analytic view of the construct.” Am Psychol 42, no. 6 (June 1987): 539–55. https://doi.org/10.1037//0003-066x.42.6.539.Full Text Link to Item
-
Booth-Kewley, S., and H. S. Friedman. “Psychological predictors of heart disease: a quantitative review.” Psychol Bull 101, no. 3 (May 1987): 343–62.Link to Item
-
Warnke, P. C., H. S. Friedman, D. D. Bigner, and D. R. Groothuis. “Simultaneous measurements of blood flow and blood-to-tissue transport in xenotransplanted medulloblastomas.” Cancer Res 47, no. 6 (March 15, 1987): 1687–90.Link to Item
-
HUMPHREY, P. A., A. J. WONG, H. S. FRIEDMAN, M. H. WERNER, B. VOGELSTEIN, D. D. BIGNER, and S. H. BIGNER. “AMPLIFICATION AND EXPRESSION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR (EGFR) GENE IN HUMAN GLIOMA (HGL) XENOGRAFTS.” Proceedings of the American Association for Cancer Research 28 (March 1, 1987): 23–23.Link to Item
-
LEE, Y. S., D. E. BULLARD, H. S. FRIEDMAN, C. J. WIKSTRAND, R. E. COLEMAN, M. ZALUTSKY, L. H. MUHLBAIER, and D. D. BIGNER. “EXPERIMENTAL RADIOTHERAPY OF SUBCUTANEOUS (SC) AND INTRACRANIAL (IC) HUMAN GLIOMA (HGL) XENOGRAFTS IN RODENTS WITH I-131 MONOCLONAL-ANTIBODY (MAB) 81C6.” Proceedings of the American Association for Cancer Research 28 (March 1, 1987): 392–392.Link to Item
-
SCHOLD, S. C., H. S. FRIEDMAN, G. B. ELION, S. MITRA, and D. D. BIGNER. “THERAPEUTIC SYNERGY OF THIOPURINES AND ALKYLATING DRUGS IN A HUMAN GLIOMA XENOGRAFT.” Proceedings of the American Association for Cancer Research 28 (March 1, 1987): 416–416.Link to Item
-
Schold, S. C., M. S. Mahaley, N. A. Vick, H. S. Friedman, P. C. Burger, E. R. DeLong, R. E. Albright, D. E. Bullard, J. D. Khandekar, and J. G. Cairncross. “Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms.” J Clin Oncol 5, no. 3 (March 1987): 464–71. https://doi.org/10.1200/JCO.1987.5.3.464.Full Text Link to Item
-
FRIEDMAN, H. S., O. M. COLVIN, J. HILTON, S. C. SCHOLD, G. B. ELION, S. X. SKAPEK, M. R. BLUM, P. M. SAVINA, L. H. MUHLBAIER, and D. D. BIGNER. “MELPHALAN CYTOTOXICITY AND RESISTANCE IN MEDULLOBLASTOMA (MBT).” Proceedings of the American Association for Cancer Research 28 (March 1, 1987): 447–447.Link to Item
-
Trojanowski, J. Q., H. S. Friedman, P. C. Burger, and D. D. Bigner. “A rapidly dividing human medulloblastoma cell line (D283 MED) expresses all three neurofilament subunits.” Am J Pathol 126, no. 2 (February 1987): 358–63.Link to Item
-
Becton, D. L., H. S. Friedman, B. E. Armstrong, J. Kurtzburg, S. Chaffee, J. M. Falletta, and T. R. Kinney. “Bacterial endocarditis in a child with a Broviac catheter.” Pediatr Hematol Oncol 4, no. 2 (1987): 131–36. https://doi.org/10.3109/08880018709141259.Full Text Link to Item
-
Friedman, H. S., and W. J. Oakes. “Recurrent brain tumors in children.” Pediatr Neurosci 13, no. 5 (1987): 233–41. https://doi.org/10.1159/000120336.Full Text Link to Item
-
Kurtzberg, J., H. S. Friedman, T. R. Kinney, S. Chaffee, K. Stine, J. M. Falletta, and K. J. Weinhold. “Management of human immunodeficiency virus-associated thrombocytopenia with intravenous gamma globulin.” Am J Pediatr Hematol Oncol 9, no. 4 (1987): 299–301. https://doi.org/10.1097/00043426-198724000-00003.Full Text Link to Item
-
Becton, D. L., J. Kurtzberg, T. R. Kinney, H. S. Friedman, S. Chaffee, and J. M. Falletta. “Treatment of lymphohistiocytic erythrophagocytosis with VP-16 and aziridinylbenzoquinone.” Med Pediatr Oncol 15, no. 2 (1987): 58–61. https://doi.org/10.1002/mpo.2950150203.Full Text Link to Item
-
Friedman, H. S., J. O’Connor, S. Kottmeier, E. Shaughnessy, and R. McGuinn. “The effects of atrial fibrillation on regional blood flow in the awake dog.” Can J Cardiol 3, no. 5 (1987): 240–45.Link to Item
-
Friedman, H. S., and W. J. Oakes. “The chemotherapy of posterior fossa tumors in childhood.” J Neurooncol 5, no. 3 (1987): 217–29. https://doi.org/10.1007/BF00151225.Full Text Link to Item
-
Keesling, B., and H. S. Friedman. “Psychosocial factors in sunbathing and sunscreen use.” Health Psychol 6, no. 5 (1987): 477–93. https://doi.org/10.1037//0278-6133.6.5.477.Full Text Link to Item
-
Friedman, H. S. “Randomized clinical trials and common sense.” Am J Med 81, no. 6 (December 1986): 1047. https://doi.org/10.1016/0002-9343(86)90403-1.Full Text Link to Item
-
Malik, R. K., H. S. Friedman, W. T. Djang, J. M. Falletta, E. Buckley, J. Kurtzberg, T. R. Kinney, K. Stine, S. Chaffee, and J. Hayes. “Treatment of trilateral retinoblastoma with vincristine and cyclophosphamide.” Am J Ophthalmol 102, no. 5 (November 15, 1986): 650–56. https://doi.org/10.1016/0002-9394(86)90540-4.Full Text Link to Item
-
Friedman, H. S., O. M. Colvin, S. M. Ludeman, S. C. Schold, V. L. Boyd, L. H. Mulhbaier, and D. D. Bigner. “Experimental chemotherapy of human medulloblastoma with classical alkylators.” Cancer Res 46, no. 6 (June 1986): 2827–33.Link to Item
-
Månsson, J. E., P. Fredman, D. D. Bigner, K. Molin, B. Rosengren, H. S. Friedman, and L. Svennerholm. “Characterization of new gangliosides of the lactotetraose series in murine xenografts of a human glioma cell line.” Febs Lett 201, no. 1 (May 26, 1986): 109–13. https://doi.org/10.1016/0014-5793(86)80580-4.Full Text Link to Item
-
Bigner, S. H., H. S. Friedman, T. R. Kinney, J. Kurtzberg, S. Chaffee, D. Becton, and J. M. Falletta. “9p- in a girl with acute lymphocytic leukemia and sickle cell disease.” Cancer Genet Cytogenet 21, no. 3 (April 1, 1986): 267–69. https://doi.org/10.1016/0165-4608(86)90007-5.Full Text Link to Item
-
BIEGEL, J. A., S. H. BIGNER, J. MARK, H. S. FRIEDMAN, and D. D. BIGNER. “KARYOTYPIC FINDINGS IN 6 CASES OF HUMAN MEDULLOBLASTOMA.” Proceedings of the American Association for Cancer Research 27 (March 1, 1986): 36–36.Link to Item
-
WIKSTRAND, C. J., J. P. MACH, S. CARREL, N. DETRIBOLET, H. S. FRIEDMAN, D. E. BULLARD, P. A. HUMPHREY, and D. D. BIGNER. “LOCALIZATION OF ANTI-HUMAN GLIOMA MONOCLONAL-ANTIBODIES (MABS) IN SUBCUTANEOUS (SC) AND INTRACEREBRAL (IC) GLIOMA XENOGRAFTS.” Proceedings of the American Association for Cancer Research 27 (March 1, 1986): 330–330.Link to Item
-
FRIEDMAN, H. S., O. M. COLVIN, S. M. LUDEMAN, S. C. SCHOLD, V. L. BOYD, L. H. MUHLBAIER, and D. D. BIGNER. “CHEMOTHERAPY OF HUMAN MEDULLOBLASTOMA WITH CLASSICAL ALKYLATORS.” Proceedings of the American Association for Cancer Research 27 (March 1, 1986): 381–381.Link to Item
-
Friedman, H. S., M. S. Mahaley, S. C. Schold, N. A. Vick, J. M. Falletta, D. E. Bullard, B. J. D’Souza, J. D. Khandekar, S. Lew, and W. J. Oakes. “Efficacy of vincristine and cyclophosphamide in the therapy of recurrent medulloblastoma.” Neurosurgery 18, no. 3 (March 1986): 335–40. https://doi.org/10.1227/00006123-198603000-00014.Full Text Link to Item
-
Bigner, D. D., S. H. Bigner, P. C. Burger, J. D. Shelburne, and H. S. Friedman. “Primary brain tumours in Fischer 344 rats chronically exposed to acrylonitrile in their drinking-water.” Food Chem Toxicol 24, no. 2 (February 1986): 129–37. https://doi.org/10.1016/0278-6915(86)90347-9.Full Text Link to Item
-
Friedman, H. S., B. C. Vasavada, A. M. Malec, K. K. Hassan, A. Shah, and S. Siddiqui. “Cardiac function in alcohol-associated systemic hypertension.” Am J Cardiol 57, no. 4 (February 1, 1986): 227–31. https://doi.org/10.1016/0002-9149(86)90896-9.Full Text Link to Item
-
Riggio, R. E., and H. S. Friedman. “Impression formation: the role of expressive behavior.” J Pers Soc Psychol 50, no. 2 (February 1986): 421–27. https://doi.org/10.1037//0022-3514.50.2.421.Full Text Link to Item
-
BIGNER, D. D., S. H. BIGNER, P. C. BURGER, J. D. SHELBURNE, and H. S. FRIEDMAN. “ACRYLONITRILE NEUROONCOGENESIS IN F344 RATS.” Journal of Neuro Oncology 4, no. 1 (January 1, 1986): 94–94.Link to Item
-
Becton, D. L., H. S. Friedman, J. Kurtzberg, S. Chaffee, J. M. Falletta, and T. R. Kinney. “Severe Mycoplasma pneumonia in three sisters with sickle cell disease.” Pediatr Hematol Oncol 3, no. 3 (1986): 259–65. https://doi.org/10.3109/08880018609031225.Full Text Link to Item
-
Bigner, S. H., H. S. Friedman, J. A. Biegel, C. J. Wikstrand, J. Mark, R. Gebhardt, L. F. Eng, and D. D. Bigner. “Specific chromosomal abnormalities characterize four established cell lines derived from malignant human gliomas.” Acta Neuropathol 72, no. 1 (1986): 86–97. https://doi.org/10.1007/BF00687952.Full Text Link to Item
-
Friedman, H. S., S. C. Schold, and D. D. Bigner. “Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice.” Cancer Res 46, no. 1 (January 1986): 224–28.Link to Item
-
SCHOLD, S. C., M. S. MAHALEY, H. S. FRIEDMAN, N. A. VICK, D. E. BULLARD, P. C. BURGER, J. G. CAIRNCROSS, et al. “COOPERATIVE STUDIES OF CHEMOTHERAPY FOR GLIOMAS AND MEDULLOBLASTOMAS.” Journal of Neuro Oncology 4, no. 1 (January 1, 1986): 108–108.Link to Item
-
Ware, R., T. R. Kinney, H. S. Friedman, J. M. Falletta, and W. F. Rosse. “Prognostic implications for direct platelet-associated IgG in childhood idiopathic thrombocytopenic purpura.” Am J Pediatr Hematol Oncol 8, no. 1 (1986): 32–37. https://doi.org/10.1097/00043426-198608010-00007.Full Text Link to Item
-
Bjornsson, T. D., S. C. Schold, H. S. Friedman, D. Schneider, and J. M. Falletta. “Pharmacokinetics of diaziquone after three different dosage regimens.” Cancer Treat Rep 69, no. 12 (December 1985): 1383–85.Link to Item
-
Friedman, H. S., P. C. Burger, S. H. Bigner, J. Q. Trojanowski, C. J. Wikstrand, E. C. Halperin, and D. D. Bigner. “Establishment and characterization of the human medulloblastoma cell line and transplantable xenograft D283 Med.” J Neuropathol Exp Neurol 44, no. 6 (November 1985): 592–605. https://doi.org/10.1097/00005072-198511000-00005.Full Text Link to Item
-
Friedman, H. S., and S. C. Schold. “Rational approaches to the chemotherapy of medulloblastoma.” Neurol Clin 3, no. 4 (November 1985): 843–53.Link to Item
-
Campbell, G. L., R. Bartel, H. S. Freidman, and D. D. Bigner. “Effect of glutamate analogues on brain tumor cell lines.” J Neurochem 45, no. 4 (October 1985): 1186–92. https://doi.org/10.1111/j.1471-4159.1985.tb05540.x.Full Text Link to Item
-
Friedman, H. S., J. Scorza, R. McGuinn, and E. Shaughnessy. “The effects of atrial fibrillation on myocardial blood flow and energetics.” Proc Soc Exp Biol Med 180, no. 1 (October 1985): 1–8. https://doi.org/10.3181/00379727-180-42135.Full Text Link to Item
-
Zeltzer, P. M., H. S. Friedman, D. G. Norris, and A. H. Ragab. “Criteria and definitions for response and relapse in children with brain tumors.” Cancer 56, no. 7 Suppl (October 1, 1985): 1824–26. https://doi.org/10.1002/1097-0142(19851001)56:7+<1824::aid-cncr2820561321>3.0.co;2-h.Full Text Link to Item
-
Dranoff, G., G. B. Elion, H. S. Friedman, G. L. Campbell, and D. D. Bigner. “Influence of glutamine on the growth of human glioma and medulloblastoma in culture.” Cancer Res 45, no. 9 (September 1985): 4077–81.Link to Item
-
Dranoff, G., G. B. Elion, H. S. Friedman, and D. D. Bigner. “Combination chemotherapy in vitro exploiting glutamine metabolism of human glioma and medulloblastoma.” Cancer Res 45, no. 9 (September 1985): 4082–86.Link to Item
-
Ambruso, D. R., E. R. McCabe, D. Anderson, A. Beaudet, L. M. Ballas, I. K. Brandt, B. Brown, R. Coleman, D. B. Dunger, and J. M. Falletta. “Infectious and bleeding complications in patients with glycogenosis Ib.” Am J Dis Child 139, no. 7 (July 1985): 691–97. https://doi.org/10.1001/archpedi.1985.02140090053027.Full Text Link to Item
-
Friedman, H. S., J. A. Hall, and M. J. Harris. “Type A behavior, nonverbal expressive style, and health.” J Pers Soc Psychol 48, no. 5 (May 1985): 1299–1315. https://doi.org/10.1037//0022-3514.48.5.1299.Full Text Link to Item
-
Friedman, H. S., P. C. Burger, S. H. Bigner, J. O. Trojanowski, E. D. Halperin, and D. D. Bigner. “ESTABLISHMENT AND PRELIMINARY CHARACTERIZATION OF THE HUMAN MEDULLOBLASTOMA CELL LINE AND TRANSPLANTABLE XENOGRAFT D283 MED.” Journal of Neuropathology and Experimental Neurology 44, no. 3 (May 1985): 310–310. https://doi.org/10.1097/00005072-198505000-00018.Full Text
-
DRANOFF, G., G. B. ELION, H. S. FRIEDMAN, and D. D. BIGNER. “GLUTAMINE BASED COMBINATION CHEMOTHERAPY IN CULTURE FOR HUMAN GLIOMA AND MEDULLOBLASTOMA.” Proceedings of the American Association for Cancer Research 26, no. MAR (January 1, 1985): 323–323.Link to Item
-
Dranoff, G., G. B. Elion, H. S. Friedman, and D. D. Bigner. “Glutamine based combination chemotherapy in culture for human glioma and medulloblastoma.” Proceedings of the American Association for Cancer Research VOL. 26 (January 1, 1985).
-
FRIEDMAN, H. S., J. KURTZBERG, and D. D. BIGNER. “INVITRO VERSUS INVIVO CORRELATIONS OF CHEMOSENSITIVITY OF HUMAN MEDULLOBLASTOMA - REPLY.” Cancer Research 45, no. 12 (January 1, 1985): 6538–6538.Link to Item
-
Friedman, H. S., S. M. Ludeman, and S. C. Schold. “Sensitivity of human medulloblastoma (MED) to classical alkylators.” Proceedings of the American Association for Cancer Research VOL. 26 (January 1, 1985).
-
Clark, L. T., and H. S. Friedman. “Hypertension associated with alcohol withdrawal: assessment of mechanisms and complications.” Alcohol Clin Exp Res 9, no. 2 (1985): 125–30. https://doi.org/10.1111/j.1530-0277.1985.tb05533.x.Full Text Link to Item
-
FRIEDMAN, H. S., S. M. LUDEMAN, S. C. SCHOLD, V. L. BOYD, L. H. MUHLBAIER, and D. D. BIGNER. “SENSITIVITY OF HUMAN MEDULLOBLASTOMA (MED) TO CLASSICAL ALKYLATORS.” Proceedings of the American Association for Cancer Research 26, no. MAR (January 1, 1985): 330–330.Link to Item
-
Becton, D. L., T. R. Kinney, S. Chaffee, J. Kurtzberg, H. S. Friedman, and J. M. Falleta. “High-dose intravenous immunoglobulin for severe platelet alloimmunization.” Pediatrics 74, no. 6 (December 1984): 1120–23.Link to Item
-
Becton, D. L., and H. S. Friedman. “Management of solid tumors in children.” Compr Ther 10, no. 11 (November 1984): 58–66.Link to Item
-
Friedman, H. S., S. C. Schold, L. H. Muhlbaier, T. D. Bjornsson, and D. D. Bigner. “In vitro versus in vivo correlations of chemosensitivity of human medulloblastoma.” Cancer Res 44, no. 11 (November 1984): 5145–49.Link to Item
-
Friedman, H. S., S. Kottmeier, L. Melnicker, R. McGuinn, and E. Shaughnessy. “Effects of atrial fibrillation on myocardial blood flow in the ischemic heart of the dog.” J Am Coll Cardiol 4, no. 4 (October 1984): 729–34. https://doi.org/10.1016/s0735-1097(84)80399-x.Full Text Link to Item
-
Phibbs, B., H. S. Friedman, T. B. Graboys, B. Lown, H. J. Marriott, W. P. Nelson, and T. Preston. “Indications for pacing in the treatment of bradyarrhythmias. Report of an independent study group.” Jama 252, no. 10 (September 14, 1984): 1307–11.Link to Item
-
Becton, D. L., S. Chaffee, H. S. Friedman, J. Kurtzberg, T. R. Kinney, and J. M. Falletta. “Frequency of bone marrow aspirates in leukemia.” J Pediatr 105, no. 3 (September 1984): 509–10. https://doi.org/10.1016/s0022-3476(84)80060-8.Full Text Link to Item
-
Friedman, H. S., and M. Mazuz. “Prolonged sinoatrial pauses.” Int J Cardiol 6, no. 1 (July 1984): 120–23. https://doi.org/10.1016/0167-5273(84)90259-6.Full Text Link to Item
-
Glickman, L. T., R. B. Grieve, K. T. DeGregory, H. S. Friedman, and J. A. Stockman. “Toxocara antigen and mitogen-induced lymphocyte blastogenesis for diagnosis of visceral larva migrans: clinical and experimental findings in macaques and human beings.” Am J Vet Res 45, no. 6 (June 1984): 1235–37.Link to Item
-
Schold, S. C., H. S. Friedman, T. D. Bjornsson, and D. D. Bigner. “Treatment of human glioma and medulloblastoma tumor lines in athymic mice with diaziquone and diaziquone-based drug combinations.” Cancer Res 44, no. 6 (June 1984): 2352–57.Link to Item
-
Schold, S. C., H. S. Friedman, T. D. Bjornsson, and J. M. Falletta. “Treatment of patients with recurrent primary brain tumors with AZQ.” Neurology 34, no. 5 (May 1984): 615–19. https://doi.org/10.1212/wnl.34.5.615.Full Text Link to Item
-
Dranoff, G., G. B. Elion, G. L. Campbell, H. S. Friedman, and P. P. Bigner. “130 INFLUENCE OF GLUTAMINE ON GROWTH OF HUMAN MEDULLOBLASTOMA IN CULTURE.” Journal of Neuropathology and Experimental Neurology 43, no. 3 (May 1984): 336–336. https://doi.org/10.1097/00005072-198405000-00136.Full Text
-
Friedman, H. S., J. Kurtzberg, B. Croker, J. M. Falletta, and T. R. Kinney. “Retinoblastoma metastatic to bone marrow. A case with florid spread.” Clin Pediatr (Phila) 23, no. 3 (March 1984): 184–87. https://doi.org/10.1177/000992288402300312.Full Text Link to Item
-
DRANOFF, G., G. B. ELION, H. S. FRIEDMAN, and D. D. BIGNER. “GLUTAMINE REQUIREMENTS OF HUMAN GLIOMA AND MEDULLOBLASTOMA IN CULTURE.” Journal of Neuro Oncology 2, no. 3 (January 1, 1984): 264–264.Link to Item
-
FRIEDMAN, H. S., S. C. SCHOLD, L. H. MUHLBAIER, and D. D. BIGNER. “INVITRO AND INVIVO CHEMOSENSITIVITY OF HUMAN MEDULLOBLASTOMA.” Proceedings of the American Association for Cancer Research 25, no. MAR (January 1, 1984): 376–376.Link to Item
-
SCHOLD, S. C., H. S. FRIEDMAN, D. E. BULLARD, J. M. FALLETTA, D. R. MCDONALD, J. G. CAIRNCROSS, M. S. MAHALEY, J. D. KHANDEKAR, and N. A. VICK. “CLINICAL-TRIALS OF DIAZIQUONE (AZQ) IN PATIENTS WITH PRIMARY CENTRAL NERVOUS-SYSTEM (CNS) NEOPLASMS.” Journal of Neuro Oncology 2, no. 3 (January 1, 1984): 289–289.Link to Item
-
Schold, S. C., and H. S. Friedman. “Human brain tumor xenografts.” Prog Exp Tumor Res 28 (1984): 18–31. https://doi.org/10.1159/000408235.Full Text Link to Item
-
FRIEDMAN, H. S., S. H. BIGNER, S. C. SCHOLD, P. C. BURGER, T. D. BJORNSSON, E. C. HALPERIN, M. A. VARIA, L. H. MUHLBAIER, and D. D. BIGNER. “THE USE OF HUMAN MEDULLOBLASTOMA MODELS TO DESIGN RATIONAL THERAPY.” Journal of Neuro Oncology 2, no. 3 (January 1, 1984): 286–286.Link to Item
-
Friedman, H. S., R. Lowery, M. Archer, E. Shaughnessy, and J. Scorza. “The effects of ethanol on brain blood flow in awake dogs.” J Cardiovasc Pharmacol 6, no. 2 (1984): 344–48. https://doi.org/10.1097/00005344-198403000-00021.Full Text Link to Item
-
Friedman, H. S., R. Lowery, E. Shaughnessy, and J. Scorza. “The effects of ethanol on pancreatic blood flow in awake and anesthetized dogs.” Proc Soc Exp Biol Med 174, no. 3 (December 1983): 377–82. https://doi.org/10.3181/00379727-174-41751.Full Text Link to Item
-
Chen, T. S., H. S. Friedman, A. J. Smith, and M. L. Del Monte. “Hemodynamic changes during hemodialysis: role of dialyzate.” Clin Nephrol 20, no. 4 (October 1983): 190–96.Link to Item
-
Friedman, H. S., S. H. Bigner, R. D. McComb, S. C. Schold, J. F. Pasternak, D. R. Groothuis, and D. D. Bigner. “A model for human medulloblastoma. Growth, morphology, and chromosomal analysis in vitro and in athymic mice.” J Neuropathol Exp Neurol 42, no. 5 (September 1983): 485–503. https://doi.org/10.1097/00005072-198309000-00001.Full Text Link to Item
-
Frank, J. A., H. S. Friedman, D. M. Davidson, J. M. Falletta, and T. R. Kinney. “Propionibacterium shunt nephritis in two adolescents with medulloblastoma.” Cancer 52, no. 2 (July 15, 1983): 330–33. https://doi.org/10.1002/1097-0142(19830715)52:2<330::aid-cncr2820520224>3.0.co;2-t.Full Text Link to Item
-
Friedman, H. S., S. C. Schold, M. Varia, and D. D. Bigner. “Chemotherapy and radiation therapy of human medulloblastoma in athymic nude mice.” Cancer Res 43, no. 7 (July 1983): 3088–93.Link to Item
-
Shah, K. A., M. D. Forman, and H. S. Friedman. “Munchausen's syndrome and cardiac catheterization. A case of a pernicious interaction.” Jama 248, no. 22 (December 10, 1982): 3008–9.Link to Item
-
Friedman, H. S., and M. V. Bonventre. “Erythromycin-induced digoxin toxicity.” Chest 82, no. 2 (August 1982): 202. https://doi.org/10.1378/chest.82.2.202-b.Full Text Link to Item
-
Friedman, H. S., and T. S. Chen. “Use of control steady-state serum digoxin levels for predicting serum digoxin concentration after quinidine administration.” Am Heart J 104, no. 1 (July 1982): 72–76. https://doi.org/10.1016/0002-8703(82)90643-3.Full Text Link to Item
-
Friedman, H. S. “Case 1-1982: Atrioventricular heart block.” N Engl J Med 306, no. 23 (June 10, 1982): 1429. https://doi.org/10.1056/NEJM198206103062320.Full Text Link to Item
-
Coleman, R. A., H. M. Sommerville, H. S. Friedman, J. M. Falletta, and T. R. Kinney. “Insulin therapy for ketolactic acidosis complicating malignancy.” J Pediatr 100, no. 4 (April 1982): 584–87. https://doi.org/10.1016/s0022-3476(82)80759-2.Full Text Link to Item
-
Friedman, H. S., S. C. Schold, S. H. Bigner, and D. D. Bigner. “Growth, morphology, and chemotherapeutic response of medulloblastoma in athymic mice.” Annals of Neurology 12, no. 2 (January 1, 1982): 212.
-
Friedman, H. S., S. H. Bigner, S. C. Schold, and D. D. Bigner. “Growth, morphology, and chemotherapeutic response of medulloblastoma (MBT) in athymic mice.” Pediatric Research 16, no. 4 II (January 1, 1982).
-
SCHOLD, S. C., H. S. FRIEDMAN, T. D. BJORNSSON, D. G. SHAND, and D. D. BIGNER. “TREATMENT OF HUMAN-BRAIN TUMORS IN ATHYMIC MICE WITH AZIRIDINYLBENZOQUINONE (AZQ).” Proceedings of the American Association for Cancer Research 23, no. MAR (January 1, 1982): 176–176.Link to Item
-
Schold, S. C., H. S. Friedman, and T. D. Bjornsson. “Treatment of human brain tumors in athymic mice with aziridinylbenzoquinone (AZQ).” Proceedings of the American Association for Cancer Research Vol. 23 (January 1, 1982): 693.
-
Friedman, H. S., J. K. Pincus, and J. M. Falletta. “Central nervous system leukaemia.” Lancet 2, no. 8247 (September 19, 1981): 633. https://doi.org/10.1016/s0140-6736(81)92764-1.Full Text Link to Item
-
Chokshi, A. B., H. S. Friedman, M. Malach, B. C. Vasavada, and S. J. Bleicher. “Impact of peer review in reduction of permanent pacemaker implantations.” Jama 246, no. 7 (August 14, 1981): 754–57.Link to Item
-
Friedman, H. S., B. N. Shah, H. G. Kim, L. A. Bove, M. M. Del Monte, and A. J. Smith. “Clinical study of the cardiac findings in patients on chronic maintenance hemodialysis: the relationship to coronary risk factors.” Clin Nephrol 16, no. 2 (August 1981): 75–85.Link to Item
-
Friedman, H. S., R. A. Coleman, and T. R. Kinney. “Insulin infusion in ketolactic acidosis complicating malignancy.” Clinical Research 29, no. 5 (January 1, 1981).
-
Friedman, H. S. “Acute effects of ethanol on myocardial blood flow in the nonischemic and ischemic heart.” Am J Cardiol 47, no. 1 (January 1981): 61–67. https://doi.org/10.1016/0002-9149(81)90290-3.Full Text Link to Item
-
Chen, T. S., and H. S. Friedman. “Alteration of digoxin pharmacokinetics by a single dose of quinidine.” Jama 244, no. 7 (August 15, 1980): 669–72.Link to Item
-
DiMatteo, M. R., A. Taranta, H. S. Friedman, and L. M. Prince. “Predicting patient satisfaction from physicians' nonverbal communication skills.” Med Care 18, no. 4 (April 1980): 376–87. https://doi.org/10.1097/00005650-198004000-00003.Full Text Link to Item
-
Kim, H. G., and H. S. Friedman. “Procainamide-induced sinus node dysfunction in patients with chronic renal failure.” Chest 76, no. 6 (December 1979): 699–701. https://doi.org/10.1378/chest.76.6.699.Full Text Link to Item
-
Friedman, H. S., S. Matsuzaki, S. S. Choe, H. A. Fernando, A. Celis, Q. Zaman, and C. S. Lieber. “Demonstration of dissimilar acute haemodynamic effects of ethanol and acetaldehyde.” Cardiovasc Res 13, no. 8 (August 1979): 477–86. https://doi.org/10.1093/cvr/13.8.477.Full Text Link to Item
-
Ambrose, J. A., and H. S. Friedman. “Changing diastolic closure rates (E to F slopes) in a patient with mitral stenosis: a case report.” Angiology 30, no. 1 (January 1979): 62–66. https://doi.org/10.1177/000331977903000109.Full Text Link to Item
-
Chen, T. S., H. S. Friedman, M. Del Monte, and A. J. Smith. “Hemodynamic changes during dialysis.” Proc Clin Dial Transplant Forum 9 (1979): 66–71.Link to Item
-
Friedman, H. S. “Cardiac tamponade.” Circulation 59, no. 1 (January 1979): 193–94. https://doi.org/10.1161/01.cir.59.1.193.Full Text Link to Item
-
Friedman, H. S. “Right-heart catheterization in coronary artery disease.” Angiology 29, no. 12 (December 1978): 878–87. https://doi.org/10.1177/000331977802901202.Full Text Link to Item
-
Friedman, H. S., Q. Zaman, J. I. Haft, and S. Melendez. “Assessment of atrioventricular conduction in aortic valve disease.” Br Heart J 40, no. 8 (August 1978): 911–17. https://doi.org/10.1136/hrt.40.8.911.Full Text Link to Item
-
Shaw, S., E. A. Heller, H. S. Friedman, E. Bara ona, and C. S. Lieber. “Increased hepatic oxygenation following ethanol administration in the baboon.” Proc Soc Exp Biol Med 156, no. 3 (December 1977): 509–13. https://doi.org/10.3181/00379727-156-39968.Full Text Link to Item
-
Friedman, H. S., and Q. Zaman. “Persistent repetitive supraventricular tachycardia.” Eur J Cardiol 5, no. 5 (July 1977): 405–11.Link to Item
-
Friedman, H. S., F. Lajam, J. A. Gomes, Q. Zaman, N. D. Marino, and J. Calderon. “Demonstration of a depressor reflex in acute cardiac tamponade.” J Thorac Cardiovasc Surg 73, no. 2 (February 1977): 278–86.Link to Item
-
Friedman, H. S. “Effective time management: a key to increased sales.” Dent Lab Rev 52, no. 1 (January 1977): 30–32.Link to Item
-
Friedman, H. S., F. Lajam, Q. Zaman, J. A. Gomes, J. Calderon, N. D. Marino, H. A. Fernando, and S. S. Choe. “Effect of autonomic blockade on the hemodynamic findings in acute cardiac tamponade.” Am J Physiol 232, no. 1 (January 1977): H5-11. https://doi.org/10.1152/ajpheart.1977.232.1.H5.Full Text Link to Item
-
Friedman, H. S. “Editorial: Diagnostic considerations in electromechanical dissociation.” Am J Cardiol 38, no. 2 (August 1976): 268–69. https://doi.org/10.1016/0002-9149(76)90162-4.Full Text Link to Item
-
Friedman, H. S. “Effects of self-esteem and expected duration of interaction on liking for a highly rewarding partner.” J Pers Soc Psychol 33, no. 6 (June 1976): 686–90. https://doi.org/10.1037//0022-3514.33.6.686.Full Text Link to Item
-
Friedman, H. S., N. K. Parikh, N. Chander, and J. Calderon. “Sarcoidosis with incomplete bilateral bundle branch block pattern disappearing following steroid therapy: an electrophysiological study.” Eur J Cardiol 4, no. 2 (June 1976): 141–50.Link to Item
-
Friedman, H. S., J. A. Gomes, and J. I. Haft. “An analysis of Wenckebach periodicity.” J Electrocardiol 8, no. 4 (1975): 307–15. https://doi.org/10.1016/s0022-0736(75)80003-3.Full Text Link to Item
-
Friedman, H. S., J. A. Gomes, A. Tardio, R. Levites, and J. I. Haft. “Appearance of atrial rhythm with absent P wave in longstanding atrial fibrillation.” Chest 66, no. 2 (August 1974): 172–75. https://doi.org/10.1378/chest.66.2.172.Full Text Link to Item
-
Sakurai, H., A. Ackad, H. S. Friedman, E. Lajam, J. I. Haft, and R. M. Stein. “Aorto-coronary bypass graft surgery in a patient on home hemodialysis.” Clin Nephrol 2, no. 5 (1974): 208–10.Link to Item
-
Friedman, H. S., J. Lipski, J. Pantazopoulos, G. Genkins, and E. Donoso. “Bundle of His electrograms in congenital corrected transposition of the great arteries. A study of two adult cases.” Br Heart J 35, no. 12 (December 1973): 1307–14. https://doi.org/10.1136/hrt.35.12.1307.Full Text Link to Item
-
Schwertner, H. A., and H. S. Friedman. “Changes in lipid values and lipoprotein patterns of serum samples contaminated with bacteria.” Am J Clin Pathol 59, no. 6 (June 1973): 829–35. https://doi.org/10.1093/ajcp/59.6.829.Full Text Link to Item
-
Friedman, H. S., and C. S. Cheek. “Simultaneous and completely automated methods for serum iron and iron-binding capacity determinations.” Clin Chim Acta 31, no. 2 (February 1971): 315–27. https://doi.org/10.1016/0009-8981(71)90400-1.Full Text Link to Item
-
Rose, L. I., H. S. Friedman, S. C. Beering, and K. H. Cooper. “Plasma cortisol changes following a mile run in conditioned subjects.” J Clin Endocrinol Metab 31, no. 3 (September 1970): 339–41. https://doi.org/10.1210/jcem-31-3-339.Full Text Link to Item
-
Friedman, H. S. “Further notes on gravimetric serum total lipid determinations.” Clin Chim Acta 25, no. 1 (July 1969): 173. https://doi.org/10.1016/0009-8981(69)90244-7.Full Text Link to Item
-
Friedman, H. S. “Quantitative determination of total lipids in serum.” Clin Chim Acta 19, no. 2 (February 1968): 291–95. https://doi.org/10.1016/0009-8981(68)90338-0.Full Text Link to Item
-
FRIEDMAN, H. S. “Observations on the determination of serum protein-bound iodine.” Clinica Chimica Acta; International Journal of Clinical Chemistry, Not Available 7 (January 1962): 111–13.
-
FRIEDMAN, H. S. “A rapid screening test for abnormal hemoglobins. The detection of hemoglobin-A2.” Clinica Chimica Acta; International Journal of Clinical Chemistry, Not Available 7 (January 1962): 100–107.
-
FRIEDMAN, H. S. “A standardized procedure for serum protein electrophoresis on cellulose acetate membrane strips.” Clinica Chimica Acta; International Journal of Clinical Chemistry, Not Available 6 (November 1961): 775–81.
-
FRIEDMAN, H. S. “Otoplasty for lop ear correction.” Eye, Ear, Nose & Throat Monthly, Not Available 39 (September 1960): 728–29.
-
FRIEDMAN, H. S. “Simplification of certain aspects in the performance and interpretation of complement-fixation tests.” Technical Bulletin of the Registry of Medical Technologists, Not Available 30 (February 1960): 22–25.
-
FRIEDMAN, H. S. “Spectrophotometric studies of the Zimmermann reaction.” Clinical Chemistry, Not Available 5 (December 1959): 575–86.
-
FRIEDMAN, H. S. “Oroplasty. A new simplified technique.” A.M.A. Archives of Otolaryngology, Not Available 70 (October 1959): 454–58.
-
FRIEDMAN, H. S., E. W. PARISI, and O. M. KURSCHNER. “Intramuscular iron therapy.” The Journal of the American Osteopathic Association, Not Available 57, no. 10 (June 1958): 665–66.
-
FRIEDMAN, H. S. “Torsion of the appendix testis.” United States Armed Forces Medical Journal, Not Available 8, no. 6 (June 1957): 896–900.
-
FRIEDMAN, H. S. “Azorubin in aqueous and methanolic solutions; spectrophotometric studies.” Clinical Chemistry, Not Available 2, no. 3 (June 1956): 160–65.
-
FOWLER, E. P., F. ALTMANN, D. C. BAKER, V. EPANCHIN, H. S. FRIEDMAN, B. MARQUIT, and D. MARKLE. “Twenty-five years of otolaryngology in a university hospital.” A.M.A. Archives of Otolaryngology, Not Available 63, no. 5 (May 1956): 481–512.
-
FRIEDMAN, H. S., and M. A. RUBIN. “Clinical significance of the magnesium: calcium ratio; technic for the determination of magnesium and calcium in biologic fluids.” Clinical Chemistry, Not Available 1, no. 2 (April 1955): 125–33.
-
FRIEDMAN, H. S. “The use of glycogen as a substrate for the determination of serum amylase.” The Journal of Laboratory and Clinical Medicine, Not Available 44, no. 2 (August 1954): 308–11.
-
FRIEDMAN, H. S. “Boeck's sarcoid; a review and a report of a case demonstrating multiple iris nodules, acute secondary glaucoma, and keratopathy.” American Journal of Ophthalmology, Not Available 34, no. 8 (August 1951): 1126–36.
-
-
Book Sections
-
Desjardins, A., and H. S. Friedman. “Chemotherapy for gliomas.” In The Duke Glioma Handbook: Pathology, Diagnosis, and Management, 76–90, 2016. https://doi.org/10.1017/CBO9781107588721.005.Full Text
-
Friedman, H. S., S. D. Averbuch, and J. Kurtzberg. “Alkylating agents: Part B. methylating agents.” In Cancer Chemotherapy and Biotherapy: Principles and Practice, 732–68, 2011.
-
-
Other Articles
-
Augustine, C. K., J. S. Yoo, A. Potti, Y. Yoshimoto, P. A. Zipfel, H. S. Friedman, J. R. Nevins, F. Ali-Osman, and D. S. Tyler. “Correction: Article on genomic and molecular profiling to predict response to temozolomide (Clinical Cancer Research (2009) 15, (502-510)).” Clinical Cancer Research, May 1, 2009. https://doi.org/10.1158/1078-0432.CCR-15-9-COR.Full Text
-
Rasheed, B. K., R. E. McLendon, H. S. Friedman, A. H. Friedman, H. E. Fuchs, D. D. Bigner, and S. H. Bigner. “Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25.” Oncogene, June 1, 1995.Link to Item
-
Furie, D. M., G. J. Felsberg, R. D. Tien, H. S. Friedman, H. Fuchs, and R. McLendon. “MRI of gangliocytoma of cerebellum and spinal cord.” J Comput Assist Tomogr, 1993. https://doi.org/10.1097/00004728-199305000-00031.Full Text Link to Item
-
Abramson, D. H. “Successful therapy for trilateral retinoblastoma.” Am J Ophthalmol, November 15, 1992. https://doi.org/10.1016/s0002-9394(14)74509-x.Full Text Link to Item
-
Lueder, G. T. “Successful therapy for trilateral retinoblastoma.” Am J Ophthalmol, November 15, 1992. https://doi.org/10.1016/s0002-9394(14)74507-6.Full Text Link to Item
-
-
Journal Issues
-
Ghiaseddin, Ashley, David Reardon, Woody Massey, Alex Mannerino, Eric S. Lipp, James E. Herndon, Frances McSherry, et al. “Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.” Oncologist, February 2018. https://doi.org/10.1634/theoncologist.2017-0501.Full Text Link to Item
-
-
Conference Papers
-
Desjardins, Annick, Vidyalakshmi Chandramohan, Daniel B. Landi, Margaret O. Johnson, Mustafa Khasraw, Katherine B. Peters, Justin Low, et al. “A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convectionenhanced delivery for adult patients with recurrent malignant glioma (MG).” In Journal of Clinical Oncology, Vol. 40, 2022.Link to Item
-
Sampson, John H., Kristen A. Batich, Duane Anthony Mitchell, James Emmett Herndon, Gloria Broadwater, Patrick Healy, Luis Sanchez-Perez, et al. “Reproducibility of outcomes in sequential trials using CMV-targeted dendritic cell vaccination for glioblastoma.” In Journal of Clinical Oncology, Vol. 40, 2022.Link to Item
-
Singh, Kirit, Matthew Foster, Elizabeth S. Miller, Simon Gregory, Kent J. Weinhold, David M. Ashley, Annick Desjardins, et al. “A phase 0/surgical window-of-opportunity study in progress, evaluating evolocumab in patients with high-grade glioma or glioblastoma.” In Journal of Clinical Oncology, Vol. 40, 2022.Link to Item
-
Batich, Kristen, Duane Mitchell, Patrick Healy, James Herndon, Gloria Broadwater, Gunn Michael, Min-Nung Huang, et al. “CTIM-10. REPRODUCIBILITY OF CLINICAL TRIALS USING CMV-TARGETED DENDRITIC CELL VACCINES IN PATIENTS WITH GLIOBLASTOMA.” In Neuro Oncology, 23:vi51–vi51. Oxford University Press (OUP), 2021. https://doi.org/10.1093/neuonc/noab196.202.Full Text Open Access Copy Link to Item
-
Johnson, Margaret, Mustafa Khasraw, Jung-Young Kim, Nicole Cort, James Herndon, Luis Ramirez, Eric Lipp, et al. “QOLP-28. COMPARING KNOWLEDGE OF AND BELIEFS ABOUT PALLIATIVE CARE AMONG NEURO-ONCOLOGY PATIENTS, CAREGIVERS, PROVIDERS AND A NATIONALLY-REPRESENTATIVE U.S. SAMPLE.” In Neuro Oncology, 23:vi189–vi189. Oxford University Press (OUP), 2021. https://doi.org/10.1093/neuonc/noab196.748.Full Text Open Access Copy Link to Item
-
Peters, Katherine, Mallika Patel, Candice Alford, Gerardo Chavez, Jung-Young Kim, Jennifer Durling, Tracy Novack, et al. “INNV-20. RADIOGRAPHIC RESPONSE AND SEIZURE CONTROL IN IDH1 MUTANT GLIOMA PATIENTS USING IVOSIDENIB.” In Neuro Oncology, 23:vi109–vi109. Oxford University Press (OUP), 2021. https://doi.org/10.1093/neuonc/noab196.431.Full Text Open Access Copy Link to Item
-
Sloan, Andrew E., Robin Arthur Buerki, Christopher Murphy, Andrea True Kelly, Prakash Ambady, Michael Brown, Nicholas A. Butowski, et al. “LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma.” In Journal of Clinical Oncology, 39:TPS2065–TPS2065. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.tps2065.Full Text
-
Lee, J. W. C., M. O. Johnson, J. P. Kirkpatrick, F. McSherry, J. Herndon, E. S. Lipp, A. Desjardins, et al. “Outcomes Following Adjuvant Radiation Therapy in Elderly Patients with Glioblastoma: A Retrospective Single Institution Analysis.” In International Journal of Radiation Oncology*Biology*Physics, 105:E102–E102. Elsevier BV, 2020. https://doi.org/10.1016/j.ijrobp.2019.06.2296.Full Text Link to Item
-
Desjardins, Annick, Dina Randazzo, Vidyalakshmi Chandramohan, Peters Katherine B., Margaret O. Johnson, Steve Threat, Chevelle A. Bullock, et al. “Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).” In Journal of Clinical Oncology, 38:20s-20s. American Society of Clinical Oncology, 2020. https://doi.org/10.1200/JCO.2020.38.15_suppl.2566.Full Text Link to Item
-
Peters, Katherine B., John Kirkpatrick, I. Batinic-Haberle, Mary L. Affronti, Sarah Woodring, Deborah Iden, Eric S. Lipp, et al. “Cognitive Outcomes of Phase I Trial of Novel Metalloporphyrin Radioprotectant and Radiosensitizer in Newly Diagnosed High Grade Glioma Patients.” In Supportive Care in Cancer. Springer (part of Springer Nature), 2020.
-
Desjardins, Annick, Dina Randazzo, Vidyalakshmi Chandramohan, Katherine B. Peters, Margaret O. Johnson, Stevie Threatt, Chevelle A. Bullock, et al. “Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).” In Journal of Clinical Oncology, Vol. 38, 2020.Link to Item
-
Peters, K. B., J. P. Kirkpatrick, I. Batinic-Haberle, M. L. Affronti, S. Woodring, D. Iden, E. S. Lipp, et al. “First in Human Clinical Trial of a Metalloporphyrin Dual Radioprotectant and Radiosensitizer, BMX-001, in Newly Diagnosed High-Grade Glioma Undergoing Concurrent Chemoradiation.” In International Journal of Radiation Oncology*Biology*Physics, 105:E106–E106. Elsevier BV, 2019. https://doi.org/10.1016/j.ijrobp.2019.06.2305.Full Text Link to Item
-
Desjardins, Annick, Matthias Gromeier, James Emmett Herndon, Dina Randazzo, Stevie Threatt, Eric S. Lipp, Elizabeth S. Miller, et al. “Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.” In Journal of Clinical Oncology, 37:101s-101s. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/JCO.2019.37.15_suppl.2060.Full Text Link to Item
-
Peters, Katherine B., Gerald E. Archer, Pamela Norberg, Weihua Xie, Stevie Threatt, Eric S. Lipp, James Emmett Herndon, et al. “Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.” In Journal of Clinical Oncology, 37:e13526–e13526. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.e13526.Full Text
-
Kang, J., C. Swisher, John Kirkpatrick, James Herndon, Eric Lipp, Leslie Thomas, Margaret O. Johnson, et al. “Primary brain tumors admitted to the neurological intensive care unit: a single institution observational study.” In Neurology, 92:P1.6-009-P1.6-009. American Academy of Neurology, 2019.Link to Item
-
Ashley, David M., Eric M. Thompson, Daniel Landi, Annick Desjardins, Allan H. Friedman, Stevie Threatt, James E. Herndon, et al. “PHASE 1B STUDY POLIO VACCINE SABIN-RHINOVIRUS POLIOVIRUS (PVSRIPO) FOR RECURRENT MALIGNANT GLIOMA IN CHILDREN.” In Neuro Oncology, 20:93–93. OXFORD UNIV PRESS INC, 2018.Link to Item
-
Vaslow, Zachary, Katherine Peters, John Kirkpatrick, Frances McSherry, James Herndon, Eric Lipp, Margaret O. Johnson, et al. “Long-term outcomes of adult patients with ependymoma.” In Neurology, 90:P6–P6. American Academy of Neurology, 2018.Link to Item
-
Inamullah, O., John Kirkpatrick, Patrick Healy, Eric Lipp, Margaret Johnson, David Ashley, Dina Randazzo, Henry Friedman, and Katherine Peters. “Adult pilocytic astrocytoma: clinical management and prognostic factors.” In Neurology, 90:P6.158-P6.158. American Academy of Neurology, 2018.Link to Item
-
Desjardins, Annick, Dina Randazzo, Katherine B. Peters, Margaret O. Johnson, Woody Massey, James E. Herndon, Frances McSherry, et al. “PHASE 2 STUDY OF SYM004 FOR ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM).” In Neuro Oncology, 19:vi14–vi14. OXFORD UNIV PRESS INC, 2017. https://doi.org/10.1093/neuonc/nox168.871.Full Text Link to Item
-
Dunn-Pirio, Anastasie, Sarah Woodring, Sujata Panta, Eric S. Lipp, Patrick Healy, James E. Herndon, Eric Fountain, et al. “PERAMPANEL FOR TREATMENT OF REFRACTORY SEIZURES IN PATIENTS WITH GLIOMAS.” In Neuro Oncology, 19:168–168. OXFORD UNIV PRESS INC, 2017.Link to Item
-
Peters, Katherine B., Mary Lou Affronti, Stevie Threatt, Patrick Healy, James E. Herndon, Eric S. Lipp, Sujata Panta, Dina Randazzo, Henry S. Friedman, and Annick Desjardins. “INCREASED FATIGUE ASSOCIATED WITH TUMOR PROGRESSION IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS.” In Neuro Oncology, 19:170–170. OXFORD UNIV PRESS INC, 2017.Link to Item
-
Peters, Katherine B., Mary Lou Affronti, Stevie Threatt, Patrick Healy, James E. Herndon, Eric S. Lipp, Sujata Panta, Dina Randazzo, Henry S. Friedman, and Annick Desjardins. “MAINTENANCE OF HEALTH RELATED QUALITY OF LIFE (QOL) BEYOND PROGRESSION IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED WITH BEVACIZUMAB.” In Neuro Oncology, 19:206–206. OXFORD UNIV PRESS INC, 2017.Link to Item
-
Randazzo, Dina, Frances McSherry, James E. Herndon, Mary Lou Affronti, Patrick Healy, Eric S. Lipp, Annick Desjardins, Henry S. Friedman, and Katherine B. Peters. “A SINGLE INSTITUTION'S EXPERIENCE EXPLORING THE ASSOCIATION OF INTEGRATIVE MEDICINE AND SURVIVORSHIP IN GLIOBLASTOMA.” In Neuro Oncology, 19:202–202. OXFORD UNIV PRESS INC, 2017.Link to Item
-
Weant, Mallika P., John Kirkpatrick, Margaret O. Johnson, Ashley Dunn-Pirio, Patrick Healy, James E. Herndon, Eric Lipp, et al. “PATTERNS OF RELAPSE AFTER SUCCESSFUL COMPLETION OF INITIAL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA.” In Neuro Oncology, 19:vi217–vi217. Oxford University Press (OUP), 2017. https://doi.org/10.1093/neuonc/nox168.878.Full Text Link to Item
-
Desjardins, Annick, John H. Sampson, Gordana Vlahovic, Katherine B. Peters, Dina Randazzo, Stevie Threatt, James Emmett Herndon, et al. “Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG).” In Journal of Clinical Oncology, 35:e13533–e13533. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.e13533.Full Text Link to Item
-
Peters, Katherine B., Stevie Threatt, Patrick Healy, James Emmett Herndon, Eric S. Lipp, Sujata Panta, Dina Randazzo, Gordana Vlahovic, Henry S. Friedman, and Annick Desjardins. “Reductions in exercise behavior and tumor progression in newly diagnosed glioblastoma (GBM) patients.” In Journal of Clinical Oncology, 35:e21636–e21636. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/JCO.2017.35.15_suppl.e21636.Full Text Link to Item
-
Dunn-Pirio, Anastasie, Katherine Peters, Dina Randazzo, Hentry Friedman, Patrick Healy, James Herndon, Elizabeth Reap, et al. “Tumor stem cell RNA-leaded dedritic cell vaccine for recurrent glioblastoma: a phase 1 trail.” In Neurology, 88:S41–S41. American Academy of Neurology, 2017.Link to Item
-
Affronti, Mary Lou, Sarah Woodring, Karen Allen, John Kirkpatrick, Katherine B. Peters, James E. Herndon, Frances McSherry, et al. “Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).” In Support Care Cancer, 24:4365–75, 2016. https://doi.org/10.1007/s00520-016-3276-1.Full Text Link to Item
-
Desjardins, Annick, John H. Sampson, Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Stevie Threatt, James Emmett Herndon, et al. “Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.” In Journal of Clinical Oncology, 34:2061–2061. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.2061.Full Text Link to Item
-
Peters, Katherine B., Sarah Woodring, Patrick Healy, James Emmett Herndon, Eric S. Lipp, Janet Minchew, Ben Zalutsky, et al. “Baseline cognitive function to predict survival in patients with glioblastoma.” In Journal of Clinical Oncology, 34:10125–10125. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.10125.Full Text Link to Item
-
Vlahovic, Gordana, Gerald E. Archer, Elizabeth Reap, Annick Desjardins, Katherine B. Peters, Dina Randazzo, Patrick Healy, et al. “Phase I trial of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, 34:e13518–e13518. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.e13518.Full Text Link to Item
-
Mowery, Y. M., G. J. Kim, A. Wright, A. Desjardins, K. B. Peters, G. Vlahovic, H. S. Friedman, J. H. Sampson, and J. P. Kirkpatrick. “Outcomes for Patients With Intracranial Meningiomas Treated With Radiation therapy and Bevacizumab: A Single-Institution Retrospective Analysis.” In International Journal of Radiation Oncology*Biology*Physics, 93:E104–E104. Elsevier BV, 2015. https://doi.org/10.1016/j.ijrobp.2015.07.813.Full Text
-
Ghiaseddin, Ashley, David Reardon, Woody Massey, Alexandra Mannerino, Eric Lipp, James Herndon, Frances McSherry, et al. “Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.” In Journal of Clinical Oncology, 33:104s-104s. American Society of Clinical Oncology, 2015.Link to Item
-
Kim, Jung-Young, Sarah Woodring, Mary Lou Affronti, Dina Randazzo, Frances McSherry, James Emmett Herndon, Eric S. Lipp, et al. “Secondary cancers in long-term survivors of primary glioblastoma.” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.Link to Item
-
Desjardins, Annick, John H. Sampson, Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Stevie Threatt, James Emmett Herndon, et al. “Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.” In Journal of Clinical Oncology, 33:2068–2068. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.2068.Full Text
-
Desjardins, Annick, Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Susan Boulton, Woody C. Massey, Eric S. Lipp, et al. “Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1.” In Journal of Clinical Oncology, 33:2067–2067. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.2067.Full Text
-
Friedman, Henry S., Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Susan Boulton, Sarah Woodring, Eric S. Lipp, et al. “Phase 1 clinical trial of carboxyamidotriazole orotate (CTO) in combination with lomustine (CCNU) for adult patients with recurrent malignant glioma (MG).” In Journal of Clinical Oncology, 33:e13004–e13004. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.e13004.Full Text
-
Ghiaseddin, Ashley, David A. Reardon, Woody Massey, Alexandra Mannerino, Eric S. Lipp, James E. Herndon, Frances McSherry, et al. “Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.” In Journal of Clinical Oncology, 33:2034–2034. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.2034.Full Text
-
Vlahovic, Gordana, Gerald E. Archer, Denise Lally-Goss, Elizabeth Reap, Annick Desjardins, Katherine B. Peters, Dina Randazzo, et al. “Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, 33:e13030–e13030. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.e13030.Full Text
-
Peters, Katherine, Mary Lou Affronti, Sarah Woodring, Eric Lipp, Patrick Healy, Frances McSherry, James Herndon, et al. “Placebo-controlled, double-blind, randomized pilot study to evaluate the effects of low-dose naltrexone on quality of life and fatigue in newly diagnosed high-grade glioma.” In Neurology, 84:P4–P4, 2015.Link to Item
-
Peters, Katherine, Mary Lou Affronti, Sarah Woodring, Eric Lipp, Patrick Healy, Frances McSherry, James Herndon, et al. “Placebo-controlled, double-blind, randomized pilot study to evaluate the effects of low-dose naltrexone on quality of life and fatigue in newly diagnosed high-grade glioma.” In Neurology, 84:P4–P4, 2015.Link to Item
-
Keir, Stephen T., B Ahmed Rasheed, Katherine A. Hoadley, Martin A. Roskoski, Danuta Gasinski, Madan M. Kwatra, Henry S. Friedman, and Dare D. Bigner. “Identification and treatment data of xenografts representing TCGA-defined glioblastoma subtypes.” In Cancer Research, Vol. 75, 2015. https://doi.org/10.1158/1538-7445.AM2015-2435A.Full Text Link to Item
-
Randazzo, Dina, Mary L. Affronti, Eric Lipp, Frances McSherry, James Herndon, Charlene Flahiff, Elizabeth Miller, et al. “Complementary and alternative medicine in the primary brain tumor population and its association with health-related quality of life.” In Supportive Care in Cancer, 22:S191–S191. Springer (part of Springer Nature), 2014.Link to Item
-
Desjardins, Annick, John Howard Sampson, Katherine B. Peters, Tulika Ranjan, Gordana Vlahovic, Jason Watts, Stevie Threatt, et al. “Phase I study of the intratumoral administration of an oncolytic polio/rhinovirus recombinant (PVSRIPO) in recurrent glioblastoma (GBM).” In Journal of Clinical Oncology, 32:TPS2106–TPS2106. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.tps2106.Full Text
-
Friedman, Henry S., James Emmett Herndon, Frances McSherry, Arliene Ravelo, Eric S. Lipp, Patrick Healy, Katherine B. Peters, et al. “Single-institution retrospective review of newly diagnosed glioblastoma (GBM) patients (pts) treated on bevacizumab (BEV) in clinical practice.” In Journal of Clinical Oncology, 32:2082–2082. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.2082.Full Text
-
Peters, Katherine B., Sarah Woodring, Mary Lou Affronti, Frances McSherry, James Emmett Herndon, Annick Desjardins, Tulika Ranjan, Gordana Vlahovic, Allan H. Friedman, and Henry S. Friedman. “Long-term survivorship in adult primary glioblastoma: Clinical and neurological outcomes of a large, single-center study.” In Journal of Clinical Oncology, 32:9519–9519. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.9519.Full Text
-
Sampson, John Howard, Gordana Vlahovic, Annick Desjardins, Henry S. Friedman, Joachim M. Baehring, David Hafler, Linda Rollin, Vlad Coric, Susan N. Perez, and David A. Reardon. “Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).” In Journal of Clinical Oncology, 32:TPS2101–TPS2101. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.tps2101.Full Text
-
Vlahovic, Gordana, Gerald E. Archer, Denise Lally-Goss, Sharon Norman, Annick Desjardins, Katherine B. Peters, Tulika Ranjan, et al. “Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, 32:3069–3069. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.3069.Full Text
-
Desjardins, Annick, J. H. Sampson, K. B. Peters, T. Ranjan, G. Vlahovic, S. Threatt, J. E. Herndon, et al. “Intratumoral administration of an Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) in recurrent glioblastoma(GBM): Preliminary results of the Phase I clinical trial.” In Cancer Research, Vol. 74, 2014. https://doi.org/10.1158/1538-7445.AM2014-CT416.Full Text Link to Item
-
Keir, Stephen T., B Ahmed Rasheed, Katherine A. Hoadley, Martin A. Roskoski, Danuta Gasinski, Patrick J. Killela, Hai Yan, Madan M. Kwatra, Henry S. Friedman, and Darell D. Bigner. “Establishment, identification and treatment data of TCGA glioblatoma xenograft subtypes.” In Cancer Research, Vol. 74, 2014. https://doi.org/10.1158/1538-7445.AM2014-838.Full Text
-
Fangusaro, Jason, Sridharan Gururangan, Tina Young Poussaint, Roger E. McLendon, Arzu Onar-Thomas, Katherine E. Warren, Shengjie Wu, et al. “Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).” In Cancer, 119:4180–87, 2013. https://doi.org/10.1002/cncr.28343.Full Text Link to Item
-
Desjardins, Annick, John Howard Sampson, Katherine B. Peters, Tulika Ranjan, Gordana Vlahovic, Stevie Threatt, James Emmett Herndon, et al. “Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.Link to Item
-
Lindhorst, Scott Michael, Frances McSherry, Annick Desjardins, Henry S. Friedman, and Katherine B. Peters. “Analysis of high-dose methotrexate with rituximab versus other treatment regimens for primary central nervous system (CNS) lymphoma.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.Link to Item
-
Ranjan, Tulika, Katherine B. Peters, Gordana Vlahovic, Lloyd M. Alderson, James Emmett Herndon, Frances McSherry, Stevie Threatt, et al. “Phase II trial for patients with newly diagnosed glioblastoma (GBM) treated with carmustine wafers followed by concurrent radiation therapy (RT), temozolomide (TMZ), and bevacizumab (BV), then followed by TMZ and BV post-RT.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.Link to Item
-
Keir, Stephen T., Martin A. Roskoski, Sabrina Wagner, Ralph Tiedt, Darell D. Bigner, and Henry S. Friedman. “Abstract 2079: Antitumoral activity of INC280 against adult glioblastoma brain tumors xenografts.” In Cancer Research, 73:2079–2079. American Association for Cancer Research (AACR), 2013. https://doi.org/10.1158/1538-7445.am2013-2079.Full Text
-
Gromeier, Matthias, Annick Desjardins, John H. Sampson, Stevie J. E. Threatt, James E. Herndon, Allan Friedman, Henry S. Friedman, and Darell D. Bigner. “ONCOLYTIC POLIOVIRUS IMMUNOTHERAPY OF PRIMARY CNS TUMORS.” In Neuro Oncology, 15:20–20. OXFORD UNIV PRESS INC, 2013.Link to Item
-
Desjardins, Annick, John Howard Sampson, Katherine B. Peters, Tulika Ranjan, Gordana Vlahovic, Stevie Threatt, James Emmett Herndon, et al. “Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.” In Journal of Clinical Oncology, Vol. 31, 2013.Link to Item
-
Keir, Stephen T., Martin A. Roskoski, Michael Kragh, Mikkel W. Pederson, Helle J. Jacobsen, Ivan D. Horak, Henry S. Friedman, and Darell D. Bigner. “Efficacy of Sym004, a novel anti-EGFR antibody mixture, against EGFRvIII positive glioblastoma xenografts.” In Cancer Research, Vol. 73, 2013. https://doi.org/10.1158/1538-7445.AM2013-4322.Full Text Link to Item
-
Affronti, Mary Lou, Sarah Woodring, James E. Herndon, Frances McSherry, Katherine B. Peters, Henry S. Friedman, Annick Desjardins, et al. “A PHASE II SINGLE-ARM TRIAL OF PALONOSETRON FOR THE PREVENTION OF ACUTE AND DELAYED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN MALIGNANT GLIOMA PATIENTS RECEIVING IRINOTECAN IN COMBINATION WITH BEVACIZUMAB.” In Neuro Oncology, 14:156–156. OXFORD UNIV PRESS INC, 2012.Open Access Copy Link to Item
-
Alderson, Lloyd M., Annick Desjardins, Tulika Ranjan, Katherine B. Peters, Henry S. Friedman, and James J. Vredenburgh. “BEVACIZUMAB GIVEN WITH TEMOZOLOMIDE AND RADIATION THERAPY (RT) IN NEWLY DIAGNOSED PATIENTS WITH GLIOBLASTOMA MULTIFORME (GBM) REDUCES THE CHANCE OF EARLY RADIOLOGIC PROGRESSION.” In Neuro Oncology, 14:81–81. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Desjardins, Annick, Katherine B. Peters, James E. Herndon, Leigh Ann Bailey, Lloyd M. Alderson, Tulika Ranjan, John H. Sampson, et al. “NEWLY DIAGNOSED GLIOBLASTOMA TREATED WITH GLIADEL (R) FOLLOWED BY RADIATION THERAPY (RT), TEMOZOLOMIDE AND BEVACIZUMAB, AND POST-RT BEVACIZUMAB AND TEMOZOLOMIDE: A PHASE II STUDY.” In Neuro Oncology, 14:104–104. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Keir, Stephen T., Henry S. Friedman, and Darell D. Bigner. “EZN-2208, A NOVEL PEGYLATED SN38 DRUG CONJUGATE, MARKEDLY INHIBITS TUMOR GROWTH IN COMPARISON TO IRINOTECAN.” In Neuro Oncology, 14:29–29. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Peters, Katherine B., David A. Reardon, James J. Vredenburgh, Annick Desjardins, James E. Herndon, April Coan, Frances McSherry, et al. “VORINOSTAT, BEVACIZUMAB, AND METRONOMIC TEMOZOLOMIDE FOR RECURRENT HIGH-GRADE GLIOMA: A PHASE I/II CLINICAL TRIAL.” In Neuro Oncology, 14:81–81. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Peters, Katherine B., Sarah Woodring, James E. Herndon, Frances McSherry, James J. Vredenburgh, Annick Desjardins, and Henry S. Friedman. “LONG-TERM SURVIVORSHIP IN PRIMARY GLIOBLASTOMA: A FOCUS ON NEUROCOGNITION.” In Neuro Oncology, 14:62–62. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Peters, Katherine B., Sarah Woodring, James E. Herndon, Frances McSherry, James J. Vredenburgh, Annick Desjardins, and Henry S. Friedman. “LONG-TERM SURVIVORSHIP IN PRIMARY GLIOBLASTOMA: A FOCUS ON QUALITY OF LIFE.” In Neuro Oncology, 14:158–158. OXFORD UNIV PRESS INC, 2012.Link to Item
-
Desjardins, Annick, James J. Vredenburgh, Katherine B. Peters, Stevie Threatt, James Emmett Herndon, John Howard Sampson, Allan H. Friedman, Henry S. Friedman, and David A. Reardon. “Phase II study of bevacizumab plus irinotecan and carboplatin for recurrent WHO grade 3 malignant gliomas with no prior bevacizumab failure.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.Link to Item
-
Friedman, Henry S., Annick Desjardins, Katherine B. Peters, David A. Reardon, John Kirkpatrick, James Emmett Herndon, April D. Coan, et al. “The addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly diagnosed glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.Link to Item
-
Peters, Katherine B., James J. Vredenburgh, Annick Desjardins, Henry S. Friedman, James Emmett Herndon, April D. Coan, Frances McSherry, et al. “Vorinostat, temozolomide, and bevacizumab for patients with recurrent glioblastoma: A phase I/II trial.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.Link to Item
-
Vredenburgh, James J., Annick Desjardins, Katherine B. Peters, David A. Reardon, James Emmett Herndon, April D. Coan, John Kirkpatrick, et al. “Safety and efficacy of the addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma multiforme.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.Link to Item
-
Jiang, X., D. A. Reardon, A. Desjardins, J. J. Vredenburgh, J. A. Quinn, A. D. Austin, J. E. Herndon, R. E. McLendon, and H. S. Friedman. “O6-Methylguanine-DNA Methytransferase (MGMT) Immunohistochemistry as a Predictor of Resistance to Temozolomide in Primary CNS Lymphoma.” In Laboratory Investigation, 91:382A-382A. NATURE PUBLISHING GROUP, 2011.Link to Item
-
Desjardins, Annick, David A. Reardon, Katherine B. Peters, James E. Herndon, John P. Kirkpatrick, Henry S. Friedman, and James J. Vredenburgh. “SURVIVAL AND TOXICITY UPDATE OF THE PHASE 2 TRIAL OF BEVACIZUMAB (BV) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND RADIATION THERAPY (RT) FOLLOWED BY BV, TMZ, AND IRINOTECAN (CPT-11) FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) PATIENTS.” In Neuro Oncology, 12:77–77. OXFORD UNIV PRESS INC, 2010.Link to Item
-
Desjardins, Annick, Katherine B. Peters, James J. Vredenburgh, Henry S. Friedman, and David A. Reardon. “DASATINIB (SPRYCEL) AND ERLOTINIB (TARCEVA) FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMA: A PHASE 1 TRIAL.” In Neuro Oncology, 12:51–51. OXFORD UNIV PRESS INC, 2010.Link to Item
-
Keir, Stephen T., David A. Reardon, Mark Watson, Gordon C. Shore, Darell D. Bigner, and Henry S. Friedman. “ACTIVITY OF GMX1777 AGAINST A PANEL OF BRAIN TUMOR XENOGRAFTS.” In Neuro Oncology, 12:99–99. OXFORD UNIV PRESS INC, 2010.Link to Item
-
Keir, Stephen T., Sri Gururangan, David A. Reardon, Darell D. Bigner, and Henry S. Friedman. “EFFICACY OF LBH589 (PANOBINOSTAT) AGAINST A PANEL OF PEDIATRIC BRAIN TUMOR XENOGRAFTS.” In Neuro Oncology, 12:99–99. OXFORD UNIV PRESS INC, 2010.Link to Item
-
Peters, Katherine B., David A. Reardon, James J. Vredenburgh, Annick Desjardins, and Henry S. Friedman. “CHARACTERIZATION OF LONG-TERM SURVIVORS OF PRIMARY GLIOBLASTOMA MULTIFORME AND THEIR USE OF PSYCHOACTIVE MEDICATIONS.” In Neuro Oncology, 12:59–60. OXFORD UNIV PRESS INC, 2010.Link to Item
-
Peters, Katherine B., David A. Reardon, James J. Vredenburgh, Annick Desjardins, and Henry S. Friedman. “RETROSPECTIVE ANALYSIS OF INSOMNIA IN RECURRENT GLIOMA PATIENTS AND ITS ASSOCIATION WITH DEXAMETHASONE AND ANTI-EPILEPTICS.” In Neuro Oncology, 12:104–104. OXFORD UNIV PRESS INC, 2010.Link to Item
-
Reardon, David A., James J. Vredenburgh, Annick Desjardins, Dorothea E. Janney, Katherine Peters, John Sampson, Sri Gururangan, and Henry S. Friedman. “A PHASE I/II STUDY OF VORINOSTAT PLUS DAILY TEMOZOLOMIDE AND BEVACIZUMAB IN THE TREATMENT OF PATIENTS WITH RECURRENT MALIGNANT GLIOMA.” In Neuro Oncology, 12:73–73. OXFORD UNIV PRESS INC, 2010.Link to Item
-
Reardon, David A., Katherine Peters, Annick Desjardins, John Sampson, James J. Vredenburgh, Sri Gururangan, and Henry S. Friedman. “FINAL RESULTS OF A PHASE II STUDY OF IMATINIB MESYLATE (GLEEVEC) PLUS HYDROXYUREA FOR ADULTS WITH RECURRENT/PROGRESSIVE LOW-GRADE GLIOMA.” In Neuro Oncology, 12:49–49. OXFORD UNIV PRESS INC, 2010.Link to Item
-
Reardon, David A., Annick Desjardins, James J. Vredenburgh, Sridharan Gururangan, Katherine B. Peters, Julie A. Norfleet, Allan H. Friedman, and Henry S. Friedman. “PHASE II STUDY OF BEVACIZUMAB PLUS ETOPOSIDE AMONG RECURRENT MALIGNANT GLIOMA PATIENTS: FINAL STUDY RESULTS.” In Neuro Oncology, 11:905–905. OXFORD UNIV PRESS INC, 2009.Link to Item
-
Reardon, David A., James J. Vredenburgh, Annick Desjardins, Dorothea E. Janney, Katherine B. Peters, Allan H. Friedman, Sridharan Gururangan, and Henry S. Friedman. “A PHASE I STUDY OF SUNITINIB PLUS IRINOTECAN IN THE TREATMENT OF PATIENTS WITH RECURRENT MALIGNANT GLIOMA.” In Neuro Oncology, 11:946–946. OXFORD UNIV PRESS INC, 2009.Link to Item
-
Sathornsumetee, Sith, Annick Desjardins, James J. Vredenburgh, Jeremy N. Rich, Sridharan Gururangan, D. E. Janney, Allan H. Friedman, Henry S. Friedman, and David A. Reardon. “BEVACIZUMAB PLUS ERLOTINIB IN RECURRENT HIGH-GRADE GLIOMA: A PHASE II TRIAL.” In Neuro Oncology, 11:906–906. OXFORD UNIV PRESS INC, 2009.Link to Item
-
Sithornsumetee, Sith, Annick Desjardins, James J. Vredenburgh, Jeremy N. Rich, Sridharan Gururangan, D. E. Janney, Allan H. Friedman, Henry S. Friedman, and David A. Reardon. “BEVACIZUMAB PLUS ERLOTINIB IN RECURRENT HIGH-GRADE GLIOMA: A PHASE II TRIAL.” In Neuro Oncology, 11:926–926. OXFORD UNIV PRESS INC, 2009.Link to Item
-
Kirkpatrick, J. P., A. Desjardins, D. A. Reardon, A. H. Friedman, H. S. Friedman, and J. J. Vredenburgh. “Radiotherapy, Temozolomide and Bevacizumab followed by Irinotecan, Temozolomide and Bevacizumab Appears Well-tolerated and Efficacious in Newly Diagnosed Glioblastoma Multiforme: Results from a Phase II Trial.” In International Journal of Radiation Oncology*Biology*Physics, 75:S102–3. Elsevier BV, 2009. https://doi.org/10.1016/j.ijrobp.2009.07.250.Full Text
-
Prados, M., T. Cloughesy, M. K. Samant, L. Fang, A. Das, and H. S. Friedman. “8721 Evaluation of objective response as a predictor of survival in bevacizumab-treated patients with glioblastoma at first or second relapse in the BRAIN Study.” In European Journal of Cancer Supplements, 7:499–500. Elsevier BV, 2009. https://doi.org/10.1016/s1359-6349(09)71695-7.Full Text
-
Vredenburgh, J. J., J. Wefel, T. Cloughesy, J. Zazzali, M. K. Samant, M. Zheng, L. Fang, A. Das, and H. S. Friedman. “8707 Clinical assessment of corticosteroid use and neurocognitive function in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.” In European Journal of Cancer Supplements, 7:495–96. Elsevier BV, 2009. https://doi.org/10.1016/s1359-6349(09)71681-7.Full Text
-
Heimberger, A. B., G. E. Archer, D. A. Mitchell, D. D. Bigner, R. J. Schmittling, J. E. Herndon, T. Davis, et al. “Epidermal growth factor receptor variant III (EGFRvIII) vaccine ( CDX-110) in GBM.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.Link to Item
-
Herndon, J., J. Vredenburgh, D. Reardon, A. Desjardins, K. Peters, S. Gururangan, J. Norfleet, A. Friedman, D. Bigner, and H. S. Friedman. “Phase I trial of vendetanib and oral etoposide for recurrent malignant gliomas.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.Link to Item
-
Kirkpatrick, J. P., J. J. Vredenburgh, A. Desjardins, S. Gururangan, K. B. Peters, S. T. Boulton, A. H. Friedman, H. S. Friedman, and D. A. Reardon. “Phase I study of vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.Link to Item
-
Paldino, M., A. Desjardins, H. S. Friedman, J. J. Vredenburgh, and D. P. Barboriak. “Prognostic significance of early changes in the apparent diffusion coefficient that occurs after treatment of patients with glioblastoma multiforme with bevacizumab.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.Link to Item
-
Peters, K., A. Desjardins, D. A. Reardon, S. Perry, J. E. Herndon, L. Bailey, A. H. Friedman, H. S. Friedman, D. D. Bigner, and J. J. Vredenburgh. “Temozolomide (TMZ) and bevacizumab (BV) as initial treatment for unresectable or multifocal glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.Link to Item
-
Sampson, J. H., G. E. Archer, D. D. Bigner, R. J. Schmittling, J. E. Herndon, T. Davis, H. S. Friedman, T. Keler, D. A. Reardon, and D. A. Mitchell. “Effect of daclizumab on T-Reg counts and EGFRvIII-specific immune responses in GBM.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.Link to Item
-
Sathornsumetee, S., A. Desjardins, J. J. Vredenburgh, J. N. Rich, S. Gururangan, A. H. Friedman, H. S. Friedman, and D. A. Reardon. “Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.Link to Item
-
Vredenburgh, J. J., A. Desjardins, D. A. Reardon, K. Peters, J. E. Herndon, J. Kirkpatrick, S. Gururangan, L. Bailey, A. H. Friedman, and H. S. Friedman. “Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.Link to Item
-
Wefel, J. S., T. Cloughesy, J. Zazzali, J. Yi, and H. S. Friedman. “Neurocognitive function in patients with glioblastoma multiforme in first or second relapse treated with bevacizumab in the BRAIN study.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.Link to Item
-
Mitchell, Duane A., Gary E. Archer, Darell D. Bigner, Henry S. Friedman, Denise Lally-Goss, Beth Perry, James E. Herndon, et al. “RNA Transfected Dendritic Cell Vaccines Targeting Human Cytomegalovirus Antigens in Patients with Glioblastoma.” In Molecular Therapy, 17:S93–S93. NATURE PUBLISHING GROUP, 2009.Link to Item
-
Kolb, E. A., C. Morton, P. J. Houghton, J. M. Maris, H. S. Friedman, S. T. Kier, R. G. Gorlick, M. H. Kang, C. P. Reynolds, and M. A. Smith. “558 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the fully human anti-IGF-1R antibody IMC-A12.” In European Journal of Cancer Supplements, 6:176–176. Elsevier BV, 2008. https://doi.org/10.1016/s1359-6349(08)72492-3.Full Text
-
Affronti, M. L., J. M. Day, J. E. Herndon, J. N. Rich, J. A. Quinn, D. A. Reardon, J. J. Vredenburgh, A. Desjardins, R. E. McLendon, and H. S. Friedman. “Radiation and concurrent temozolomide followed by rotational multi-agent chemotherapy for glioblastoma (GBM) patients.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.Link to Item
-
Bohlin, C. W., D. A. Reardon, A. Desjardins, J. A. Quinn, J. N. Rich, D. A. Bota, K. Goli, H. S. Friedman, and J. J. Vredenburgh. “Tinzaparin prophylaxis in brain tumor patients.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.Link to Item
-
Bota, D. A., A. Desjardins, J. A. Quinn, J. N. Rich, J. J. Vredenburgh, S. Sathornsumetee, K. Goli, A. Salvado, H. S. Friedman, and D. A. Reardon. “Phase II trial of imatinib mesylate and hydroxyurea for adults with recurrent/progressive low-grade glioma.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.Link to Item
-
Desjardins, A., D. P. Barboriak, J. E. Herndon, D. A. Reardon, J. A. Quinn, J. N. Rich, S. Sathornsumetee, S. Gururangan, H. S. Friedman, and J. J. Vredenburgh. “Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation in glioblastoma (GBM) patients treated with bevacizumab (BEV) and irinotecan (CPT-11).” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.Link to Item
-
Goli, K. J., A. Desjardins, J. E. Herndon, J. N. Rich, D. A. Reardon, J. A. Quinn, S. Sathornsumetee, D. A. Bota, H. S. Friedman, and J. J. Vredenburgh. “Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.Link to Item
-
Gururangan, S., C. Turner, C. F. Stewart, M. Kocak, T. Y. Poussaint, J. M. Boyett, L. E. Kun, V. Karsten, S. L. Gerson, and H. S. Friedman. “Phase I trial of VNP40101M in children with recurrent brain tumors-A Pediatric Brain Tumor Consortium (PBTC) study.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.Link to Item
-
Jones, L., M. L. Affronti, C. W. Bohlin, J. E. Herndon, J. A. Quinn, D. A. Reardon, J. N. Rich, H. S. Friedman, and J. J. Vredenburgh. “Prevalence of osteoporosis in glioma patients on enzyme inducing anticonvulsants (EIAC) and/or glucocorticoids.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.Link to Item
-
Quinn, J. A., J. J. Vredenburgh, J. N. Rich, D. A. Reardon, A. Desjardins, S. Gururangan, A. H. Friedman, J. H. Carter, S. Threatt, and H. S. Friedman. “Phase II trial of Gliadel plus O-6-benzylguanic (O-6-BG) for patients with recurrent glioblastoma multiforme.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.Link to Item
-
Rich, J. N., M. L. Affronti, J. M. Day, J. E. Herndon, J. A. Quinn, D. A. Reardon, J. J. Vredenburgh, A. Desjardins, and H. S. Friedman. “Overall survival of primary glioblastoma (GBM) patients (pts) receiving carmustine (BCNU) wafers followed by radiation (RT) and concurrent temozolomide (TMZ) plus rotational multi-agent.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.Link to Item
-
Sathornsumetee, S., J. N. Rich, J. J. Vredenburgh, A. Desjardins, J. A. Quinn, S. Gururangan, M. J. Egorin, A. J. Salvado, H. S. Friedman, and D. A. Reardon. “Phase I trial of imatinib mesylate, hydroxyurea and vatalanib for patients with recurrent glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.Link to Item
-
Vredenburgh, J. J., C. H. Bohlin, D. A. Reardon, A. Desjardins, J. A. Quinn, J. N. Rich, D. A. Bota, K. J. Goli, H. S. Friedman, and D. H. Allen. “Pilot study of dronabinol for adult patients with primary malignant gliomas.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.Link to Item
-
Broniscer, A., S. Gururangan, S. Goldman, T. MacDonald, D. Wallace, C. F. Stewart, R. Jakacki, et al. “Phase I trial of oral temozolomide and intravenous O-6-benzylguanine (O-6-BG), a methylguanine methyltransferase inhibitor, in pediatric patients with recurrent brain tumors.” In Neuro Oncology, 9:189–189. DUKE UNIV PRESS, 2007.Link to Item
-
Gururangan, S., J. Provenzale, and H. S. Friedman. “Pilot phase II study of metrenomic oral cyclophosphamide plus thalidomide in children with recurrent malignant brain tumors.” In Neuro Oncology, 9:203–203. DUKE UNIV PRESS, 2007.Link to Item
-
Affronti, Mary Lou, Jeannette M. Dowell, James E. Herndon, Joan Cahill, Jeremy N. Rich, Jennifer A. Quinn, David A. Reardon, et al. “Overall survival of primary glioblastoma (GBM) patients receiving radiation and concurrent temozolomide followed by rotational multi-agent chemotherapy.” In Neuro Oncology, 8:437–437. DUKE UNIV PRESS, 2006.Link to Item
-
Brigidi, Bart D., Renee H. Raynor, Melanie Bonner, Holly Schweitzer, Karen Carter, Bebe Guill, and Henry S. Friedman. “Development of the duke cancer cognitions inventory-brain tumor version (DCCI-BT).” In Neuro Oncology, 8:476–476. DUKE UNIV PRESS, 2006.Link to Item
-
Brigidi, Bart D., Renee H. Raynor, and Henry S. Friedman. “Neurocognitive deficits according to hemisphere and diagnosis among patients with high-grade CNS tumors.” In Neuro Oncology, 8:476–77. DUKE UNIV PRESS, 2006.Link to Item
-
Desjardins, A., J. A. Quinn, J. N. Rich, J. J. Vredenburgh, S. Sathornsumetee, S. Gururangan, A. H. Friedman, et al. “A phase I trial of imatinib (GLEEVEC), hydroxyurea and RAD001 for patients with recurrent malignant glioma.” In Neuro Oncology, 8:441–441. DUKE UNIV PRESS, 2006.Link to Item
-
Hjelmeland, Anita B., Katie Lattimore, Brian Fee, Sarah Wickman, Stephen T. Keir, Mark D. Hjelmeland, David Batt, et al. “The combination of novel low-molecular-weight inhibitors of Raf (LBT 613) and TOR (RAD001, everolimus) decreases glioma proliferation and invasion.” In Neuro Oncology, 8:412–412. DUKE UNIV PRESS, 2006.Link to Item
-
Quinn, J. A., A. Desjardins, J. N. Rich, J. J. Vredenburgh, D. A. Reardon, S. Gururangan, S. Sathornsumetee, et al. “Phase I trial of Temodar plus O-6-benzylguanine 5-day regimen for patients with progressive glioblastoma multiforme.” In Neuro Oncology, 8:450–450. DUKE UNIV PRESS, 2006.Link to Item
-
Sathornsumetee, Sith, Anita B. Hjelmeland, Stephen T. Keir, Roger E. McLendon, David Batt, Timothy Ramsey, Naeem Yusuff, et al. “AAL881, a novel small molecule inhibitor of RAF and VEGFR activities, blocks growth of malignant glioma.” In Neuro Oncology, 8:417–417. DUKE UNIV PRESS, 2006.Link to Item
-
Sathornsumetee, Sith, Jeremy N. Rich, James J. Vredenburgh, Annick Desjardins, Jennifer A. Quinn, Sri Gururangan, Allan H. Friedman, et al. “Phase I trial of temozolomide plus dose-escalating imatinib mesylate for patients with malignant glioma.” In Neuro Oncology, 8:451–451. DUKE UNIV PRESS, 2006.Link to Item
-
Shi, Qing, Anita B. Hjelmeland, Stephen T. Keir, Sarah K. Wickman, Guanghong Wu, Dowdy Jackson, Osamu Ohmori, Darell D. Bigner, Henry S. Friedman, and Jeremy N. Rich. “A novel low-molecular-weight inhibitor of focal adhesion kinase, inhibits glioma growth.” In Neuro Oncology, 8:417–417. DUKE UNIV PRESS, 2006.Link to Item
-
Desjardins, A., D. A. Reardon, J. A. Quinn, J. N. Rich, J. J. Vredenburgh, S. Sathornsumetee, A. Salvado, and H. S. Friedman. “Phase II trial of imatinib mesylate and hydroxyurea for grade III malignant gliomas.” In Journal of Clinical Oncology, 24:76S-76S. AMER SOC CLINICAL ONCOLOGY, 2006.Link to Item
-
Korones, D. N., M. Benita-Weiss, T. Coyle, P. Bushunow, L. Mechtler, and H. S. Friedman. “A phase II study of temozolomide and oral VP-16 for adults with recurrent glioma - Final results.” In Journal of Clinical Oncology, 24:74S-74S. AMER SOC CLINICAL ONCOLOGY, 2006.Link to Item
-
Quinn, J. A., J. J. Vredenburgh, J. N. Rich, D. A. Reardon, A. Desjardins, S. Gururangan, A. H. Friedman, et al. “Phase II trial of Gliadel plus 0(6)-benzylguanine (0(6) -BG) for patients with recurrent glioblastoma multiforme.” In Journal of Clinical Oncology, 24:74S-74S. AMER SOC CLINICAL ONCOLOGY, 2006.Link to Item
-
Reardon, D., J. A. Quinn, J. N. Rich, J. J. Vredenburgh, A. Desjardins, S. Sathornsumetee, S. Gururangan, M. J. Egorin, A. Salvado, and H. S. Friedman. “A phase I trial of imatinib, hydroxyurea and RAD001 for patients with recurrent malignant glioma.” In Journal of Clinical Oncology, 24:77S-77S. AMER SOC CLINICAL ONCOLOGY, 2006.Link to Item
-
Sathornsumetee, S., D. A. Reardon, J. A. Quinn, J. N. Rich, J. J. Vredenburgh, A. Desjardins, S. Gururangan, M. Egorin, A. Salvado, and H. S. Friedman. “An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma.” In Journal of Clinical Oncology, 24:72S-72S. AMER SOC CLINICAL ONCOLOGY, 2006.Link to Item
-
Vredenburgh, J. J., A. Desjardins, J. E. Herndon, J. Quinn, J. Rich, S. Sathornsumetee, H. S. Friedman, D. Reardon, S. Gururangan, and A. Friedman. “Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas.” In Journal of Clinical Oncology, 24:59S-59S. AMER SOC CLINICAL ONCOLOGY, 2006.Link to Item
-
Cui, Bo, Stewart P. Johnson, Francis Ali-Osman, Darell D. Bigner, and Henry S. Friedman. “Constitutive phosphorylation of Chk1 at serine 317 in a medulloblastoma cell line is sensitive to the inhibition of the phosphatidyalinositol-3-kinase-related kinase (PIKK) pathway.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.Link to Item
-
Houghton, Peter J., John Maris, Henry S. Friedman, Stephen T. Kier, Richard B. Lock, Richard Gorlick, E Anders Kolb, C Patrick Reynolds, Christopher Morton, and Malcolm A. Smith. “Evaluation of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, KOS-1022) against Childhood Cancer Models by the Pediatric Preclinical Testing Program (PPTP).” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.Link to Item
-
Johnson, Stewart P., Barton A. Kamen, Robert C. Moschel, and Henry S. Friedman. “Characterization of membrane transport of the novel O-6-alkylguanine-DNA alkyltransferase inactivator, O-4-benzylfolic acid.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.Link to Item
-
Maxwell, Jill A., Stewart P. Johnson, Roger E. McLendon, Francis Ali-Osman, Jennifer A. Quinn, Allan H. Friedman, James E. Herndon, et al. “O-6-alkylguanine-DNA alkyltransferase (AGT) and microsatellite instability (MSI) analyses in malignant glioma.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.Link to Item
-
Yoshimoto, Y., J. S. Yoo, C. K. Augustine, S. K. Pruitt, H. S. Friedman, and D. S. Tyler. “The role of chemoresistance in regional infusion therapy for melanoma.” In Annals of Surgical Oncology, 13:82–82. SPRINGER, 2006.Link to Item
-
Houghton, P. J., J. M. Maris, H. S. Friedman, S. T. Keir, R. B. Lock, R. Gorlick, E. A. Kolb, C. P. Reynolds, C. Morton, and M. A. Smith. “Evaluation of bortezomib against childhood tumor models by the pediatric preclinical testing program (PPTP).” In Clinical Cancer Research, 11:8987S-8988S. AMER ASSOC CANCER RESEARCH, 2005.Link to Item
-
Reardon, D. A., P. Y. Wen, P. Lyons, J. N. Rich, L. Berk, H. L. Knowles, V. M. Rivera, C. L. Bedrosian, and H. S. Friedman. “A phase I trial of AP23573, a novel mTOR inhibitor, in patients (Pts) with recurrent malignant glioma.” In Clinical Cancer Research, 11:9012S-9012S. AMER ASSOC CANCER RESEARCH, 2005.Link to Item
-
Friedman, H. S., J. Quinn, J. Rich, J. Vredenburgh, A. Desjardins, S. Sathornsumetee, A. Salvado, Z. Nikolova, D. Bigner, and D. Reardon. “Efficacy of imatinib mesylate plus hydroxyurea regimen in the treatment of recurrent malignant glioma: Phase II study results.” In Journal of Clinical Oncology, 23:117S-117S. AMER SOC CLINICAL ONCOLOGY, 2005.Link to Item
-
Rich, J. N., D. A. Reardon, J. A. Quinn, J. J. Vredenburgh, A. Desjardins, S. Sathornsumetee, S. Gururangan, P. Lyons, D. D. Bigner, and H. S. Friedman. “A phase I trial of gefitinib (ZD1 839) plus rapamycin for patients with recurrent malignant glioma.” In Journal of Clinical Oncology, 23:130S-130S. AMER SOC CLINICAL ONCOLOGY, 2005.Link to Item
-
Sathornsumetee, S., D. A. Reardon, J. Quinn, J. N. Rich, J. J. Vredenburgh, A. Desjardins, S. Gururangan, P. Lyons, A. Salvado, and H. S. Friedman. “A phase 1 dose escalation study of imatinib mesylate plus standard-dosed temozolomide in the treatment of patients with malignant glioma.” In Journal of Clinical Oncology, 23:124S-124S. AMER SOC CLINICAL ONCOLOGY, 2005.Link to Item
-
Badruddoja, M. A., D. A. Reardon, J. J. Vredenburgh, J. A. Quinn, J. N. Rich, A. Desjardins, A. Friedman, et al. “Phase II upfront CPT-11 plus celecoxib for adults with glioblastoma multiforme.” In Neuro Oncology, 6:369–70. DUKE UNIV PRESS, 2004.Link to Item
-
Brashears, J., S. Gururangan, C. McLaughlin, M. Morgan, J. Provenzale, E. C. Halperin, and H. S. Friedman. “Incidence and patterns of neuraxis metastasis (NM) in patients (PTS) with diffuse pon'ine glioma (DPG).” In Neuro Oncology, 6:417–417. DUKE UNIV PRESS, 2004.Link to Item
-
Desjardins, A., D. Reardon, J. Vredenburgh, J. Rich, S. Gururangan, A. Friedman, J. Sampson, et al. “Phase I trial of adults with primary malignant glioma with irinotecan (CPT-11) plus temozolomide (Temodar).” In Neuro Oncology, 6:373–74. DUKE UNIV PRESS, 2004.Link to Item
-
Gondar, R. K., M. D. Hjelmeland, S. T. Keir, C. A. Conrad, R. E. McLendon, C. J. Wikstrand, P. Traxler, et al. “Inhibition of receptor tyrosine kinases and mammalian target of rapamycin offers combinatorial benefit in tumor control.” In Neuro Oncology, 6:407–407. DUKE UNIV PRESS, 2004.Link to Item
-
Gururangan, S., J. A. Bridge, T. J. Cummings, E. C. Halperin, and H. S. Friedman. “Extraosseous Ewings sarcoma (EES) of the central nervous system (CNS) - Case reports and molecular diagnosis.” In Neuro Oncology, 6:457–457. DUKE UNIV PRESS, 2004.Link to Item
-
Gururangan, S., J. C. Allen, P. C. Phillips, E. Dillard, and H. S. Friedman. “Phase II study of oral temozolomide (TMZ) in children with progressive low-grade gliomas (LGG).” In Neuro Oncology, 6:457–457. DUKE UNIV PRESS, 2004.Link to Item
-
Quinn, J. A., A. Desjardins, D. Reardon, J. Vredenburgh, J. Rich, S. Gururangan, A. Friedman, et al. “Phase I trial of temozolomide (Temodar) plus irinotecan (CPT-11) plus O6-benzylguanine (O6-BG) in the treatment of recurrent or progressive cerebral anaplastic gliomas.” In Neuro Oncology, 6:380–380. DUKE UNIV PRESS, 2004.Link to Item
-
Quinn, J. A., A. Desjardins, D. Reardon, J. Vredenburgh, J. Rich, S. Gururangan, A. Friedman, et al. “Phase II trial of temozolomide (Temodar) plus O6-benzylguanine (O6-BG) in the treatment of patients with Temodar-resistant malignant glioma.” In Neuro Oncology, 6:380–380. DUKE UNIV PRESS, 2004.Link to Item
-
Rich, J. N., D. Loncar, S. Sathornsumetee, S. Keir, C. Wheeler, I. Dimery, D. D. Bigner, and H. S. Friedman. “ZD6474, a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, inhibits growth of multiple primary central nervous system tumor types.” In Neuro Oncology, 6:413–413. DUKE UNIV PRESS, 2004.Link to Item
-
Vaidyanathan, G., A. Boskovitz, H. S. Friedman, D. J. Affleck, and M. R. Zalutsky. “Somatostatin targeted radiotherapeuiccs for medulloblastoma.” In Neuro Oncology, 6:416–416. DUKE UNIV PRESS, 2004.Link to Item
-
Badruddoja, M. A., D. A. Reardon, G. Akabani, A. H. Friedman, H. S. Friedman, J. N. Rich, J. A. Quinn, K. Penne, J. J. Vredenburgh, and D. D. Bigner. “Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors.” In Journal of Clinical Oncology, 22:124S-124S. AMER SOC CLINICAL ONCOLOGY, 2004.Link to Item
-
Desjardin, A., J. A. Quinn, D. A. Reardon, J. N. Rich, J. J. Vredenburgh, C. Efird, and H. S. Friedman. “Phase II study of thalidomide and daily cyclophosphamide for adults with malignant glioma.” In Journal of Clinical Oncology, 22:120S-120S. AMER SOC CLINICAL ONCOLOGY, 2004.Link to Item
-
Goudar, R., S. Keir, M. Hjelmeland, C. Conrad, P. Traxler, H. Lane, X. F. Wang, D. D. Bigner, H. S. Friedman, and J. N. Rich. “Combination therapy of inhibitors of the epidermal growth factor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.” In Clinical Cancer Research, 9:6090S-6090S. AMER ASSOC CANCER RESEARCH, 2003.Link to Item
-
Rich, J. N., D. Loncar, S. Keir, C. Wheeler, I. Dimery, D. D. Bigner, and H. S. Friedman. “ZD6474, a vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, inhibits growth of multiple primary central nervous system tumor types.” In Clinical Cancer Research, 9:6143S-6143S. AMER ASSOC CANCER RESEARCH, 2003.Link to Item
-
McLendon, R. E., R. N. Wiltshire, J. E. Herndon, A. Lloyd, H. S. Friedman, D. D. Bigner, and S. H. Bigner. “Sub-classification of glioblastoma defined by comparative genomic hybridization alterations.” In Journal of Neuropathology and Experimental Neurology, 62:542–542. AMER ASSN NEUROPATHOLOGISTS INC, 2003.Link to Item
-
Provenzale, J. M., M. Sakurai, K. S. Bottom, G. K. Klintworth, E. G. Buckley, and H. S. Friedman. “Patterns of CNS involvement and clinical outcome in trilateral retinoblastoma.” In Radiology, 209P:203–203, 1998.Link to Item
-
McLendon, R. E., H. S. Friedman, D. C. Lonuee, H. E. Fuchs, and R. B. Hessler. “SYNCHRONOUS EPENDYMO-GLIOMAS.” In Journal of Neuropathology and Experimental Neurology, 54:422–422. Oxford University Press (OUP), 1995. https://doi.org/10.1097/00005072-199505000-00062.Full Text
-
Kreek, M. J., T. Eisenstein, H. Friedman, P. Peterson, L. Soderberg, L. S. Brown, T. J. Rogers, et al. “Drugs of abuse and immunosuppression.” In Nida Research Monograph Series, 89–93, 1994.
-
Archer, G. E., J. M. Schuster, H. E. Fuchs, A. Guaspari, D. P. Bigner, H. S. Friedman, and R. E. McLendon. “NEUROPATHOLOGY OF MULTIPLE VERSUS SINGLE DOSE INTRATHECAL MELPHALAN IN RATS.” In Journal of Neuropathology and Experimental Neurology, 52:298–298. Oxford University Press (OUP), 1993. https://doi.org/10.1097/00005072-199305000-00152.Full Text
-
Fuchs, H. E., G. E. Archer, J. M. Schuster, O. M. Colvin, S. H. Bigner, L. H. Muhlbaier, H. S. Friedman, and D. D. Bigner. “A NUDE RAT MODEL OF LEPTOMENINGEAL TUMOR DISSEMINATION (LTD) OF HUMAN MEDULLOBLASTOMA.” In Journal of Neuropathology and Experimental Neurology, 48:356–356. Oxford University Press (OUP), 1989. https://doi.org/10.1097/00005072-198905000-00173.Full Text
-
Barboriak, Daniel P., Sarah Woodring, Sujata Panta, Eric Lipp, Frances McSherry, James Herndon, Annick Desjardins, Dina Randazzo, Henry Friedman, and Katherin Peters. “Scan-rescan Repeatability of Hippocampal Volume Measurements in Patients with Low-grade Glioma: Comparison of Automated Software Packages.,” n.d.
-
Desjardins, Annick, Dina Randazzo, V. Chandramohan, Katherine B. Peters, Margaret O. Johnson, Steve Threatt, James E. Herndon, et al. “Dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for recurrent malignant glioma.,” n.d.
-
Desjardins, Annick, Dina Randazzo, V. Chandramohan, Katherine Peters, Margaret O. Johnson, Stevie Threatt, James Herndon, et al. “Dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for recurrent malignant glioma.,” n.d.
-
Desjardins, Annick, John Sampson, Katherine Peters, Gordana Vlahoci, Dina Randazzo, Stevie Threatt, James Herndon, et al. “Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.,” 33:112s-112s, n.d.Link to Item
-
Desjardins, Annick, Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Susan Boulton, Eric Lipp, Woody Massey, et al. “Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1.,” 33:112s-112s, n.d.Link to Item
-
Kim, Jung, Sarah Woodring, Mary L. Affronti, Dina Randazzo, Frances McSherry, James Herndon, Eric Lipp, et al. “Secondary cancers in long-term survivors of primary glioblastoma.” In Journal of Clinical Oncology, Vol. 33, n.d.Link to Item
-
Peters, Katherine, Mary Affronti, Sarah Woodring, Stevie Threatt, Patrick Healy, James Herndon, Eri Lipp, Dina Randazzo, Annick Desjardins, and Henry Friedman. “Taking sides: importance of tumor laterality in understanding cognitive testing in primary brain tumor patients.,” n.d.
-
Peters, Katherine, Mary L. Affronti, Sarah Woodring, Eric Lipp, Patrick Healy, Frances McShwrry, James Herndon, et al. “QOL-20. Low-dose Naltrexone in newly diagnosed high-grade glioma: placebo-controlled, double-blind, randomized pilot study.” In Neuro Oncology, 17:v192–v192. Oxford University Press (OUP), n.d. https://doi.org/10.1093/neuonc/nov230.20.Full Text Link to Item
-
Peters, Katherine, Mary L. Affronti, Sarah Woodring, Eric Lipp, Patrick Healy, Frances McShwrry, James Herndon, et al. “QOL-20. Low-dose Naltrexone in newly diagnosed high-grade glioma: placebo-controlled, double-blind, randomized pilot study.” In Neuro Oncology, 17:v192–v192. Oxford University Press (OUP), n.d. https://doi.org/10.1093/neuonc/nov230.20.Full Text Link to Item
-
Peters, Katherine, Patrick Healy, James Herndon, Eric Lipp, Sujata Panta, Dina Randazzo, Gordana Vlahovic, Henry Friedman, and Annick Desjardins. “Perceived cognitive dysfunction at diagnosis and beyond disease progression in newly diagnosed glioblastoma patients.” In Supportive Care in Cancer, 25:S60–S60. Springer (part of Springer Nature), n.d.
-
Peters, Katherine, Stevie Threatt, Patrick Healy, James Herndon, Eric Lipp, Sujata Panta, Dina Randazzo, Henry Friedman, and Annick Desjardsin. “Cognitive performance at diagnosis and beyond disease progression in newly diagnosed glioblastoma patients.” In Supportive Care in Cancer, 26:S162–S162. Springer (part of Springer Nature), n.d. https://doi.org/10.1007/s00520-018-4193-2.Full Text
-
Randazzo, Dina, Frances McSherry, James Herndon, Mary L. Affronti, Eric Lipp, Charlene Flahiff, Elizabeth Miller, et al. “Complementary and Alternative Medicine in the Primary Brain Tumor Population and its Association with Health-Related Quality of Life.,” n.d.
-
Randazzo, Dina, Frances McSherry, James Herndon, Mary Lou Affronti, Eric Lipp, Charlene Flahiff, Elizabeth Miller, et al. “QOL-21 Diet and health-related quality of life (HRQoL) in the primary brain tumor population.” In Neuro Oncology, 17:v192–v192. Oxford University Press (OUP), n.d. https://doi.org/10.1093/neuonc/nov230.21.Full Text Link to Item
-
Randazzo, Dina, Mary Affronti, Eric Lipp, Frances McSherry, James Hernson, Charlene Flahiff, Elizabeth Miller, et al. “Psychosocial Distress and its Effects on the Health-Related Quality of Life of Primary Brain Tumor Patients.,” n.d.
-
Randazzo, Dina, Mary L. Affronti, Eric Lipp, Frances McSherry, James Herndon, Charlene Flahiff, Sarah Woodring, et al. “Complementary and alternative medicine in the primary brain tumor population and its association with health reported Quality of Life.” In Neurology, 84:S18–S18. American Academy of Neurology, n.d.Link to Item
-
Weant, Erin H., Sarah Woodring, Din Randazzo, Henry Friedman, Annick Desjardins, Gordana Vlahovic, Patrick Healy, et al. “Randomized open-label phase II tril of aprepitant plus ondansetron compared to ondansetron alone in prevention of chemotherapy-induced-nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.” In Supportive Care in Cancer, 25:S128–S128. Springer (part of Springer Nature), n.d. https://doi.org/10.1007/s00520-017-3704-x.Full Text Link to Item
-
Weant, Mallika, Anastasie Dunn-Pirio, Katherine Peters, Gordana Vlahovic, Dina Randazzo, James Herndon, Patrick Healy, et al. “Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial.” In Neuro Oncology, Vol. 17. Oxford University Press (OUP), n.d. https://doi.org/10.1093/neuonc/nov206.13.Full Text Link to Item
-
Weant, Mallika, Anastasie Dunn-Pirio, Katherine Peters, Gordana Vlahovic, Dina Randazzo, James Herndon, Patrick Healy, et al. “Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial.” In Neuro Oncology, Vol. 17. Oxford University Press (OUP), n.d. https://doi.org/10.1093/neuonc/nov206.13.Full Text Link to Item
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.